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Abstract
Systematic review of the clinical effectiveness and cost-
effectiveness of oesophageal Doppler monitoring in 
critically ill and high-risk surgical patients
G Mowatt,1 G Houston,3 R Hernández,2 R de Verteuil,1,2 C Fraser,1  
B Cuthbertson1,3 and L Vale1,2*
1Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK
2Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK
3NHS Grampian, UK
*Corresponding author
Objectives: To assess the effectiveness and cost-
effectiveness of oesophageal Doppler monitoring 
(ODM) compared with conventional clinical assessment 
and other methods of monitoring cardiovascular 
function. 
Data sources: Electronic databases and relevant 
websites from 1990 to May 2007 were searched.
Review methods: This review was based on a 
systematic review conducted by the US Agency 
for Healthcare Research and Quality (AHRQ), 
supplemented by evidence from any additional studies 
identified. Comparator interventions for effectiveness 
were standard care, pulmonary artery catheters (PACs), 
pulse contour analysis monitoring and lithium or 
thermodilution cardiac monitoring. Data were extracted 
on mortality, length of stay overall and in critical 
care, complications and quality of life. The economic 
assessment evaluated strategies involving ODM 
compared with standard care, PACs, pulse contour 
analysis monitoring and lithium or thermodilution 
cardiac monitoring. 
Results: The AHRQ report contained eight RCTs 
and was judged to be of high quality overall. Four 
comparisons were reported: ODM plus central venous 
pressure (CVP) monitoring plus conventional assessment 
vs CVP monitoring plus conventional assessment 
during surgery; ODM plus conventional assessment 
vs CVP monitoring plus conventional assessment 
during surgery; ODM plus conventional assessment 
vs conventional assessment during surgery; and ODM 
plus CVP monitoring plus conventional assessment 
vs CVP monitoring plus conventional assessment 
postoperatively. Five studies compared ODM plus CVP 
monitoring plus conventional assessment with CVP 
monitoring plus conventional assessment during surgery. 
There were fewer deaths [Peto odds ratio (OR) 0.13, 
95% CI 0.02–0.96], fewer major complications (Peto 
OR 0.12, 95% CI 0.04–0.31), fewer total complications 
(fixed-effects OR 0.43, 95% CI 0.26–0.71) and shorter 
length of stay (pooled estimate not presented, 95% 
CI –2.21 to –0.57) in the ODM group. The results of 
the meta-analysis of mortality should be treated with 
caution owing to the low number of events and low 
overall number of patients in the combined totals. Three 
studies compared ODM plus conventional assessment 
with conventional assessment during surgery. There was 
no evidence of a difference in mortality (fixed-effects 
OR 0.81, 95% CI 0.23–2.77). Length of hospital stay 
was shorter in all three studies in the ODM group. 
Two studies compared ODM plus CVP monitoring 
plus conventional assessment vs CVP monitoring plus 
conventional assessment in critically ill patients. The 
patient groups were quite different (cardiac surgery and 
major trauma) and neither study, nor a meta-analysis, 
showed a statistically significant difference in mortality 
(fixed-effects OR 0.84, 95% CI 0.41–1.70). Fewer 
patients in the ODM group experienced complications 
(OR 0.49, 95% CI 0.30–0.81) and both studies reported 
a statistically significant shorter median length of hospital 
stay in that group. No economic evaluations that met 
the inclusion criteria were identified from the existing 
literature so a series of balance sheets was constructed. 
The results show that ODM strategies are likely to be 
cost-effective.
Conclusions: More formal economic evaluation would 
allow better use of the available data. All identified Abstract
iv
studies were conducted in unconscious patients. 
However, further research is needed to evaluate new 
ODM probes that may be tolerated by awake patients. 
Given the paucity of the existing economic evidence 
base, any further primary research should include an 
economic evaluation or should provide data suitable for 
use in an economic model.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Description of 
proposed service
Oesophageal Doppler monitoring (ODM) measures 
blood velocity in the descending thoracic aorta 
using a flexible probe inserted into the patient’s 
oesophagus. This information is combined with an 
estimate of aortic cross-sectional area (derived from 
a nomogram based on the patient’s age, height 
and weight) allowing continuous monitoring of 
cardiac output and haemodynamic status. ODM is 
a relatively simple procedure, generally limited in 
use to a critical care or theatre setting, that requires 
no calibration and minimal training.
Epidemiology and 
background
Optimal management of cardiac output, fluid 
balance and haemodynamic status is considered 
key to improving outcome in high-risk surgical 
and critically ill patients. Traditionally, pulmonary 
artery catheters (PACs) have been used to monitor 
cardiac output and haemodynamic status to guide 
treatment, but they have been shown to provide no 
benefit to this patient group.
Less invasive methods of monitoring cardiac output 
and other haemodynamic variables include ODM, 
transoesophageal echocardiography, transthoracic 
impedance, carbon dioxide elimination and 
systems based upon pulse contour analysis and dye 
dilution methods. These may be used alongside 
conventional clinical assessment which involves 
assessment of various clinical markers, e.g. heart 
rate, systolic blood pressure and urinary output, 
with or without a measure of blood flow or central 
venous pressure.
Objective
To assess the effectiveness and cost-effectiveness 
of ODM, in comparison with conventional clinical 
assessment and other methods of monitoring 
cardiovascular function.
Executive summary
Methods
A systematic review of studies of effectiveness and 
cost-effectiveness was conducted.
Data sources
Searches of electronic databases [including 
MEDLINE, EMBASE, Cumulative Index to 
Nursing and Allied Health Literature (CINAHL) 
and the Cochrane Library] and relevant websites 
until May 2007 were undertaken to identify 
published and unpublished reports, including 
previous systematic reviews.
Study selection
For the review of effectiveness, randomised 
controlled trials (RCTs), or systematic reviews 
of RCTs, assessing the effects of ODM in the 
target populations were identified. Comparator 
interventions considered were standard care, PACs, 
pulse contour analysis monitoring and lithium or 
thermodilution cardiac monitoring. Non-English 
language studies and studies reported only as 
abstracts were excluded.
For the review of economic evaluations studies had 
to compare, in terms of both costs and outcomes, 
strategies involving ODM compared with standard 
care, PACs, pulse contour analysis monitoring and 
lithium or thermodilution cardiac monitoring. 
No language restrictions or other limitations to 
searches were imposed.
Data extraction
For the review of effectiveness a recent high-quality 
systematic review, conducted by the US Agency 
for Healthcare Research and Quality (AHRQ), 
was identified. A judgement was made to base this 
review on this study, supplemented by evidence 
from any additional studies identified. Data were 
extracted on mortality, length of stay overall and in 
critical care, complications and quality of life.
The quality of primary studies was assessed using 
the Emergency Care Research Institute (ECRI) Executive summary
x
25-question quality scale. The systematic review 
was assessed using a 10-item checklist developed 
by Oxman and Guyatt. Where appropriate, meta-
analysis was employed to estimate a summary 
measure of effect on relevant outcomes. Where 
a quantitative synthesis was considered to be 
inappropriate or not feasible, a narrative synthesis 
of results was provided.
Economic modelling
Partial economic modelling exercises were explored 
for pairwise comparisons between strategies that 
used ODM and those that did not. Differences in 
mortality and length of stay were considered within 
these exercises. Where data allowed, probability 
distributions were attached to model parameters 
[e.g. lognormal probability distributions for 
odds ratios and normal distributions for length 
of hospital stay differences using information 
on the confidence intervals (CIs) surrounding 
point estimates], and probabilistic analyses were 
conducted. Costs were stated in £ sterling for 
2006–7. Cost-effectiveness results were expressed in 
additional cost per additional quality-adjusted life-
year (QALY), as well as the average extra cost per 
additional survivor that would need to be incurred 
before ODM would no longer be considered cost-
effective. For the former the results were presented 
in the form of incremental cost-effectiveness planes 
and for the latter the data were presented as 
histograms.
Results
Number and quality of studies 
and direction of evidence
The AHRQ report contained eight RCTs involving 
757 adult patients. Two additional RCTs, involving 
202 patients, were identified. Eight of these 
primary studies were judged to be of high quality 
and two were judged to be of moderate quality. 
The AHRQ report was judged to be of high quality 
overall. The 10 primary studies reported four 
comparisons (one study reported two):
ODM plus central venous pressure (CVP)  •	
monitoring plus conventional assessment 
versus CVP monitoring plus conventional 
assessment during surgery
ODM plus conventional assessment versus  •	
CVP monitoring plus conventional assessment 
during surgery
ODM plus conventional assessment versus  •	
conventional assessment during surgery
ODM plus CVP monitoring plus conventional  •	
assessment versus CVP monitoring plus 
conventional assessment in critically ill patients 
postoperatively.
For the review of cost-effectiveness no studies were 
identified and as a consequence the data from the 
review of effectiveness were organised into a series 
of balance sheets.
Summary of benefits
During surgery
Five studies (453 patients) compared ODM plus 
CVP monitoring plus conventional assessment 
with CVP monitoring plus conventional assessment 
during surgery. There were fewer deaths [Peto odds 
ratio (OR) 0.13, 95% CI 0.02–0.96], fewer major 
complications (Peto OR 0.12, 95% CI 0.04–0.31), 
fewer total complications (fixed-effects OR 0.43, 
95% CI 0.26–0.71) and shorter length of stay 
(pooled estimate not presented, 95% CI –2.21 to 
–0.57) in the ODM group. These analyses included 
a study of patients undergoing cardiac surgery, the 
results of which were consistent with those from 
the other four studies. The results of the meta-
analysis of mortality should be treated with caution 
owing to the low number of events and low overall 
number of patients in the combined totals.
One study (61 patients) compared ODM plus 
conventional assessment with CVP monitoring 
plus conventional assessment during surgery. 
Confidence intervals for differences in mortality, 
total complications and length of hospital stay 
were wide enough to include clinically important 
differences favouring either intervention.
Three studies (139 patients) compared ODM 
plus conventional assessment with conventional 
assessment during surgery. There was no evidence 
of a difference in mortality (fixed-effects OR 0.81, 
95% CI 0.23–2.77). No data were available on 
major complications. One study reported total 
complications, with fewer in the ODM group (OR 
0.23, 95% CI 0.07–0.72) but no fewer patients 
experiencing complications (OR 0.41, 95% CI 
0.14–1.16). Length of hospital stay was shorter in 
all three studies in the ODM group.
Critically ill patients
Two studies (366 patients) compared ODM plus 
CVP monitoring plus conventional assessment 
versus CVP monitoring plus conventional 
assessment. The patient groups were quite different 
(cardiac surgery and major trauma) and neither © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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study, nor a meta-analysis, showed a statistically 
significant difference in mortality (fixed-effects OR 
0.84, 95% CI 0.41–1.70). No data were available 
for major complications but fewer patients in the 
ODM group experienced complications (OR 0.49, 
95% CI 0.30–0.81) and both studies reported a 
statistically significant shorter median length of 
hospital stay in the ODM group.
No evidence was available on quality of life and 
five studies reported the outcome of ODM-related 
complications, with all stating that none occurred.
Costs
No studies reporting costs were identified. The 
addition of ODM would incur the cost of a monitor 
(approximately £10,000) which will last several 
years and typically a single disposable probe per 
patient (approximately £60–£120). In addition, 
maintenance contracts might be necessary 
(approximately £550). Apart from the few minutes 
required to insert the probe there are few other 
additional costs. Any changes in length of stay, 
complications and mortality would also affect total 
costs.
Cost-effectiveness
No economic evaluations that met inclusion 
criteria were identified from the existing literature 
and a series of balance sheets were constructed 
to highlight the choices and trade-offs that 
may exist. For ODM plus CVP monitoring plus 
conventional assessment versus CVP monitoring 
plus conventional assessment during surgery, the 
ODM strategy is likely to be more effective and the 
costs of ODM are likely to be offset by reductions 
in length of stay and complications. However, the 
cost of interventions prompted by monitoring 
(intravenous fluids and vasoactive drugs, etc.) is 
not known. For ODM plus conventional assessment 
versus conventional assessment during surgery, 
it is likely that the costs of ODM will be offset by 
the reductions in length of stay, but the overall 
differences in costs and effectiveness are unclear 
as there is insufficient evidence on mortality 
and complications. For ODM plus conventional 
assessment versus CVP monitoring plus 
conventional assessment during surgery, there is 
insufficient evidence available and where data are 
available the confidence intervals are sufficiently 
wide to cover clinically and economically important 
differences favouring either intervention. In 
critically ill patients the cost of ODM appeared 
to be compensated for by differences in length of 
stay and its use may reduce complications, but the 
effect on mortality and on the cost of interventions 
prompted by monitoring is unclear.
A partial economic modelling exercise was 
conducted for ODM plus CVP monitoring plus 
conventional clinical assessment versus CVP 
monitoring plus conventional clinical assessment 
and ODM plus conventional clinical assessment 
versus conventional clinical assessment for high-
risk surgical patients, as well as for ODM plus CVP 
monitoring plus conventional clinical assessment 
versus CVP monitoring plus conventional clinical 
assessment comparison for critically ill hospitalised 
patients. Results show that ODM strategies 
are likely to be considered cost-effective. More 
specifically, the threshold value for the extra 
cost per additional survivor that would need to 
be incurred before ODM would no longer be 
considered cost-effective was estimated. The 
required magnitude of these costs ranged from 
£581 to £11,600. However, these results are heavily 
dependent on the underlying assumptions of the 
analyses (e.g. pairwise comparisons rather than 
comparisons of all relevant methods of monitoring, 
limited number of studies, limited or non-existent 
data on relevant outcomes, small sample sizes and 
different underlying conditions).
Recommendations 
for research
Although some modest data are available and 
consideration can be given to the balance of costs 
and benefits using the data from the balance 
sheets, more formal economic evaluation would be 
desirable to make better use of the data available 
and to make valuations implicit in any decision 
more explicit. Furthermore, well-designed, 
multicentre RCTs are required among high-
risk surgical patients to address the following 
question: Does ODM-guided fluid therapy plus 
conventional clinical assessment improve outcome 
with and without CVP monitoring compared with 
conventional clinical assessment with and without 
CVP monitoring?
All the identified studies were conducted in 
unconscious patients. Newer ODM probes that 
may be tolerated by awake patients are now 
manufactured and further research is needed to 
evaluate these.Executive summary
xii
Further research is required to assess the benefits 
of ODM-guided fluid administration during 
surgery and continuing into the early postoperative 
period versus the benefits of ODM-guided fluid 
administration during surgery alone. Further 
research is also required to determine the 
optimal number of hours for ODM-guided fluid 
administration to continue after surgery once the 
patient has been admitted to a critical care facility.
Given the paucity of the existing economic 
evidence base any further primary research should 
include an economic evaluation or should provide 
data suitable for use in an economic model.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Description of 
health problem
Optimal management of cardiac output, fluid 
balance and haemodynamic status has long been 
considered key to improving outcome in critically 
ill patients and in high-risk patients undergoing 
major surgery. Traditionally, pulmonary artery 
catheters (PACs) have been used to monitor 
cardiac output and haemodynamic status to guide 
treatment. A recent Health Technology Assessment 
(HTA) Programme-funded study demonstrated 
that PAC insertion and management of critically 
ill patients using the variables monitored by PACs 
fails to confer an outcome benefit.1 Further studies 
have also cast doubt on the value of PACs in high-
risk major surgery.2 This, coupled with concerns 
related to procedural complications associated 
with the insertion and use of the PAC, along with 
the development of less invasive cardiac output 
monitors in clinical practice, has resulted in a 
global decline in the usage of the PAC in recent 
years.
Less invasive technologies to monitor cardiac 
output and other haemodynamic variables 
include oesophageal Doppler monitoring (ODM), 
transoesophageal echocardiography, transthoracic 
impedance, carbon dioxide elimination and 
systems based upon pulse contour analysis and dye 
dilution methods.
Oesophageal Doppler monitoring measures blood 
flow velocity in the descending thoracic aorta 
using a flexible probe inserted into the patient’s 
oesophagus with an ultrasound transducer at its 
tip. The information is combined with an estimate 
of aortic cross-sectional area (derived from a 
nomogram based on the patient’s age, height 
and weight) and an estimate of the fraction of the 
cardiac output perfusing the upper body, allowing 
continuous monitoring of cardiac output and 
haemodynamic status. ODM is a relatively simple 
procedure requiring no calibration and minimal 
training and has a good safety profile. The probe 
itself is uncomfortable and often poorly tolerated 
by awake patients, therefore patients monitored 
with ODM generally need to be adequately sedated 
or anaesthetised. While this is often undertaken in 
patients requiring such monitoring, it does tend to 
limit the use of the probes to an operating theatre, 
high dependency unit (HDU) or intensive care unit 
(ICU) environment. Newer, softer probes designed 
to be tolerated in awake patients have been 
developed, but at present are not widely available.
Although described as continuously monitoring, 
the ODM probes often need to be refocused prior 
to each measurement, so they are normally used to 
make frequent, repeated measurements rather than 
to provide a beat-by-beat measure of stroke volume.
Transoesophageal echocardiography allows direct 
assessment of the heart’s structure and function. 
It can also be used to derive cardiac output by 
measuring the Doppler shift in the reflected 
ultrasound beam to determine blood velocity and 
by direct measurement of the cross-sectional area of 
the aorta. It has several limitations as a technique: 
the probe is large and expensive; patients require 
considerable amounts of sedation or an anaesthetic 
to tolerate it; and a highly-skilled, highly-trained 
operator is required to operate the probe, as 
without one continuous monitoring of cardiac 
function is impossible.
Pulse contour analysis devices employ algorithms 
to calculate cardiac output from analysis of the 
arterial pressure/time waveform, and so require 
the presence of an indwelling arterial catheter 
(often present anyway in the targeted populations). 
There are several types of device available, but all 
require initial calibration with another measure of 
cardiac output which may be by means of either 
a transpulmonary thermodilution or lithium 
dilution technique. Systems using thermodilution 
to calibrate also require the presence of a central 
venous catheter, with its associated hazards. While 
lithium dilution calibration does not require 
the presence of a central venous catheter, the 
lithium used to calibrate the system can interact 
with muscle relaxant drugs used in anaesthesia. 
Therefore, care needs to be taken regarding 
timing of calibration. Pulse contour devices, while 
requiring calibration and taking slightly longer to 
set up than ODM, do have the advantage that they 
can be tolerated by awake patients.
Chapter 1  
BackgroundBackground
2
Proponents of the use of cardiac output monitoring 
to guide fluid replacement and pharmacological 
treatment suggest this allows optimisation of 
the patient’s haemodynamic status, helping to 
maintain adequate tissue perfusion. This, in 
turn, prevents overt or occult organ damage 
which hinders the patient’s recovery. Thus, 
monitoring has the potential to reduce mortality, 
complications, lengths of stay in critical care 
facilities and overall hospital stays, all of which 
could result in savings in health-care costs.
Approximately 3 million surgical operations are 
conducted in the UK annually, with an overall 
hospital mortality rate of 0.8–1.0%.3 The National 
Confidential Enquiry into Patient Outcome and 
Deaths (NCEPOD) reports that there were over 
20,000 deaths following surgery in England, Wales 
and Northern Ireland alone in 2003.4 Therefore, 
any improvement in morbidity and mortality for 
these patient groups would markedly improve 
important patient outcomes for large groups 
of patients as well as significantly improving 
utilisation of health-care resources.
Current service provision
In the NHS, variation in practice exists with 
regard to haemodynamic optimisation and patient 
monitoring during the perioperative period and 
in critical care environments. Inevitably, the lack 
of published national guidelines or frameworks in 
this area contributes to these differences. The only 
published statement from the National Institute 
for Health and Clinical Excellence (NICE) with 
regard to ODM to date has been as part of NICE’s 
Interventional Procedures (IP) Programme, relating 
only to safety and efficacy.5 ODM was not felt to fall 
within the IP Programme’s remit as it is considered 
standard clinical practice with risks and benefits 
that are sufficiently well known.
Within the NHS the ODM that is most widely 
used is the CardioQ device (Deltex Medical, 
Chichester, UK). There are CardioQ monitors in 
around two-thirds of the 300 or so NHS hospitals 
that regularly undertake moderate or major 
surgery within the UK. The probes are single 
use, and several types exist which can be used to 
monitor for periods of from 6 hours to 10 days. 
Currently the CardioQ is used to monitor around 
25,000 patients each year within the NHS. While 
it is difficult to state accurately the categories of 
patients in whom the ODM probes are being used, 
information from the manufacturer suggests that 
approximately one-third are used in intensive 
care, one-third intraoperatively (theatre only) and 
one-third throughout the perioperative period 
(although given the large number of potential 
patients their use overall remains infrequent).
Given the large number of operations carried out 
within the NHS each year (in excess of 2 million) 
and the relatively small number of cardiac output 
monitors, many patients receive what might be 
termed conventional clinical assessment. The 
recent Agency for Health Care Research and 
Quality (ARHQ) report6 defined this as follows:
Conventional clinical assessment usually 
refers to non-invasive assessment of various 
clinical markers. In some institutions, fluid 
management may be based only on assessment 
of hemodynamic variables such as heart rate, 
systolic blood pressure and urinary output, with 
no measure of blood flow or CVP.
Such a definition would seem to be applicable to 
the NHS (although considerable variation in actual 
practice throughout the NHS might be expected).
Description of technology 
under assessment
Oesophageal Doppler monitoring was first 
described by Side and Gosling in the early 1970s 
and since then there have been significant advances 
in the technology and its clinical use. ODM is 
currently used in a variety of clinical settings, 
most commonly in critical care environments 
and in patients undergoing surgery (particularly 
patients with significant co-morbidity or those 
undergoing major surgery with a high incidence 
of blood loss and/or significant fluid shifts.) 
ODM allows continuous monitoring of a patient’s 
haemodynamic variables and, more importantly, 
allows the display of trends in these variables. This 
allows the clinician to titrate intravenous fluids 
and inotropic drugs to optimise tissue perfusion 
and oxygen delivery. The length of time this 
monitoring is required depends on the individual 
clinical situation. Upon completion of ODM the 
probe is simply removed.
The procedure measures blood velocity in the 
descending thoracic aorta using a flexible probe 
inserted into the patient’s oesophagus via the 
mouth or nose. The tip of the probe contains a 
transducer which transmits an ultrasound beam. 
The tip is advanced to mid-thoracic level and © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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rotated to direct the ultrasound beam towards the 
descending aorta, allowing measurement of blood 
velocity using the Doppler frequency shift in the 
reflected ultrasound. This information is combined 
with an estimate of aortic cross-sectional area 
(derived from a nomogram based on the patient’s 
age, height and weight) and upper body blood 
flow, allowing haemodynamic variables such as 
cardiac output, stroke volume and systolic flow time 
to be continuously measured. In addition, if other 
variables such as central venous pressure (CVP) and 
blood pressure are known, derived variables such as 
systemic vascular resistance can be calculated.
The probe and monitor are simple to use, and a 
period of training in groups of no more than 12 
patients has been shown to be sufficient to ensure 
reliable measurements of cardiac output.7 Generally 
speaking, the probe can be inserted and a clear 
signal can be obtained within a few minutes.
Oesophageal Doppler monitoring has been shown 
to have a high validity (no bias and high clinical 
agreement) for monitoring changes in cardiac 
output during the management of critically ill 
patients in both operating rooms and ICUs.8 Good 
correlation also exists when comparing cardiac 
output measurements derived from ODM and 
PACs by means of thermodilution.7,9–11
Contraindications to insertion of ODM probes 
include patients under 16 years of age (special 
alternative probes and equipment are necessary 
for these patients), severe bleeding diathesis, facial 
trauma, oesophageal abnormalities such as varices, 
stents, strictures, carcinoma or oesophagitis and 
recent oesophageal or upper airway surgery. The 
presence of arrhythmias, severe aortic valve disease 
or a thoracic aortic aneurysm or the use of an intra-
aortic balloon counterpulsation device, while not 
absolute contraindications to inserting the probe, 
may lead to difficulty in obtaining an accurate 
waveform and meaningful information.
Care needs to be taken in interpreting the data 
in certain other clinical situations as ODM makes 
the assumption that a constant proportion of the 
cardiac output enters the descending aorta, which 
is not always the case. Redistribution of blood flow 
between the ascending and descending aorta may 
occur during cross clamping of the aorta and with 
acute haemorrhage, where more of the cardiac 
output may be selectively diverted to coronary and 
cerebral circulation as opposed to the descending 
aorta. In addition, the presence of a sympathetic 
block to the lower body (such as that caused by 
epidural or spinal anaesthesia/analgesia) may lead 
to an overestimation of cardiac output.
Although there are no reported major 
complications resulting directly from the use 
of the ODM probe, a small number of minor 
complications have been reported in the literature, 
such as minor oral trauma and inadvertent tracheal 
placement of the probe.6© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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A
s stated in Chapter 1, optimal management of 
cardiac output and haemodynamic status have 
long been considered key to improving outcome 
in critically ill patients and in high-risk patients 
undergoing major surgery. Currently, there are no 
universally accepted guidelines on how to select 
patients requiring cardiac output monitoring either 
perioperatively or in a critical care environment. 
Practice varies within the NHS because of a 
number of variables, notably individual clinician 
preferences, patient characteristics and local 
practices, guidelines or protocols.
Aim and objectives 
of this review
Given this uncertainty about the role of cardiac 
output monitoring, the aim of this review was to 
assess the effectiveness and cost-effectiveness of one 
particular type of monitoring, ODM, when used 
for monitoring cardiac function in comparison with 
(a) standard care (i.e. no cardiac output monitor 
perioperatively) among critically ill patients and 
patients undergoing major surgery, and (b) other 
methods of monitoring heart function (such as PAC 
or pulse contour monitoring devices) in critically ill 
patients or in patients undergoing major surgery.
As described in subsequent chapters, the analysis 
focused on outcomes of most importance to 
patients (e.g. mortality, length of hospitalisation, 
length of stay in critical care and complication 
rates). Cost-effectiveness was assessed from the 
perspective of the NHS and personal social 
services.
In the following two sections, the place of cardiac 
output monitoring in the pathways of care of both 
patients undergoing major surgery and critically ill 
patients is briefly described.
Use of cardiac output 
monitoring among patients 
undergoing major surgery
Cardiac output monitoring systems are used in 
operating theatres across all the major surgical 
specialties. They tend to be used predominantly 
for surgery of moderate to major severity, often 
in patients with significant co-morbidity or 
where significant blood loss or fluid shifts may 
be anticipated, as a consequence of either the 
patient’s underlying condition or their anticipated 
surgery. However, not every patient undergoing 
major surgery will need to have their cardiac 
output monitored; generally they will be assessed 
preoperatively and the need for cardiac output 
monitoring will be determined by the anaesthetist 
based upon the clinical assessment, taking into 
account surgical factors and patient factors 
including co-morbidities (Figures 1 and 2). The 
anaesthetist may also be guided by the results 
of preoperative cardiac testing such as stress 
echocardiography or radionuclide cardiography 
(such tests are likely to be performed regardless of 
whether the use of ODM is an option).12 Although 
the decision to use cardiac output monitoring 
is usually made preoperatively, occasionally 
factors encountered during surgery may lead 
to a decision to adopt monitoring during the 
intraoperative period, and this may continue into 
the postoperative period. Monitoring of surgical 
patients typically finishes at the end of the surgery.
Use of cardiac output 
monitoring among 
critically ill patients
Patients requiring treatment in an ICU (level 3 
care) or an HDU (level 2 care), by definition, need 
a higher level of care and monitoring than that 
available in general wards (level 1 care) (based on 
the Department of Health classification system). 
The decision to utilise these higher levels of care 
may be affected by a number of factors including 
patients’ underlying surgical condition, their co-
morbidities and the nature of surgery performed. 
In these complicated patients, haemodynamic 
function is frequently disturbed owing to a 
combination of the patient’s existing disease(s) 
interacting with acute haemodynamic instability 
caused by surgery, anaesthesia, acute blood loss 
and fluid shifts. These complex interactions 
are not always apparent or easily interpretable 
using conventional clinical assessment and 
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Patient
characteristics
Haemodynamic status
(e.g. blood loss and
body fluid instability)
Underlying
disease/condition
Surgery-
related factors
Patient
assessment
FIGURE 1  Pre-surgery assessment of patient.
Patient
assessment
No monitoring
device needed
PAC
ODM
Pulse contour:
LiDCO
Pulse contour:
PICCO
Monitoring
device needed
Will follow with
conventional
clinical assessment
Conventional clinical
assessment only
Conventional clinical
assessment +
monitoring device
FIGURE 2  Decision regarding use of cardiac output monitoring system.
monitoring alone. In such patients, in addition 
to helping to guide and monitor operative 
fluid therapy, haemodynamic monitoring may 
also assist in differentiating between varying 
aetiologies of haemodynamic instability including 
hypovolaemia, sepsis and cardiogenic causes of 
tissue hypoperfusion or shock. This is important 
as the treatment for each of these pathologies is 
different. Among critically ill patients, monitoring 
would typically continue until there is a resolution 
of cardiovascular instability, which will be based on 
a broader clinical assessment.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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n March 2007, a report conducted by the 
Emergency Care Research Institute (ECRI) 
Evidence-based Practice Center and commissioned 
by the US Agency for Healthcare Research and 
Quality (AHRQ) on behalf of the Centers for 
Medicare & Medicaid Services was identified. 
This report included a systematic review of ODM 
in patients during and/or after surgery, and 
reported patient-based outcomes that were similar 
to those included in the protocol for this review 
prepared by the Aberdeen Technology Assessment 
Review (TAR) group (see Appendix 1). Following 
discussion with the National Co-ordinating Centre 
for Health Technology Assessment (NCCHTA) it 
was agreed that the Aberdeen TAR group should 
base its review on the evidence contained in 
the AHRQ report, should it be judged to be of 
sufficiently high quality, supplemented by evidence 
from any additional studies identified.
The AHRQ report addressed the following four key 
questions:
What types of devices/techniques are currently  1. 
used to assess cardiac output?
Does therapeutic management based on  2. 
ODM during surgery lead to improved patient 
outcomes (fewer complications and shorter 
hospital stay)?
Does therapeutic management based on ODM  3. 
during hospitalisation (defined hereafter as 
the use of ODM among critically ill patients) 
lead to improved patient outcomes (fewer 
complications and shorter hospital stay)?
What complications, harms and adverse events  4. 
associated with ODM have been reported?
The comparators for key questions 2 and 3 were:
PAC-based measurement of cardiac output  •	
using thermodilution
Catheter-based measurement of CVP •	
Conventional clinical assessment (physical  •	
examination, fluid input and output 
measurements).
This review focuses on the evidence presented 
in the AHRQ report, key questions 2 and 3. 
Definitions of the interventions are as described in 
the AHRQ report.6
The AHRQ report was critically appraised 
using the Database of Abstracts of Reviews of 
Effectiveness (DARE) criteria (see Appendix 2 for 
the appraisal of the AHRQ report, including details 
of inclusion and exclusion criteria, search strategy, 
data extraction and quality assessment strategy, 
methods, results and conclusions).
Methods for reviewing 
effectiveness (Aberdeen 
TAR group)
Search strategy
The search strategy involved the searching 
of electronic databases and relevant websites, 
contact with experts in the field and the scrutiny 
of bibliographies of retrieved papers. Extensive 
electronic searches were conducted to identify 
reports of published and ongoing studies on 
the clinical effectiveness of ODM. Searches were 
carried out for full text papers reporting on RCTs. 
The databases searched, from 1990 onwards, 
were: MEDLINE (1990–May week 3 2007), 
MEDLINE In-Process (23 May 2007), EMBASE 
(1990– 2007 week 20), CINAHL (1990–May 
week 2 2007), Science Citation Index (1990–20 
May 2007), BIOSIS (1990–17 May 2007) and 
Cochrane Controlled Trials Register (Cochrane 
Library, Issue 2 2007) as well as current research 
registers [National Research Register (Issue 2 
2007), Current Controlled Trials (May 2007) and 
Clinical Trials (May 2007)]. Additional databases 
searched for systematic reviews and other 
background information included the Cochrane 
Database of Systematic Reviews (Cochrane Library, 
Issue 2 2007), DARE (May 2007) and the HTA 
Database (May 2007). Websites of both professional 
organisations (including Anaesthesia UK, Critical 
Care, Intensive Care Society, International 
Collaboration for Excellence in Critical Care 
Medicine) and manufacturers (Deltex Medical, 
Arrow International) were also searched. Full 
details of the search strategies used and websites 
consulted are documented in Appendix 3.
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Inclusion and exclusion criteria
Types of study
The types of study considered were randomised 
controlled trials (RCTs) and systematic reviews of 
such evidence.
The following types of study were excluded:
non-randomised studies •	
studies in which ODM was used as a measure of  •	
study outcome rather than as a monitoring tool 
leading to a clinical intervention
non-English language studies •	
animal models •	
pre-clinical and biological studies •	
narrative reviews, editorials and opinions •	
reports published as meeting abstracts only. •	
Types of intervention
The intervention considered was ODM.
Types of comparator
Comparator interventions considered were:
no cardiac output monitoring •	
pulmonary artery catheters •	
pulse contour analysis cardiac output  •	
monitoring
lithium dilution cardiac output monitors, i.e.  •	
LiDCO monitor (LiDCO Group, London, 
UK)
thermodilution cardiac output monitors, i.e.  •	
PiCCO® monitor (PULSION Medical Systems, 
Munich, Germany).
Types of participant
The types of participant considered comprised:
adults during major surgery •	
adults managed in critical care facilities who  •	
required cardiac output monitoring.
The following subgroup analysis was considered 
in the event that sufficient evidence was available: 
patients with sepsis compared with those without 
sepsis.
Types of outcome
The following patient-related outcomes were 
considered:
mortality (30-day; hospital; longer-term) •	
length of stay [critical care (ICU, HDU);  •	
hospital]
days of organ support in the ICU •	
postoperative complications and morbidity  •	
such as cardiac events and organ system 
failures
quality of life in the year after surgery. •	
Length of hospital stay was defined as time from 
admission to discharge or death, and length of stay 
in critical care was defined as time from admission 
to critical care until discharge from critical care or 
death in a critical care facility.
Data extraction strategy
One reviewer screened the titles (and abstracts if 
available) of all reports identified by the search 
strategy. Full text copies of all studies thought to 
be potentially relevant were obtained and one 
reviewer assessed them for inclusion. In the event 
of any uncertainty a second reviewer was consulted. 
Any disagreements were resolved by arbitration by 
a third party.
Data were extracted by one reviewer. Information 
was recorded on: year of publication; source of 
funding; study design; methods pre-randomisation 
(e.g. stratification); method of randomisation; 
concealment of allocation; blinding procedures; 
number and characteristics of participants; 
duration of interventions; choice of outcome 
measures; and length of follow-up. Reviewers were 
not blinded to authors, institutions or publications. 
Where there was deemed to be insufficient 
information in the published report, the authors 
were not contacted owing to the time constraints 
involved.
Quality assessment strategy
The methodological quality of RCTs included 
in the review was to be assessed using the 
Delphi criteria list, adapted from Verhagen and 
colleagues.13 However, in order to be consistent 
with the approach taken by the AHRQ report, 
the methodological quality of the two additional 
studies that were identified was appraised using the 
ECRI 25-question quality scale (see Appendix 4). 
ECRI used these 25 items to compute a summary 
score ranging from 0 to 10, with 10 indicating an 
ideal study and 0 indicating a study of the poorest 
quality. Individual item answers were converted 
to numerical scores by allocating 1 for each ‘Yes’ 
answer, −1 for each ‘No’ answer and −0.5 for each 
item that was not reported. The numerical scores 
for all 25 items were then added, 25 was added 
to the total, and this number was then divided by 
50 and then multiplied by 10. These calculations © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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resulted in the 0–10 summary scale. Studies that 
scored < 5 were considered unacceptable quality, 
> 5 but ≤ 6.7 were considered low quality, > 6.7 but 
≤ 8.4 were considered moderate quality, and ≥ 8.5 
were considered high quality.6
The methodological quality of the AHRQ report 
(key questions 2 and 3) was assessed using a 
previously validated 10-item checklist developed 
by Oxman and Guyatt (see Appendix 5).14,15 This 
checklist contained nine criteria, checked as ‘Yes’, 
‘Partially’ or ‘No’ depending on the extent to which 
they had been met. There was also one summary 
criterion for overall scientific quality, scored on a 
scale of 1–7, with 1 indicating ‘extensive flaws’ and 
7 indicating ‘minimal flaws’.
Data analysis
For trials with multiple publications, only the most 
up-to-date or complete data for each outcome 
were included. Where appropriate, meta-analysis 
was employed to estimate a summary measure of 
effect on relevant outcomes based on intention-to-
treat analyses. It was originally planned to combine 
dichotomous outcome data using the Mantel–
Haenszel relative risk (RR) method. However, to be 
consistent with the approach taken by the AHRQ 
report, dichotomous data were combined instead 
using odds ratios (ORs). When trials had roughly 
equal numbers of participants in each group and 
events were rare the Peto OR method was used. 
Continuous outcomes were combined using the 
inverse variance weighted mean difference (WMD) 
method. For the estimates of RR and WMD, 95% 
CIs and p-values were calculated. The results 
were reported using a fixed-effects model. Chi-
squared tests and I2 statistics were used to explore 
statistical heterogeneity across studies. Possible 
reasons for heterogeneity were explored using 
sensitivity analysis. Where there was no clear reason 
for heterogeneity, the implications were explored 
using random effects methods. All meta-analyses 
were undertaken using Review Manager (RevMan) 
software. Where a quantitative synthesis was 
considered to be inappropriate or not feasible, a 
narrative synthesis of results was provided. Where a 
lack of uniformity of the data was present in many 
studies, a qualitative review looking for consistency 
between studies was performed. This was 
supplemented, where appropriate, by investigation 
of the consistency in the direction of the results 
using the Sign test.16
Results
Number of studies identified
The results of the searches are summarised in 
Table 1 and Figure 3. The numbers retrieved from 
the searches in CINAHL, Science Citation Index 
(SCI), BIOSIS and CENTRAL include only the 
additional reports found after excluding those 
identified from the MEDLINE/EMBASE multifile 
search. A total of 663 reports were identified, of 
which 42 were selected for full assessment. As well 
TABLE 1  Search results
Database Number retrieved Number selected for assessment
MEDLINE/EMBASE/MEDLINE In Process multifile search 
(after deduplication in Ovid)
444 15
CINAHL 4 0
SCI 69 6
BIOSIS 74 2
CENTRAL 15 5
National Research Register 32 8
Current Controlled Trials 10 2
Clinical Trials 1 1
DARE 5 2
HTA Database 6 0
Cochrane Database of Systematic Reviews 3 1
Total retrieved 663 42Effectiveness
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FIGURE 3  Flow diagram outlining the screening process.
11 reports included:
1 systematic review
(AHRQ report)
8 studies already included
in systematic review
2 additional studies
42 selected for
full assessment
663 reports identified
for screening
621 excluded
12 retained for
background information
19 reports excluded
as the AHRQ review,6 10 reports met inclusion 
criteria; eight of which had already been identified 
in the AHRQ review.
Number and type of 
included studies
The AHRQ report6 included eight RCTs.17–24 Two 
additional RCTs were identified.25,26
Number and type of 
excluded studies
A list of potentially relevant studies identified by 
the search strategy, for which full text papers were 
obtained but which subsequently failed to meet 
the inclusion criteria, is given in Appendix 6. 
These studies were excluded because they failed 
to meet one or more of the inclusion criteria in 
terms of types of study, participant, intervention or 
outcome.
Characteristics of the 
included studies
The characteristics of the included studies are 
summarised in Table 2 and the algorithms used to 
determine clinical responses are summarised in 
Appendix 7.
AHRQ report
Eight RCTs17–24 involving 757 patients were 
included that assessed the use of ODM either 
during surgery or among critically ill patients 
and reported patient-based outcomes. Seven 
studies17,18,20–24 assessed ODM during surgery. 
The types of surgery performed included elective 
bowel surgery,17,21,24 hip fracture repair surgery,22,23 
or elective general, urological or gynaecological 
surgery.18 One study considered the use of ODM 
during elective cardiac surgery,20 which might 
be considered separate from the other types 
of surgery. A further study by McKendry and 
colleagues19 considered the use of ODM following 
surgery and compared ODM plus CVP monitoring 
plus conventional assessment with CVP monitoring 
plus conventional assessment in 174 patients 
admitted to cardiac intensive care following cardiac 
surgery.
Seven studies used the CardioQ ODM system 
(Deltex Medical Ltd, UK) or an earlier model while 
Conway and colleagues17 used the TECO™ system 
(Medicina Ltd, UK), although the latter is no 
longer commercially available.
Additional studies
Appendix 8 summarises the characteristics and 
results of the two additional studies that were 
identified. Dodd and colleagues26 assessed the use 
of ODM (CardioQ) during surgery, comparing 
ODM plus conventional assessment with 
conventional assessment in 40 patients undergoing 
colorectal surgery. Chytra and colleagues25 assessed 
the use of ODM (HemoSonic™ 100, Arrow 
International Inc., USA) in 162 multiple-trauma 
patients with major blood loss and compared ODM 
plus CVP monitoring plus conventional clinical 
assessment with CVP monitoring plus conventional 
clinical assessment in these patients.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 2  Characteristics of the included studiesa
AHRQ report Additional studies Total
Number of studies 8 2 10
Number of patients 757 202 959
Age [years (range of 
means/medians)]
ODM group: 56–82;  
control group: 59–85
ODM group: 33–76;  
control group: 40–76
ODM: 33–82; 
control: 40–85
Sex Male: 258 (52%);  
female: 234 (48%); NR: 265
Male: 163 (81%);  
female: 39 (19%); NR: 0
Male: 421 (61%);  
female: 273 (39%);  
NR: 265
System used CardioQ (7 studies);  
TECO (1 study)
CardioQ (1 study);  
HemoSonic 100 (1 study)
CardioQ: 8 studies; 
TECO: 1 study; 
HemoSonic 100: 1 study
Comparisons
During surgery ODM + CVP + conventional 
assessment vs CVP + 
conventional assessment 
(5 studies; 453 patients)
5 studies; 453 patients
ODM + conventional assessment 
vs CVP + conventional 
assessment (1 study; 61 patients)
1 study; 61 patients
ODM + conventional assessment 
vs conventional assessment 
(2 studies; 99 patients) 
ODM + conventional assessment 
vs conventional assessment 
(1 study; 40 patients)
3 studies; 139 patients
In critically ill patients ODM + CVP + conventional 
assessment vs CVP + 
conventional assessment 
(1 study; 174 patients)
ODM + CVP + conventional 
assessment vs CVP + 
conventional assessment (1 study; 
162 patients)
2 studies; 336 patients
Type of surgery Elective bowel surgery 
(3 studies; 293 patients)
3 studies; 293 patients
Hip fracture repair surgery 
(2 studies; 130 patients)
2 studies; 130 patients
Elective cardiac surgery 
(1 study; 60 patients)
1 study; 60 patients
Elective general, urological 
or gynaecological surgery 
(1 study; 100 patients)
1 study; 100 patients
Colorectal surgery 
(1 study; 40 patients)
1 study; 40 patients
NR, not reported.
a  The study by Venn and colleagues23 reported two comparisons, and hence the ODM group appears twice. This study 
compared ODM plus conventional assessment (n = 30) vs CVP plus conventional assessment (n = 31) vs conventional 
assessment (n = 29).
Quality of the included studies
Table 3 summarises the quality assessment results 
for the studies included in the AHRQ report and 
for the two additional studies identified.
AHRQ report
For ODM during surgery, the five studies 
comparing ODM plus CVP monitoring plus 
conventional clinical assessment with CVP 
monitoring plus conventional clinical assessment 
had a median quality score of 8.9 (range 8.1–9.7) 
on the ECRI quality scale. This equates to a 
quality rating of ‘high’. The two studies comparing 
ODM plus conventional clinical assessment with 
conventional clinical assessment had a median 
quality score of 9.0 (range 8.9–9.0). This also 
equates to a quality rating of ‘high’. One of these 
studies23 also compared ODM plus conventional Effectiveness
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TABLE 3  Summary of quality assessment results for studies included in the AHRQ report and the two additional studies identifieda
AHRQ report Additional studies
Comparison
Number of 
studies
Median 
quality score 
(range)
Number of 
studies Quality score
ODM during 
surgery
ODM + CVP + conventional clinical 
assessment vs CVP + conventional 
clinical assessment
5 8.9 (8.1–9.7) 0 NA
ODM + conventional clinical 
assessment vs CVP + conventional 
clinical assessment
1 9.0 0 NA
ODM + conventional clinical 
assessment vs conventional clinical 
assessment
2 9.0 (8.9–9.0) 1 8.8
ODM in 
critically ill 
patients
ODM + CVP + conventional 
assessment vs CVP + conventional 
assessment
1 8.5 1 7.4
NA, not applicable.
a  The study by Venn and colleagues23 appears twice in the table as it compared ODM plus conventional clinical assessment 
vs CVP plus conventional clinical assessment vs conventional clinical assessment.
clinical assessment with CVP monitoring plus 
conventional clinical assessment. For ODM use 
postoperatively among  patients cared for in a 
cardiac care unit, McKendry and colleagues19 
compared ODM plus CVP monitoring plus 
conventional assessment with CVP monitoring 
plus conventional assessment, and their study had 
a quality score of 8.5, again equating to a quality 
rating of ‘high’.
In terms of the individual studies’ ratings against 
each of the 25 questions on the ECRI quality 
scale, for 17 of the questions all eight studies were 
checked ‘Yes’. Table 4 shows the questions which 
were checked ‘No’ or not reported (‘NR’) and in 
which studies this occurred. 
Additional studies
For ODM during surgery, the study by Dodd 
and colleagues,26 which compared ODM plus 
conventional clinical assessment with conventional 
clinical assessment, had a quality score of 8.8 on 
the ECRI quality scale – a quality rating of ‘high’. 
For ODM use postoperatively, the study by Chytra 
and colleagues,25 which compared ODM plus CVP 
monitoring plus conventional clinical assessment 
with CVP monitoring plus conventional clinical 
assessment, had a quality score of 7.4 – a quality 
rating of ‘moderate’. The ECRI quality scale with 
the results for the two additional studies and an 
explanation of how the summary scores were 
calculated and categorised is given in Appendix 4.
In terms of the individual studies’ rating against 
each of the 25 questions on the ECRI quality scale, 
for 18 of the questions both studies were checked 
‘Yes’. Table 4 shows the questions that were checked 
‘No’ or ‘Not reported’ (NR) and in which studies 
this occurred.
Methodological quality 
of the AHRQ report
The methodological quality of the AHRQ report 
was assessed using the Oxman and Guyatt 
checklist14,15 (see Appendix 5). This checklist 
contained nine criteria, checked as ‘Yes’ (the 
optimal answer), ‘Partially’ or ‘No’ depending 
on the extent to which they had been met. Six 
of the nine items were checked ‘Yes’, including 
whether the search methods were stated, whether 
the inclusion criteria were reported, whether 
the criteria used for assessing the validity of the 
included studies were reported, whether the 
validity of the included studies was assessed using 
appropriate criteria, whether the methods used to 
combine the findings of the studies were reported, 
and whether the authors’ conclusions supported 
the data and/or the analysis reported in the review 
(although recommendations for further research 
were not provided).
Three items were checked as having been partially 
met, including whether the search for evidence was 
reasonably comprehensive (non-English language © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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studies were excluded), whether bias was avoided 
in the selection of articles (the number of reviewers 
who screened full text articles for inclusion was not 
stated) and whether the findings of the relevant 
studies were combined appropriately relative 
to the primary question (the participants were 
not considered homogeneous across studies as 
they were undergoing different types of surgery, 
although all involved procedures anticipating 
a major loss of blood or significant fluid shifts 
requiring fluid replacement; it was not stated how 
unit of analysis errors would be handled).
The AHRQ report scored 5 (minor bias) on the 
10th item, a summary criterion for overall scientific 
quality on a scale of 1 (extensive flaws) to 7 
(minimal flaws).
Assessment of effectiveness
ODM during surgery
ODM plus CVP plus conventional 
clinical assessment versus CVP plus 
conventional clinical assessment
The only data available for this comparison came 
from the AHRQ report, from five studies involving 
453 patients. The type of surgery performed 
included elective bowel surgery,17,21,24 elective 
cardiac surgery20 and elective general, urological or 
gynaecological surgery.18
Mortality
All five studies reported that no deaths occurred 
during surgery in either the ODM or the control 
group. Three studies17,20,21 reported one death each 
in the control group (1/28; 1/30; 1/52, respectively) 
within 30 days following surgery, and one study24 
reported one death in the control group (1/64) 
within 60 days following surgery. However, the 
AHRQ report stated that the between-group 
differences were not statistically significant.
Figure 4 shows a meta-analysis (Peto method) 
undertaken by the Aberdeen group of the five 
studies reporting mortality. This shows that ODM 
was associated with statistically significantly fewer 
deaths compared with control (OR 0.13, 95% CI 
0.02–0.96). In this analysis the study by Mythen 
and colleagues,20 which investigated elective cardiac 
surgery patients, has also been included and, even 
though the study is small, it exhibits a similar 
trend to that observed in the other studies. The 
meta-analysis results should be interpreted with 
caution because of the low number of events and 
the overall low number of patients in the combined 
totals.
Major complications
Three of five studies reported major 
complications,17,20,21 which were generally defined 
as life threatening or requiring intensive or high-
dependency care. The type of complications 
reported included severe tachyarrhythmias17 and 
chest infection, multiple organ failure, respiratory 
failure, cerebrovascular accident and paralytic 
ileus.20 All three studies showed a statistically 
significant difference in major complications 
that favoured the ODM groups (all of the major 
Review:  Oesophageal Doppler monitoring
Comparison:  ODM + CVP + conventional assessment vs CVP + conventional assessment
Outcome:  Mortality
Study or 
subcategory
ODM
n/N
Control
n/N
Peto OR
95% CI
Weight
%
Peto OR
95% CI Order
Gan, 2002
18 0/50 0/50 Not estimable0
Conway, 2002
17 0/29 1/28 24.99 0.13 (0.00–6.59)0
Mythen, 1995
20 0/30 1/30 25.00 0.14 (0.00–6.82)0
Noblett, 2006
21 0/51 1/52 25.00 0.14 (0.00–6.95)0
Wakeling, 2005
24 0/64 1/64 25.00 0.14 (0.00–6.82)0
Total (95% CI) 224 224 100.00 0.13 (0.02–0.96)
Total events: 0 (ODM),4(Control)
Test for heterogeneity: χ
2 = 0.00, df = 3( p = 1.00), I
2 = 0%
Test for overall effect: z = 2.00 (p = 0.05)
 0.01  0.1  1  10  100
Favours ODMF avours control
FIGURE 4  Meta-analysis of studies reporting mortality (Aberdeen TAR group).© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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complications occurred in the control groups). The 
AHRQ report stated that the ORs [Peto method; 
(95% CI)] for the three studies were −2.08 (−3.72 
to −0.44),21 −2.19 (−4.01 to −0.37)17 and −2.19 
(−3.86 to −0.51).20 Although a meta-analysis was 
undertaken, the AHRQ report did not present a 
pooled estimate of effect size on the grounds that 
only three of the five studies (i.e. less than 80%) 
reported separate data on major complications. 
The 95% CI around the pooled estimate was 
0.04–0.31, indicating that ODM was associated with 
statistically significantly fewer major complications.
Figure 5 shows a meta-analysis (Peto method) 
undertaken by the Aberdeen group of the three 
studies reporting major complications, with 
the pooled estimate showing that ODM was 
associated with statistically significantly fewer major 
complications (OR 0.12, 95% CI 0.04–0.31). It is 
again worth noting that the data relating to use of 
ODM in cardiac surgery patients20 are similar to 
those from the other studies reporting outcomes 
conducted on non-cardiac patients.
Total complications
Four studies reported total complications.17,18,21,24 
The AHRQ report stated that two studies showed 
a statistically significant difference, indicating 
fewer total complications in the ODM group 
(OR 0.23, 95% CI 0.10–0.54;18 OR 0.41, 95% CI 
0.20–0.8424). The other two studies also showed 
fewer complications in the ODM group, without 
reaching statistical significance (OR 0.44, 95% CI 
0.13–1.54;17 OR 0.47, 95% CI 0.20–1.0721). Gan 
and colleagues18 reported the total number of 
complications rather than the number of patients 
with complications. Although a random-effects 
meta-analysis was undertaken, the AHRQ report 
did not present a pooled estimate of effect on the 
grounds that the studies reported complications 
somewhat differently (patients versus events). The 
95% CI around the pooled estimate was −1.43 to 
−0.57, indicating that ODM was associated with 
statistically significantly fewer total complications.
Figure 6 shows a meta-analysis undertaken by 
the Aberdeen group of the three studies that 
reported the number of patients in each group who 
experienced complications. The pooled estimate 
shows that ODM was associated with statistically 
significantly fewer total complications (OR 0.43, 
95% CI 0.26–0.71).
Length of hospital stay
All five studies reported this outcome. The 
AHRQ report stated that four studies reported a 
statistically significant reduction in length of stay 
(based on either medians or means) associated with 
ODM, with a median of 6 versus 7 days, p = 0.03;18 
7 (IQR 3–35) versus 9 (IQR 4–45) days, p = 0.005;21 
10 (IQR 5.75) versus 11.5 (IQR 4.75) days, 
p = 0.03;24 and a mean of 6.4 (range 5–9) versus 
10.1 (range 5–48) days, p = 0.01.20 The fifth study, 
by Conway and colleagues,17 reported a median of 
12 (range 7–103) days for the ODM group versus 
11 (range 7–30) days for the control group (p-value 
not reported). Table 5 shows the length of hospital 
stay for the five studies.
The AHRQ used a conservative method to impute 
effect sizes from the median, range and sample 
size when possible and conducted a random-effects 
Review:  Oesophageal Doppler monitoring
Comparison:  ODM + CVP + conventional assessment vs CVP + conventional assessment
Outcome:  Major complications
Study or 
subcategory
ODM
n/N
Control
n/N
Peto OR
95% CI
Weight
%
Peto OR
95% CI Order
Conway, 2002
17 0/29 5/28 29.31 0.11 (0.02–0.69)0
Mythen, 1995
20 0/30 6/30 34.67 0.11 (0.02–0.60)0
Noblett, 2006
21 0/51 6/52 36.02 0.12 (0.02–0.64)0
Total (95% CI) 110 110 100.00 0.12 (0.04–0.31)
Total events: 0 (ODM), 17 (Control)
Test for heterogeneity: χ
2 = 0.01,d f = 2( p = 0.99), I
2 = 0%
Test for overall effect: z = 4.28 (p < 0.0001)
 0.01  0.1  1  10  100
 Favours ODM  Favours control
FIGURE 5  Meta-analysis of studies reporting major complications (Aberdeen TAR group).Effectiveness
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FIGURE 6  Meta-analysis of studies reporting total number of patients with complications (Aberdeen TAR group).
Review:  Oesophageal Doppler monitoring
Comparison:  ODM + CVP + conventional assessment vs CVP + conventional assessment
Outcome:  Total complications
Study or 
subcategory
ODM
n/N
Control
n/N
OR (ﬁxed)
95% CI
Weight
%
OR (ﬁxed)
95% CI Order
Conway, 2002
17 5/29 9/28 15.93 0.44 (0.13–1.53) 0
Noblett, 2006
20 13/51 22/52 34.13 0.47 (0.20–1.08) 0
Wakeling, 2005
21 24/64 38/64 49.93 0.41 (0.20–0.84) 0
Total (95% CI) 144 144 100.00 0.43 (0.26–0.71)
Total events: 42 (ODM), 69 (Control)
Test for heterogeneity: χ
2 = 0.05, df = 2( p = 0.97), I
2 = 0%
Test for overall effect: z = 3.29 (p = 0.0010)
 0.1 0.2  0.5  1  2  5  10
 Favours ODM  Favours control
TABLE 5  Length of hospital stay (days)
Study  n Measure ODM group Control group p-value
aConway 200217 57 Mean (SD)
Median (range)
18.7 (20.2)
12 (7–103)
12.7 (6.0)
11 (7–30)
NR
NR
Gan 200218 100 Mean (SD)
Median
5 (3)
6
7 (3)
7
NR
0.03
Mythen 199520 60 Mean (range) 6.4 (5–9) 10.1 (5–48) 0.01
Noblett 200621 103 Median (IQR) 7 (3–35) 9 (4–45) 0.005
Wakeling 200524 128 Median (IQR) 10 (5.75) 11.5 (4.75) 0.03
IQR, interquartile range; NR, not reported; SD, standard deviation.
a  The report stated that in the study by Conway and colleagues17 one patient in the ODM group remained in hospital for 
103 days, not because of complications but because a social/community placement could not be found.
Source: AHRQ report.6
meta-analysis. An overall pooled estimate was not 
presented on the grounds that three of the five 
studies reporting this outcome did not present data 
that allowed a precise effect size to be calculated. 
However the 95% CI was presented; this was −2.21 
to −0.57 days, indicating that ODM was associated 
with a statistically significantly shorter length of 
hospital stay.
Although the data should be treated extremely 
cautiously, Figure 7 shows a meta-analysis 
undertaken by the Aberdeen group of the two 
studies reporting means and standard deviations 
for length of hospital stay. The pooled estimate 
shows that ODM was associated with a statistically 
significantly shorter length of hospital stay 
(WMD −1.82, 95% CI −2.98 to −0.65). There is 
evidence of heterogeneity which may be caused 
by differences between the two study population 
groups, although much of the difference in the 
mean length of stay in the Conway study was 
caused by one patient in the ODM group (see 
footnote, Table 5). As this meta-analysis includes 
only one of the four studies favouring ODM it 
might be argued that the estimate is slightly biased 
against ODM.
Overall, the data available for length of stay 
suggest that this may be shorter in the ODM group, 
although the precise magnitude of the difference 
is uncertain. However, the data from the Aberdeen 
meta-analysis also suggest that the type of patient 
may also be important.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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FIGURE 7  Meta-analysis of length of hospital stay (Aberdeen TAR group).
Review:  Oesophageal Doppler monitoring
Comparison:  ODM + CVP + conventional assessment vs CVP + conventional assessment
Outcome:  Length of hospital stay
Study or 
subcategory n
ODM
Mean (SD) n
Control
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI Order
Conway, 2002
17 29 18.70 (20.20) 28 12.70 (6.00)   2.29 6.00 (−1.68 to 13.68) 0
Gan, 2002
18 50 5.00 (3.00) 50 7.00 (3.00) 97.71 −2.00 (−3.18 to −0.82) 0
Total (95% CI) 79 78 100.00 −1.82 (−2.98 to −0.65)
Test for heterogeneity: χ
2 = 4.07, df = 1( p = 0.04), I
2 = 75.4%
Test for overall effect: z = 3.06 (p = 0.002)
−10 −5  0  5  10
 Favours ODM  Favours control
ODM plus conventional clinical 
assessment versus CVP plus 
conventional clinical assessment
Again, the only data for this comparison came 
from the AHRQ report.6 One study, by Venn and 
colleagues,23 compared ODM plus conventional 
assessment (n = 30) with CVP monitoring plus 
conventional assessment (n = 31) in patients 
undergoing surgery for hip fracture repair (this 
study also included conventional assessment alone 
(n = 29) as a comparator, see below).
Mortality
The AHRQ report stated that although there were 
fewer deaths in the ODM group (3/30) compared 
with the control group (6/31), the difference was 
not statistically significant (p = 0.30).
Major complications
Venn and colleagues23 did not report major 
complications separately from total complications.
Total complications
There were 46.7% (14/30) complications in 
the ODM plus conventional assessment group 
compared with 51.6% (16/31) in the CVP 
monitoring plus conventional assessment group. 
The AHRQ report6 stated that the difference in 
the rate of total complications (comprising mostly 
infections and cardiovascular events) favoured the 
ODM group without being statistically significant 
(OR 0.82, 95% CI 0.30–2.25). In terms of the 
number of patients experiencing complications, 
33.3% (10/30) patients in the ODM group 
experienced complications compared with 45.2% 
(14/31) patients in the CVP monitoring group, 
again favouring the ODM group but without 
reaching statistical significance (OR 0.61, 95% CI 
0.21–1.72).
Length of hospital stay
The AHRQ report6 stated that the difference in 
the mean length of hospital stay between the ODM 
and CVP monitoring groups was not statistically 
significant (13.5 versus 13.3 days, respectively, 
p = 0.96).
ODM plus conventional clinical 
assessment versus conventional 
clinical assessment
The AHRQ report6 included two studies that 
reported this comparison, involving 99 patients 
undergoing surgery for hip fracture repair.22,23 An 
additional study to those included by the AHRQ 
report was identified. This was a poster by Dodd 
and colleagues26 involving 40 patients undergoing 
colorectal surgery.
Mortality
The AHRQ report stated that both studies 
reported that no deaths occurred during surgery. 
Venn and colleagues23 reported that three (3/30) 
deaths occurred in the ODM group and two (2/29) 
occurred in the control group within 30 days 
following surgery, while Sinclair and colleagues22 
reported that one (1/20) death occurred in the 
control group during this period. Sinclair and 
colleagues22 reported a further two deaths [one 
(1/20) in the ODM group and one in the control 
group] after this period and within 3 months 
following surgery. In terms of total mortality rates, 
the AHRQ report stated that neither study showed 
a statistically significant difference between the two 
treatment groups.
The additional study by Dodd and colleagues26 
reported hospital mortality of one (1/20) death 
in the ODM group and two (2/20) deaths in the 
control group.Effectiveness
18
Figure 8 shows a meta-analysis of studies reporting 
mortality undertaken by the Aberdeen group, 
including the additional study by Dodd and 
colleagues,26 with the pooled estimate failing to 
reach statistical significance and with confidence 
intervals sufficiently wide to include clinically 
important differences favouring either intervention 
(OR 0.81, 95% 0.23–2.77).
Major complications
Sinclair and colleagues22 did not report 
complications and Venn and colleagues23 did not 
report major complications separately from total 
complications. The additional study by Dodd and 
colleagues26 did not report major complications.
Total complications
The AHRQ report stated that in the study by Venn 
and colleagues,23 the ODM group experienced 
statistically significantly fewer complications 
(46.7%, 14/30) than the control group (79.3%, 
23/29) (OR 0.23, 95% CI 0.07–0.72). However, 
in terms of the number of patients experiencing 
complications, the difference between the ODM 
group (33.3%, 10/30) and the control group 
(55.2%, 16/29) was not statistically significant and 
the confidence interval was sufficiently wide to 
contain clinically important differences favouring 
either intervention (OR 0.41, 95% CI 0.14–1.16).
The additional study by Dodd and colleagues26 did 
not report total complications.
Length of hospital stay
The AHRQ report stated that both studies reported 
a shorter length of stay for the ODM group. 
Sinclair and colleagues22 reported a statistically 
significantly shorter length of stay for the ODM 
group compared with the control group, with a 
median of 11 (range 3–23) days versus 20 (range 
5–220) days, p < 0.05. In the study by Venn and 
colleagues,23 although the ODM group experienced 
a shorter length of stay (mean 13.5 days, 95% CI 
10.9–17.5) compared with the control group (mean 
17.5 days, 95% CI 13.9–24.4) the difference was 
not statistically significant (p = 0.31). Table 6 shows 
the length of hospital stay. In a random-effects 
meta-analysis undertaken by the AHRQ report, the 
pooled mean difference was statistically significant 
in favour of patients receiving ODM (mean 
difference −6.76, 95% CI −11.83 to −1.68).
The additional study by Dodd and colleagues26 
reported a shorter median (range) length of stay of 
8 (5–34) days for the ODM group compared with 9 
(5– 27) days for the control group, in terms of the 
number of days until medically fit for discharge. 
However, Dodd and colleagues26 reported a longer 
median length of stay in the HDU of 3 (2–10) days 
for the ODM group (n = 7) compared with 2 (2–10) 
days for the control group (n = 5).
ODM among critically ill patients
ODM plus CVP plus conventional 
clinical assessment versus CVP plus 
conventional clinical assessment
The AHRQ report included one study19 that 
reported this comparison in 174 patients admitted 
to cardiac intensive care following cardiac surgery, 
with the intervention group allocated to a fluid 
replacement algorithm guided by ODM during 
the first 4 hours after admission to cardiac 
intensive care. An additional study by Chytra and 
colleagues25 was identified, involving 162 multiple-
Review:  Oesophageal Doppler monitoring
Comparison:  ODM + conventional assessment vs conventional assessment
Outcome:  Mortality
Study or 
subcategory
ODM
n/N
Control
n/N
OR (ﬁxed)
95% CI
Weight
%
OR (ﬁxed)
95% CI
Order
Venn, 2002
23 3/30 2/29 32.51 1.50 (0.23–9.70)0
Dodd, 2004
26 1/20 2/20 33.74 0.47 (0.04–5.69)0
Sinclair, 1997
22 1/20 2/20 33.74 0.47 (0.04–5.69)2 0
Total (95% CI) 70 69 100.00 0.81 (0.23–2.77)
Total events:5(ODM),6(Control)
Test for heterogeneity: χ² = 0.78,d f = 2( p = 0.68), I² = 0%
Test for overall effect: z = 0.34 (p = 0.73)
0.1 0.2 0.5 12 51 0
Favours ODMF avours control
FIGURE 8  Meta-analysis of studies reporting mortality (Aberdeen TAR group).© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 6  Length of hospital stay (days)
Study  n Measure ODM group Control group p-value
aDodd 200426 40 Median (range) 8 (5–34) 9 (5–27) NR
Sinclair 199722 40 Median (range) 11 (3–23) 20 (5–220) < 0.05
Venn 200223 90 Mean (95% CI) 13.5 (10.9–17.5) 17.5 (13.9–24.4) 0.31
NR, not reported.
a  Data are for number of days until medically fit for discharge.
trauma patients admitted to an ICU following 
surgery, with the intervention group allocated to 
a fluid replacement algorithm guided by ODM 
during the first 12 hours after admission to the 
ICU.
Mortality
The AHRQ report stated that in the study by 
McKendry and colleagues19 there were more 
deaths in the ODM group (4/89) compared with 
the control group (2/85) although the difference 
was not statistically significant (p = 0.43). Chytra 
and colleagues25 reported fewer deaths in the 
ODM group (13/80) compared with the control 
group (18/82). Although the groups of patients 
included in the two studies might be considered 
very different, a meta-analysis was undertaken 
by the Aberdeen group of the studies reporting 
mortality (Figure 9). The OR for each study 
individually was not statistically significant, with 
the confidence intervals being sufficiently wide to 
include clinically important differences favouring 
either intervention. The pooled estimate also 
failed to reach statistical significance (OR 0.84, 
95% CI 0.41–1.70). The results of the meta-analysis 
should be interpreted with caution owing to the 
very different types of patient included in the two 
studies.
Major complications
Although McKendry and colleagues19 stated 
that there was a trend towards fewer major 
postoperative complications and deaths in the 
ODM group, major complications were not 
reported separately from total complications. The 
additional study by Chytra and colleagues25 also 
did not report major complications separately.
Total complications
The AHRQ report stated that although fewer 
patients in the ODM group (19.1%, 17/89) 
experienced complications compared with the 
control group (30.6%, 26/85), the difference 
was not statistically significant (p = 0.08). In the 
additional study by Chytra and colleagues,25 
fewer patients in the ODM group (18.8%, 15/80) 
experienced infectious complications compared 
with the control group (34.1%, 28/82), with the 
difference being statistically significant (p = 0.032). 
Figure 10 shows a meta-analysis undertaken by 
the Aberdeen group of the studies reporting the 
number of patients with complications, with ODM 
Review:  Oesophageal Doppler monitoring
Comparison:  ODM + CVP + conventional assessment vs CVP + conventional assessment
Outcome:  Mortality
Study or 
subcategory
ODM
n/N
Control
n/N
OR (ﬁxed)
95% CI
Weight
%
OR (ﬁxed)
95% CI Order
McKendry, 2004
19 4/89 2/85 11.60 1.95 (0.35–10.95) 0
Chytra, 2007
25 13/80 18/82 88.40 0.69 (0.31–1.52) 0
Total (95% CI) 169 167 100.00 0.84 (0.41–1.70)
Total events: 17 (ODM), 20 (Control)
Test for heterogeneity: χ² = 1.16, df = 1( p = 0.28), I² = 13.6%
Test for overall effect: z = 0.50 (p = 0.62)
0.1 0.2 0.5 12 51 0
Favours ODM Favours control
FIGURE 9  Meta-analysis of studies reporting mortality (Aberdeen TAR group).Effectiveness
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being associated with statistically significantly 
fewer complications (OR 0.49, 95% CI 0.30–0.81). 
Again caution must be exercised when interpreting 
this meta-analysis as the patient groups in the two 
studies were different.
Length of hospital stay
The AHRQ report6 stated that there was a 
statistically significantly shorter median length 
of stay in the ODM group (7 days, range not 
reported) compared with the control group (9 days, 
range not reported), p = 0.02. The mean length 
of stay was also shorter in the ODM group (11.4 
days) compared with the control group (13.9 days), 
p-value not reported. In the additional study by 
Chytra and colleagues25 there was a statistically 
significantly shorter median length of stay in the 
ODM group (14 days, IQR 8.25–21) compared 
with the control group (17.5 days, IQR 11–29), 
p = 0.045. Table 7 shows the length of hospital stay.
Chytra and colleagues25 also reported a statistically 
significantly shorter ICU median length of stay in 
the ODM group (7 days, IQR 6–11) compared with 
the control group (8.5 days, IQR 6–16), p = 0.031.
Summary
The evidence on ODM presented in this chapter 
is based on the AHRQ report,6 supplemented by 
two additional studies that were identified.25,26 The 
eight RCTs17–24 included in the AHRQ report and 
the two additional RCTs25,26 reported the use of 
ODM in patients during surgery or among critically 
ill patients. The four outcomes reported by the 
AHRQ report were mortality, major complications, 
total complications and length of hospital stay. 
None of the studies reported quality of life data. 
None of the studies reported results for patients 
with sepsis compared with those without sepsis.
The AHRQ report used an ECRI 25-question scale 
to assess the quality of the included studies. This 
scale was also applied to the additional studies 
that were identified. In the AHRQ report, for all 
comparisons reported by more than one study, 
the median quality score fell within the range 
≥ 8.5 to 10.0, a quality rating of ‘high’ for this 
evidence base. The additional study by Dodd and 
colleagues26 also received a quality rating of ‘high’, 
while the study by Chytra and colleagues25 fell 
within the range > 6.7 but ≤ 8.4 and received a 
quality rating of ‘moderate’.
The AHRQ report scored 5 (minor bias) on a scale 
of 1 (extensive flaws) to 7 (minimal flaws) on the 
Oxman and Guyatt checklist14,15 for assessing the 
methodological quality of systematic reviews.
Five studies involving 453 patients reported ODM 
plus CVP monitoring plus conventional assessment 
versus CVP monitoring plus conventional 
assessment during surgery.17,18,20,21,24 The AHRQ 
report did not pool mortality data. In meta-
analyses undertaken by the Aberdeen group, 
pooled estimates showed statistically significantly 
fewer deaths in the ODM group (Peto OR 0.13, 
95% CI 0.02–0.96) and a statistically significant 
reduction in the incidence of major complications 
(Peto OR 0.12, 95% CI 0.04–0.31) and total 
complications (fixed-effects OR 0.43, 95% CI 0.26–
0.71). However, as noted above, as the number 
of deaths was low and the total combined sample 
size was modest, the pooled estimate for mortality 
should be interpreted with caution. In four of five 
Review:  Oesophageal Doppler monitoring
Comparison:  ODM + CVP + conventional assessment vs CVP + conventional assessment
Outcome:  Total complications
Study or 
subcategory
ODM
n/N
Control
n/N
OR (ﬁxed)
95% CI
Weight
%
OR (ﬁxed)
95% CI Order
McKendry, 2004
19 17/89 26/85 48.92 0.54 (0.27–1.08) 0
Chytra, 2007
25 15/80 28/82 51.08 0.45 (0.22–0.92) 0
Total (95% CI) 169 167 100.00 0.49 (0.30–0.81)
Total events: 32 (ODM), 54 (Control)
Test for heterogeneity: χ² = 0.13, df = 1( p = 0.72), I² = 0%
Test for overall effect: z = 2.78 (p = 0.005)
0.1 0.2 0.5 12 51 0
Favours ODMF avours control
FIGURE 10  Meta-analysis of studies reporting total number of patients with complications (Aberdeen TAR group).© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 7  Length of hospital stay (days)
Study  n Measure ODM group Control group p-value
Chytra 200725 162 Median (IQR) 14 (8.25–21) 17.5 (11–29) 0.045
McKendry 200419 174 Mean 11.4 13.9 NR
Median 7 9 0.02
IQR, interquartile range; NR, not reported.
studies reporting length of hospital stay, there was a 
statistically significant difference in favour of ODM, 
with a median of 6 versus 7 days, p = 0.03,18 7 (IQR 
3–35) versus 9 (IQR 4–45) days, p = 0.005,21 10 
(IQR 5.75) versus 11.5 (IQR 4.75) days, p = 0.03,24 
and a mean of 6.4 (range 5–9) versus 10.1 (range 
5–48) days, p = 0.01.20 A random-effects meta-
analysis undertaken by the AHRQ report showed 
a statistically significantly shorter length of 
hospital stay in favour of the ODM group (pooled 
estimate not presented, 95% CI −2.21 to −0.57). 
One of the studies included in this comparison 
considered the use of ODM among elective 
cardiac surgery patients.20 This group of patients 
might be considered to be different from patients 
undergoing other forms of surgery. Nevertheless, 
the results from this study were consistent with the 
results of the others.
Only Venn and colleagues23 reported ODM plus 
conventional assessment versus CVP monitoring 
plus conventional assessment during surgery, 
in a study involving 61 patients. Although the 
outcomes reported favoured the ODM group, 
none were statistically significant and confidence 
intervals were sufficiently wide to include clinically 
important differences favouring either treatment.
Two studies22,23 included in the AHRQ report 
and one additional study26 involving a total of 
139 patients reported ODM plus conventional 
assessment versus conventional assessment during 
surgery. None of the studies showed a statistically 
significant difference in mortality, and in a meta-
analysis of the three studies undertaken by the 
Aberdeen group, the pooled estimate was not 
statistically significant (fixed-effects OR 0.81, 95% 
CI 0.23–2.77). None of the studies reported the 
outcome of major complications. Only Venn and 
colleagues23 reported total complications, with the 
AHRQ report stating that there was a statistically 
significant difference in favour of the ODM group 
in terms of the number of complications (OR 0.23, 
95% CI 0.07–0.72) but not in terms of the number 
of patients experiencing complications (0.41, 95% 
CI 0.14–1.16).
One study19 included in the AHRQ report and 
one additional study25 involving a total of 336 
patients reported ODM plus CVP monitoring plus 
conventional assessment versus CVP monitoring 
plus conventional assessment among critically 
ill patients. Neither study showed a statistically 
significant difference in mortality, and in a meta-
analysis undertaken by the Aberdeen group, the 
pooled estimate was not statistically significant 
(fixed-effects OR 0.84, 95% CI 0.41–1.70). There 
may be some concerns that the patient groups 
included in the two studies were very different, so 
this pooled estimate should be treated with caution. 
Neither study reported the outcome of major 
complications. In a meta-analysis undertaken by 
the Aberdeen group of total complications, the 
two studies showed a similar trend and the pooled 
estimate showed that statistically significantly 
fewer patients in the ODM group experienced this 
outcome (OR 0.49, 95% CI 0.30–0.81). In terms 
of length of hospital stay, the AHRQ report6 stated 
that in the study by McKendry and colleagues19 
there was a statistically significantly shorter median 
length of stay in the ODM group compared with 
the control group (7 versus 9 days, p = 0.02), and 
the study by Chytra and colleagues25 also reported 
a statistically significantly shorter median length 
of stay in favour of the ODM group compared with 
the control group (14 versus 17.5 days, p = 0.045).
In terms of ODM-related complications, five 
studies17,21,22,23,25 reported that none occurred, while 
the remaining five18,19,20,24,26 made no mention of 
ODM-related complications.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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T
his chapter presents the results of a systematic 
review of economic evaluations of ODM 
compared with relevant comparators in the 
management of high-risk surgical patients and 
critically ill hospitalised patients. In order to 
better understand the choices and trade-offs 
between the various interventions, a simple balance 
sheet showing resource use and outcomes is also 
presented.
Methods
Search strategies
Studies that reported both costs and outcomes 
of ODM compared with the cardiovascular 
monitoring devices and conventional clinical care 
for the management of those undergoing major 
surgery and for critically ill patients, that met 
inclusion criteria, were sought from a systematic 
review of the literature. No language restrictions or 
limitations to searches were imposed.
Databases searched were MEDLINE (1990–June 
week 3 2007), EMBASE (1990–week 26 2007), 
MEDLINE In-Process (29 June 2007), SCI (1990–1 
July 2007), NHS Economic Evaluation Database 
(NHS EED) (May 2007), HTA Database (May 2007) 
and Health Management Information Consortium 
(HMIC) (1990–May 2007). Other sources of 
information consulted included references in 
relevant articles and selected experts in the 
field. Websites of both professional organisations 
(including Anaesthesia UK, Critical Care, 
Intensive Care Society, International Collaboration 
for Excellence in Critical Care Medicine) 
and manufacturers (Deltex Medical, Arrow 
International) were also searched. Full details of the 
search strategies used are documented in Appendix 
3.
Inclusion and exclusion criteria 
In order to be included, studies had to compare, 
in terms of both costs and outcomes, strategies 
involving ODM compared with no cardiac 
monitoring, PAC or pulse contour analysis 
monitoring for the monitoring of critically ill and 
high-risk surgical patients. Studies were included 
even if they made no formal attempt to relate cost 
to outcome data in a cost-effectiveness or cost–
utility analysis. Two reviewers assessed all abstracts 
for relevance and full papers were obtained for 
those that appeared potentially relevant.
Data extraction strategy 
It was planned that the following data be extracted 
for each included primary study using the 
framework provided for abstracts prepared for the 
NHS EED:27
Study identification information 1. 
author and year i. 
interventions studied ii. 
type of economic evaluation iii. 
country of origin and currency reported iv. 
Intervention, study design and main outcomes 2. 
fuller description of treatment i. 
numbers receiving or randomised to each  ii. 
intervention
outcomes studied iii. 
Sources of data 3. 
effectiveness data i. 
mortality and co-morbidity (if measured) ii. 
cost data iii. 
quality of life (if measured) iv. 
Methods and study perspective 4. 
Results 5. 
costs i. 
benefits ii. 
incremental  cost-effectiveness/utility  ratio  iii. 
(ICER)
sensitivity analyses iv. 
Additional comments relating to the design  6. 
and reporting of the economic evaluation. For 
reviews of economic evaluations, it was planned 
that data would be extracted on:
the nature of the review methodology used i. 
the inclusion criteria for studies ii. 
the number of studies identified iii. 
the  method  of  quality  assessment  for  iv. 
individual economic evaluations
the  conclusions  drawn  on  the  relative  v. 
efficiency of the alternative methods.
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Quality assessment strategy
One economist was to assess included studies using 
the NHS EED guidelines for reviewers.27
Data synthesis
No data synthesis was performed.
Results
Number of studies identified
The results of the literature search are presented 
in Table 8. The number of reports retrieved from 
the search in SCI and HMIC is the total after 
deduplication against the results of the MEDLINE/
EMBASE multifile search.
Eleven papers were selected from the searches, 
none of which met the inclusion criteria for the 
systematic review, and were selected for background 
information purposes only. Details of these studies 
can be obtained from the authors.
Balance sheet
As described above, no economic evaluations 
that met the inclusion criteria were found from 
the systematic search of the literature. It was, 
therefore, not possible to provide any comment 
on the comparative costs and/or effects of ODM 
in comparison with relevant comparators. To give 
an idea of the impact that regular use of ODM 
might have on the NHS in terms of costs and 
effects, a series of balance sheets were drawn up. 
The balance sheet presents the differences between 
interventions, in terms of resource use and natural 
and clinical measures of effectiveness. Such an 
approach serves to highlight the choices and trade-
offs between the various monitoring modalities. 
Nonetheless, any decision based on the balance 
sheet approach is made using an implicit (rather 
than an explicit) synthesis of the available data.
Comparisons made
Data gathered from the review of effectiveness 
reported in Chapter 3 compared various strategies 
involving ODM use for patients following major 
surgery and for hospitalised patients. In total, 
three different strategies involving ODM versus 
no ODM were extracted from the literature for 
high-risk surgical patients. Only one strategy 
involving ODM versus no ODM was extracted 
from the current literature in relation to critically 
ill hospitalised patients. No evidence was available 
for the comparison of strategies that include 
ODM compared with PAC and/or thermodilution 
techniques. Therefore, all comparisons relate to the 
use of conventional clinical assessment and/or the 
use of CVP monitoring. Separate balance sheets 
are presented for each strategy and patient group 
and, where possible, a pooled effect size from the 
meta-analysis conducted as part of the review of 
effectiveness is reported (Tables 9, 10, 11 and 12).
Results of balance sheets
High-risk surgical patients
Comparison of ODM plus 
CVP plus conventional clinical 
assessment with CVP plus 
conventional clinical assessment
This comparison (Table 9) had the greatest 
number of studies contributing data to it and, as 
the pooled estimates demonstrate, the addition 
of ODM consistently outperforms the no ODM 
strategy. However, these results should be treated 
with caution as the number of studies contributing 
for each estimate as well as the sample sizes were 
small, and some of them were conducted in patient 
groups with different underlying conditions. In 
TABLE 8  Results of searching for studies on cost-effectiveness
Database Hits screened Selected for full assessment
MEDLINE/EMBASE/MEDLINE In-Process multifile search 
(after deduplication in Ovid)
113 10
SCI 10 0
HMIC 0 0
HTA Database 6 1
NHS EED 23 0
Total 152 11© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 9  Balance sheet comparing ODM plus CVP plus conventional clinical assessment with CVP plus conventional clinical assessment 
for high-risk surgical patients
ODM + CVP + conventional clinical assessment CVP + conventional clinical assessment
Reduction in mortality (OR 0.13, 95% CI 0.02–0.96) leading 
to increased patient benefits
Reduction in mortality following use of ODM leading to 
potential increased management costs of survivors in the 
longer term
Reduction in major complications (OR 0.12, 95% CI 
0.04–0.31) leading to increased patient benefits and lower 
treatment costs
Additional costs of ODM: staff time, reusable and disposable 
equipment required for insertion, monitoring and removal of 
the probe
Reduction in total complications (OR 0.43, 95% CI 
0.26–0.71) leading to increased patient benefits and lower 
treatment costs
 
Reduction in length of hospital stay (WMD –1.82, 95% CI 
–2.98 to –0.65) acting as a proxy for earlier recovery and 
implying lower treatment costs
 
No evidence of a difference in 
Cost of additional interventions, e.g. use of intravenous fluids or drugs prompted by the monitoring
terms of resource usage, it is known that in order 
to monitor cardiac output with ODM, an ODM 
monitor and probe are required as well as an 
anaesthetist to perform the insertion (a procedure 
of only a few minutes in duration). Further, based 
on clinical advice, it is known that this technology 
would be used predominantly in an HDU/ICU or 
the operating theatre setting (Drs Gordon Houston 
and Brian Cuthbertson, July 2007, personal 
communication). Data provided by manufacturer 
Deltex Medical indicate that the one-off cost of the 
CardioQ Doppler monitor is approximately £8000. 
The disposable probe ranges in price from £60 
for a clinically clean probe lasting up to 6 hours 
to £121 for a sterile probe that lasts up to 10 days. 
Deltex Medical also states that the delivered cost 
of a probe is the only direct cost of using the probe 
other than a negligible amount per patient relating 
to the cost of ultrasound gel. It is possible that 
more than one probe may be required per patient. 
This decision will be influenced by the choice of 
the initial probe, which in turn depends upon a 
prior clinical judgement as to how a patient will 
respond. Several pricing schemes exist in relation 
to the acquirement of the monitor; e.g. a rental 
agreement for the monitor is a common method 
whereby a monitor is placed in the hospital free of 
charge with a varying incremental cost for every 
probe purchased (£0–£15), depending on the 
volume of probes purchased. With reference to the 
various pricing schemes, it should be stressed that 
significant variation between centres is common 
owing to the standard practice of direct individual 
negotiation with manufacturers in NHS centres. 
Information from Deltex Medical also suggests that 
the reusable monitoring device is likely to last many 
years, although some costs in terms of maintenance 
and servicing would be incurred. A standard 1-year 
service contract might cost approximately £550. It 
might be reasonable to assume, however, that the 
additional cost per patient in terms of reusable 
equipment alone would be negligible, and that the 
main additional cost of ODM would be the cost of 
the disposable probes.
Although it should be treated cautiously as it 
is based on the synthesis of two small studies 
considering different patient groups, the pooled 
estimate of a 1.82 day reduction in hospital stay 
for ODM patients (Table 9) would result in a cost 
saving per patient in terms of length of stay only 
on an ICU ward of £3123 per patient, given the 
unit cost of £1716 for a day on a Level 3 ICU 
ward (the most frequently cited level of care).28 
Similarly, if the hospital days saved related to a stay 
on an HDU ward, the cost saving would be £1431, 
assuming a unit cost of £786 for a day on a Level 2 
HDU ward (again the most frequently cited level).28 
Finally, if the reduction in length of stay is related 
to a stay on a general surgical ward, the cost saving 
for a 1.82 day reduction in length of stay would be 
£564.29 While the precise cost of the staff time and 
equipment required for ODM monitoring has not 
been estimated it could be inferred that the cost 
per patient of the addition of ODM is likely, at the 
very least, to be less than the cost savings associated 
with the reduction in length of stay for ICU and 
HDU patients. The use of monitoring may also Systematic review of economic evaluations
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lead to some forms of treatment being initiated 
(e.g. the use of intravenous fluids, etc.). Arguably, 
the ODM group may receive more interventions 
and/or more appropriate interventions. However, 
the net effect on cost is uncertain.
Comparison of ODM plus 
CVP plus conventional clinical 
assessment with CVP plus 
conventional clinical assessment
For this comparison, again, it is known that there 
would be additional costs associated with the use of 
ODM, i.e. equipment and staffing, although there 
is no evidence of a difference in the main selected 
measures of outcome (Table 10). As fewer studies 
contributed data to this comparison it is not as 
clear what cost savings in terms of length of stay, 
for example, might be found.
Comparison of ODM plus 
conventional clinical assessment with 
conventional clinical assessment 
for high-risk surgical patients
Table 11 shows the balance sheet for this 
comparison. As any difference in length of stay 
might be considerable (OR −6.76, 95% CI 
−11.83 to −1.68), if such a difference exists it is 
highly likely that savings in length of stay would 
more than compensate for the cost of using 
ODM. However, it is less clear from the evidence 
available whether total costs will indeed be less 
as there are insufficient data available to identify 
differences in mortality, complications or the costs 
of treatments incurred because of monitoring, 
and the confidence intervals surrounding such 
estimates are sufficiently wide to include clinically 
and economically important differences. Similarly, 
there is insufficient evidence to judge whether the 
use of ODM increases total benefits. Therefore, 
should ODM be adopted, a judgement would have 
to be made that the trends in favour observed for 
other comparisons would be maintained for this 
comparison.
Critically ill hospitalised patients
For this group of patients data were available for 
one comparison: ODM plus CVP monitoring 
plus conventional clinical assessment versus CVP 
monitoring plus conventional clinical assessment. 
The balance sheet for this comparison is shown 
in Table 12. It appears there are likely to be 
reductions in total complications and length of 
hospital stay though the evidence relating to this 
particular subgroup of patients is sparse. What we 
cannot directly tell from the balance sheet is the 
likely impact on cost. As noted above the effect 
on cost of additional interventions prompted 
by the monitoring is unclear. It is also unclear 
what savings may accrue through reductions 
in length of stay (reported as 1–2 days for this 
comparison). Given the unit cost for a day on an 
ICU ward of £1716, an HDU ward cost of £786 
and general medical ward cost of £310 then the 
cost of using ODM may reasonably be expected 
to be compensated for by this reduction in 
length of stay.28,29 However given the uncertainty 
surrounding the effect on mortality and major 
complications then a decision to adopt ODM would 
imply that a judgement has been made that the 
reduction in mortality and complications observed 
for other uses of ODM would be continued in this 
setting.
TABLE 10  Balance sheet comparing ODM plus conventional clinical assessment with CVP plus conventional clinical assessment for 
high-risk surgical patients
ODM + conventional clinical assessment CVP + conventional clinical assessment
Additional costs of CVP: staff time, reusable and disposable 
equipment required for insertion, monitoring and removing 
of catheter
Additional costs of ODM: staff time, reusable and disposable 
equipment required for insertion, monitoring and removal of 
the probe
No evidence of a difference in
Mortality
Major complications
Total complications
Length of hospital stay
Cost of additional interventions, e.g. use of intravenous fluids or drugs prompted by the monitoring© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 11  Balance sheet comparing ODM plus conventional clinical assessment with conventional clinical assessment for high-risk 
surgical patients
ODM + conventional clinical assessment Conventional clinical assessment
Reduction in length of hospital stay (WMD –6.76, 95% 
CI –11.83 to –1.68) acting as a proxy for earlier recovery 
(provided mortality in the ODM group is no greater than 
conventional assessment) and implying lower treatment costs
Additional costs of ODM: staff time, reusable and disposable 
equipment required for insertion, monitoring and removal of 
the probe
No evidence of a difference in
Mortality (OR 0.81, 95% CI 0.23–2.77). Unclear if there are any additional benefits to patients following use of ODM and if 
there are any additional costs for ODM for care in the longer term
Major complications. Total complications per patient (OR 0.41, 95% CI 0.14–1.16). Unclear if there are any additional 
benefits to patients following use of ODM and if there are any savings for ODM following a reduction in total complications
Cost of additional of interventions, e.g. use of intravenous fluids or drugs prompted by the monitoring
TABLE 12  Balance sheet comparing ODM plus CVP plus conventional clinical assessment with CVP plus conventional clinical 
assessment for critically ill hospitalised patients
ODM + CVP + conventional clinical assessment CVP + conventional clinical assessment
Reduction in total complications (OR 0.49, 95% CI 
0.30–0.81) leading to increased patient benefits and lower 
treatment costs
Additional costs of ODM: staff time, reusable and disposable 
equipment required for insertion, monitoring and removal of 
the probe
Reduction in length of hospital stay (length of stay 1–2 
days less) acting as a proxy for earlier recovery (provided 
mortality in the ODM group is no greater than conventional 
assessment) and implying lower treatment costs
 
No evidence of a difference in
Mortality (OR 0.84, 95% CI 0.41–1.70). Unclear if there are any additional benefits to patients following use of ODM and if 
there are any additional costs for ODM for care in the longer term
Major complications. Unclear if there are any additional benefits to patients following use of ODM and if there are any savings 
for ODM following a reduction in major complications
Cost of additional of interventions, e.g. use of intravenous fluids or drugs prompted by the monitoring
Recent evidence on the 
cost-effectiveness of 
alternatives to ODM
Although no data were identified that were 
relevant to a comparison of ODM, a previous HTA 
monograph reported findings from a systematic 
review and RCT of the effectiveness and cost-
effectiveness of PAC in patient management in 
intensive care.1 Within the trial, 55 (10.9%) patients 
in the PAC group and 179 (35.2%) patients in the 
control group received transoesophageal Doppler 
monitoring. However, no separate results were 
presented for these patients. The HTA suggests 
that PAC was unlikely to be cost-effective for 
this group of patients. The HTA also provided 
an indication of the cost drivers, i.e. the major 
determinants of the differences in cost between the 
interventions compared. It is likely that the costs of 
ODM compared with the costs of no ODM will be 
driven by similar factors, primarily length of stay 
differences. The trial reported in the HTA found 
that for the financial year 2002–3, the cost per day 
in an ICU was £1353. Thus, if the addition of ODM 
to high-risk surgical and critically ill hospitalised 
patients does lead to a significant reduction in 
length of ICU stay, it is likely to have a large impact Systematic review of economic evaluations
28
on cost. Other things being equal, if the costs of 
equipment and staffing associated with ODM per 
patient were to be less than £310 [a conservative 
estimate based on data from Information Servicers 
Division (ISD) Scotland]29 regular ODM use is likely 
to be cost saving, especially if we take into account 
the cost information supplied by the manufacturer 
(Ewan Phillips, Deltex Medical, July 2007, personal 
communication).
Summary
This chapter presents the overall evidence 
currently available on the cost-effectiveness of 
ODM compared with relevant comparators in 
the management of critically ill hospitalised 
patients and high-risk surgical patients, based 
on a systematic review of the literature. No 
economic evaluations that met inclusion criteria 
were identified and little extra knowledge of the 
cost-effectiveness of ODM relative to the various 
strategies could be ascertained.
In order to explore the choices and trade-offs of 
the various monitoring modalities, a balance sheet 
was presented for each strategy for which evidence 
was available from the review of effectiveness. Some 
evidence indicates that ODM might be expected 
to be more efficient than not using ODM but any 
judgement depends upon the strategies compared. 
Further information for the critically ill hospitalised 
patient group compared with high-risk surgical 
patients is required owing to the sparse data on this 
patient group. The trade-offs highlighted by the 
balance sheets could be further informed by more 
formal consideration of the balance of probabilities 
in terms of which strategy is or is not likely to be 
cost-effective.
In terms of effectiveness, it should be noted that 
no comparisons of ODM with thermodilution or 
PAC methods were found and that, therefore, such 
comparisons are not included in this review or on 
the balance sheet.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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T
he balance sheets comparing resource use 
and outcomes for the different strategies 
considered in the systematic review of effectiveness 
presented in Chapter 4 give an idea of the different 
trade-offs faced by the decision-maker when 
choosing a particular strategy. However, unless all 
relevant factors favour one strategy then decisions 
based on these usually rely on implicit valuations 
of the trade-offs that may exist. These valuations 
may differ from person to person and might lead 
to different policy decisions being made that are 
difficult to debate objectively. One of the main 
assets that economic models have is their ability to 
make explicit many of these implicit weights. This 
chapter explores the scope for an economic model 
to assess the relative cost-effectiveness of using 
ODM.
An economic model for ODM
Drummond and colleagues defined economic 
evaluation as the ‘comparative analysis of 
alternative courses of action in terms of both their 
costs and consequences,’ ideally over the remaining 
lifetime of the patient.30 Economic evaluations are 
an important aid to decision-making because (a) a 
systematic analysis makes it easier to identify clearly 
the relevant alternatives; (b) such an approach 
makes explicit the viewpoint of the analysis; and 
(c) without some attempt at measurement, the 
uncertainty surrounding orders of magnitude can 
be critical.
Moreover, there are certain characteristics that 
an economic model should have in order to be a 
sound basis for decision-making. Among these is 
that it should include all the relevant alternatives 
for comparison and should allow for appropriate 
information to be taken into account within the 
evaluation. The model can be thought of as 
describing the pathways of care that a patient 
may follow in situations where ODM is and is not 
used. A potential model structure should consider 
strategies that include no cardiac monitoring, 
alone or in combination with technologies such 
as pulse contour analysis monitoring, lithium 
dilution cardiac monitors (i.e. LiDCO monitor), 
and thermodilution cardiac monitors (i.e. PiCCO 
monitor), as comparators for strategies that include 
ODM. A similar model structure could be outlined 
for the use of ODM within hospital critical care.
By clearly structuring the decision problem it is 
possible to highlight the data that are needed to 
fully inform any decision. However, it is possible 
that decisions might be reasonably made without 
all these data. In subsequent sections we explore 
how the data that are currently available can be 
used more fully to inform judgements on cost-
effectiveness.
Cost of ODM
In this section data provided by a manufacturer, 
Deltex Medical, as well as data from public sources 
have been used to estimate the extra (incremental) 
costs associated with ODM. Table 13 shows the 
annual total cost of ODM assuming a 5-year 
lifetime for the monitor. The costs of ODM are 
based on data provided by Deltex Medical (Ewan 
Phillips, Deltex Medical, August 2007, personal 
communication).
The cost of the probes varies from £60 for a 6-hour 
oral/nasal Doppler probe for use intraoperatively 
or perioperatively to £121 for a 10-day sterilised 
oral Doppler probe for use in critical care. 
Information from the manufacturer indicated that 
the use of more than one probe by a patient was 
rare. Therefore, it was assumed that the number 
of probes used per monitor per year is similar to 
the number of patients receiving ODM per year. 
However, this will depend upon the initial selection 
of the probe and the prior clinical judgement as 
to how the patient will respond. Given the nature 
of the patient groups it might be expected that 
the use of more than one probe would be more 
common among critically ill than surgical patients.
It is unclear how many patients might use 
a monitor per year (i.e. how intensively the 
equipment is used) and what would be the optimal 
use rate in a potential steady state. For instance, 
the average length of stay in an ICU in Scotland’s 
hospitals is 4.7 days31 (for an HDU it is 3.2 days). 
This does not mean, however, that a particular 
monitor would be used, on average, every 5 days 
as this would imply a full-time usage assumption 
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TABLE 13  Cost per year for ODM equipment (£) 2007–8
Concept CardioQ CardioQPa
1 Cost of monitor  8000 11,000
2 Monitor lifetime (assumption)  5 years 5 years
3 Yearly instalments 1600 2200
4 Other yearly costs (maintenance and software) 1200 1200
5 Total yearly cost 2800 3400
a   CardioQ supports only adult probes while CardioQP supports both adult and paediatric probes.
TABLE 14  ODM equipment cost per patient (£) 2007–8
Concept CardioQ CardioQPa
Monitor cost per year  2800.00 3400.00
Assumption
(a) 36 patients per monitor per year 76.71 93.15
(b) 125 patients per monitor per year 22.40 27.20
(c) 500 patients per monitor per year 5.60 6.80
a  CardioQ supports only adult probes while CardioQP supports both adult and paediatric probes.
for this equipment. Moreover, patients receiving 
critical care (within either an ICU or an HDU) 
who require ODM might not be representative of 
the whole population of patients receiving critical 
care, and their length of stay may be higher or 
lower than the average. Given the absence of data 
on the length of use of ODM, a simple assumption 
can be made about the number of patients who 
might be treated with a single monitor within a 
given year. For illustrative purposes, in this exercise 
three usage rates per monitor per year have been 
considered (36, 125 and 500) to explore the impact 
of different levels of intensity of use (Table 14). 
These figures result from an assumption of 250 
days of usage of equipment per year and different 
numbers of patients treated (i.e. one patient every 
7 days, one patient every 2 days and two patients 
per day, respectively).
Table 15 shows estimations of the total cost for 
ODM equipment and probe per patient. Based 
on the assumptions stated above and according to 
the probe used the total equipment cost can range 
from around £66 to £214 per patient.
When estimating costs of a procedure it would be 
usual to include other categories of cost such as 
the staff time involved. However, the marginal staff 
cost of using ODM may be minimal as the staff 
required to interpret the outputs of the monitor 
will be there anyway. Furthermore, the time it takes 
to insert the probe and obtain the initial readings 
is also minimal (e.g. about 5 minutes; Dr Gordon 
Houston, July 2007, personal communication). 
Other direct costs associated with the procedure, 
such as ultrasound gel or other disposal materials, 
are negligible. As indicated in Chapter 4, one 
category of costs not included in these analyses 
is the cost of treatments incurred as a result of 
monitoring. The net effect and magnitude of these 
costs is uncertain.
Further estimation of 
the implications for 
cost-effectiveness
This section explores the cost-effectiveness of 
ODM for the different comparisons presented in 
Chapters 3 and 4. The analyses focused on two 
outcomes: mortality and length of hospital stay. 
Worst- and best-case scenarios for the use of ODM 
were constructed for each comparison. These 
scenarios differed in terms of the cost of ODM 
equipment (e.g. £214 for worst-case and £66 for 
best-case scenario, as reported in Table 15), and the © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 15  Total equipment cost (equipment and probe) for ODM (£) 2007–8
Concept CardioQ CardioQP
Assumptiona
Using assumption (a) and £121 probe price 197.71 214.15
Using assumption (b) and £96 probe price 118.40 123.20
Using assumption (b) and £60 probe price 82.40 87.20
Using assumption (c) and £96 probe price 101.60 123.20
Using assumption (c) and £60 probe price 65.60 66.80
a  £121 for a 10-day sterilised oral Doppler probe (critical care); £96 for a 72-hour awake nasal Doppler probe (intra- and 
perioperative); £60 for a 6-hour oral/nasal Doppler probe (intra- and perioperative).
cost attached to any reduction in the length of stay 
due to ODM. For the worst-case scenario this was 
taken to be equal to £310 per day (corresponding 
to the cost of a day in a general medical ward) and 
for the best-case scenario the cost used was £1680 
per day, which corresponds to the cost of a day in 
an ICU.31 Finally, the mean length of survival per 
additional survivor was taken to be 1 year for the 
worst-case scenario and 5 years for the best-case 
scenario. These numbers help to illustrate the 
trade-offs that might be faced.
Results are presented in terms of QALYs. For these 
calculations a quality of life weight [as measured 
by the European Quality of Life-5 Dimensions 
(EQ-5D) scale] at 12 months of 0.66 was used. This 
estimate is based on quality of life of ICU survivors 
at 12 months (lower than the 0.88 score that might 
be estimated for the general population32).
Finally, in order to allow for the statistical 
imprecision surrounding estimates of the 
differences in mean length of stay and survival, 
normal and lognormal distributions, respectively, 
were used to describe the uncertainty in these 
parameters. The data required to construct these 
distributions were the estimated confidence 
intervals reported in Chapter 3 and, as such, the 
same limitations as stated in Chapters 3 and 4 
apply to this economic evaluation exercise.
High-risk surgical patients
ODM plus CVP plus conventional 
clinical assessment versus CVP plus 
conventional clinical assessment 
for high-risk surgical patients
Table 9 shows a balance sheet for the ODM 
plus CVP monitoring plus conventional 
clinical assessment versus CVP monitoring plus 
conventional clinical assessment comparison for 
high-risk surgical patients. In favour of ODM it 
shows reduction in mortality (OR 0.13, 95% CI 
0.02–0.96), reduction in major complications 
(OR 0.12, 95% CI 0.04–0.31), reduction in total 
complications (OR 0.43, 95% CI 0.26–0.71) and 
reduction in length of hospital stay (WMD −1.82, 
95% CI −2.98 to −0.65). Conversely, favouring the 
non-use of ODM there are the additional costs for 
ODM and potentially increased management costs 
for survivors due to a lower mortality rate in the 
ODM group. With the cost calculations obtained 
for ODM in the previous section and focusing on 
the reduction in mortality, it is possible to illustrate 
the extent of the increment in health-care costs and 
QALYs per additional survivor before ODM would 
not be considered cost-effective at a £30,000 per 
QALY threshold.33
Figure 11 shows the results for ODM plus CVP 
monitoring plus conventional clinical assessment 
versus CVP monitoring plus conventional clinical 
assessment for high-risk surgical patients. The 
probabilistic sensitivity analysis was based on 
1000 iterations of a Monte Carlo analysis. The 
black line represents the £30,000 cost per QALY 
threshold and the circles on the right and below 
this line are iterations of the model that indicate 
that the use of ODM would be cost-effective. The 
more circles there are to the right of and below 
the line the more likely it is that the use of ODM 
would be cost-effective. The white circle in the 
middle of the black circle ‘cloud’ is the incremental 
cost-effectiveness based on the point estimates 
for each of the parameters used in assessing cost-
effectiveness.
It can be seen in Figure 11 that a great majority 
of the points lie within the second quadrant; this 
indicates that using ODM together with CVP Economic modelling
32
0
0.1
–8000
4000
2000
–2000
–4000
–6000
–0.5 –0.4 –0.3
Incremental QALYs
I
n
c
r
e
m
e
n
t
a
l
 
c
o
s
t
 
(
£
)
 
2
0
0
6
–
7
–0.2 –0.1 0
FIGURE 11  Incremental cost-effectiveness plane – best-case ODM scenario: ODM + CVP + conventional clinical assessment vs CVP 
+ conventional clinical assessment for high-risk surgical patients.
monitoring and conventional clinical assessment 
seems to be more effective and less costly than 
using only CVP monitoring and conventional 
clinical assessment. A similar result can be observed 
in Figure 12 for the worst-case ODM scenario. 
Note that the cloud appears truncated on the 
right because of our assumption of a 1- or 5-year 
increment to length of life for additional survivors.
Figures 13 and 14 show the average extra cost per 
additional survivor that would need to be incurred 
before ODM would no longer be considered 
cost-effective. In terms of Figures 11 and 12 this 
is equivalent to moving the circles upward and 
crossing the £30,000 threshold. For the best-
case scenario this mean that the extra cost per 
additional survivor would be £4441 (95% CI 
£2151–£6732) and for the worst-case scenario the 
extra cost per additional survivor would be £642 
(95% CI £225–£1060).
Caution should be taken when reading these 
results as calculations did not take into account the 
other issues favouring ODM (e.g. the reductions 
in complications that the calculations assume are 
fully captured by the reductions in length of stay 
and increases in survival). The incorporation of all 
these factors into a full economic model might give 
a better idea of the likelihood of ODM being cost-
effective.
Further analysis was undertaken using data from 
the AHRQ report on the difference in length of 
hospital stay. These data are more conservative 
than those used above. A lognormal distribution 
was attached to these data using the 95% CI, i.e. 
−2.21 to −0.57 days. The other data used in this 
model are the same as those used for the worst-case 
model presented above.
The great majority of points from the probabilistic 
sensitivity analysis lie in the second quadrant, 
where using ODM together with CVP monitoring 
and conventional clinical assessment seems to be 
more effective and less costly than using only CVP 
monitoring and conventional clinical assessment 
(Figure 15). However, should the mean incremental 
cost per additional survivor be £448 or more (95% 
CI £117–£779) then the ODM-based strategy 
would no longer be considered cost-effective 
(Figure 16).
ODM plus conventional clinical assessment 
versus CVP plus conventional clinical 
assessment for high-risk surgical patients
Unfortunately, there are no feasible exercises for 
this comparison as there are no data on which 
calculations could be based. This means that it is 
not possible to provide any sensible estimates of 
the incremental costs and benefits of ODM for this 
clinical scenario.
ODM plus conventional clinical 
assessment versus conventional clinical 
assessment for high-risk surgical patients
Table 11 shows the balance sheet for this 
comparison. In favour of ODM a reduction in 
length of hospital stay (OR −6.76, 95% CI −11.83 © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
33
DOI: 10.3310/hta13070  Health Technology Assessment 2009; Vol. 13: No. 7
0.02
–1500
500
300
100
–300
–700
–1100
–0.04 –0.03 –0.02
Incremental QALYs
I
n
c
r
e
m
e
n
t
a
l
 
c
o
s
t
 
(
£
)
 
2
0
0
6
–
7
–0.01 0 0.01
–100
–500
–900
–1300
0
10
20
30
40
50
60
70
7779
Incremental cost (£) 2006–7
I
n
c
r
e
m
e
n
t
a
l
 
Q
A
L
Y
s
6470 5161 3852 2543 1234
0
10
20
30
40
50
60
70
1251
Incremental cost (£) 2006–7
I
n
c
r
e
m
e
n
t
a
l
 
Q
A
L
Y
s
1012 774 535 296 57
FIGURE 14  Histogram: extra NHS survival costs for ODM to stop being considered cost-effective – worst-case ODM scenario: ODM + 
CVP + conventional clinical assessment vs CVP + conventional clinical assessment for high-risk surgical patients.
FIGURE 13  Histogram: extra NHS survival costs for ODM to stop being considered cost-effective – best-case ODM scenario: ODM + 
CVP + conventional clinical assessment vs CVP + conventional clinical assessment for high-risk surgical patients.
FIGURE 12  Incremental cost-effectiveness plane – worst-case ODM scenario: ODM + CVP + conventional clinical assessment vs CVP 
+ conventional clinical assessment for high-risk surgical patients.Economic modelling
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FIGURE 16  Histogram: extra NHS survival costs for ODM to stop being considered cost-effective – sensitivity analysis using AHRQ 
meta-analysis on length of stay: ODM + CVP + conventional clinical assessment vs CVP + conventional clinical assessment for high-risk 
surgical patients.
to −1.68) can be observed. The difference in 
mortality is not statistically significant as the 
confidence intervals are sufficiently wide to favour 
any of the comparators (OR 0.81, 95% CI 0.23–
2.77). The same analyses as used previously were 
undertaken in this case.
Figures 17 and 18 show the results for best- and 
worst-case ODM scenarios, respectively. In both 
these figures more than half of the iterations 
from the Monte Carlo simulation are in the 
second quadrant (i.e. ODM is more effective and 
less costly); therefore, no matter how much the 
decision-maker would value a QALY gained, these 
results will always favour the ODM strategy. The 
remainder of the iterations are mainly in the third 
quadrant, where ODM is both less costly and less 
effective. Consequently, cost-effectiveness for these 
results will depend on how much society values the 
QALY gain from not using ODM. For the £30,000 
threshold (black line), in the majority of these 
iterations the use of ODM would be considered 
cost-effective (i.e. the circles are to the right of and 
below the threshold line).© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Figures 19 and 20 show the histograms for the 
average extra cost per additional survivor that 
would need to be incurred before ODM would no 
longer be considered cost-effective for the best- 
and worst-case scenarios, respectively. For the best-
case scenario a mean extra cost of £11,588 (95% 
CI −£2529 to £25,705) is needed for ODM to stop 
being considered cost-effective, while a mean extra 
cost of £1879 (95% CI −£920 to £4678) would be 
required for the worst-case scenario.
Critically ill patients
ODM plus CVP plus conventional 
clinical assessment versus CVP plus 
conventional clinical assessment for 
critically ill hospitalised patients
Table 12 shows the balance sheet for ODM plus 
conventional clinical assessment versus CVP 
monitoring plus conventional clinical assessment 
for critically ill hospitalised patients. In favour of 
ODM the reduction in total complications (OR 
0.49, 95% CI 0.30–0.81) and the reduction in 
length of stay (1–2 days less) were stated; while Economic modelling
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FIGURE 19  Histogram: extra NHS survival costs for ODM to stop being considered cost-effective – best-case ODM scenario: ODM + 
conventional clinical assessment vs conventional clinical assessment for high-risk surgical patients.
FIGURE 20  Histogram: extra NHS survival costs for ODM to stop being considered cost-effective – worst-case ODM scenario: ODM + 
conventional clinical assessment vs conventional clinical assessment for high-risk surgical patients
there was no statistically significant difference 
in mortality (OR 0.84, 95% CI 0.41–1.70) and it 
was not possible to measure the effects on other 
outcomes.
Figures 21 and 22 show the results of the 
probabilistic analyses for the best- and worst-case 
scenarios, respectively. The variability in the cost 
results comes from the uncertainty in the length 
of stay estimation. As there were no data to attach 
a probability distribution to this parameter, an 
assumption about the difference in length of stay 
was made. Differences of 2 days and 1 day in 
length of stay in favour of ODM were assumed for 
the best- and worst-case scenarios, respectively (it 
is for this reason that there is almost no variability 
in incremental cost in the probabilistic analysis). 
There is variability in QALYs, however, as estimates 
of the differences in mortality were available.
Almost 70% of the Monte Carlo simulation 
iterations lie within the second quadrant (i.e. ODM 
is more effective and less costly). The remaining 
30% of the results lie in the third quadrant (i.e. 
ODM is less effective and less costly). Therefore, 
the decision as to whether they are cost-effective 
is independent of the threshold. For the best-case 
scenario for ODM the probability of being cost-
effective at a £30,000 threshold is 90% (80% for 
worst-case ODM scenario).© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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FIGURE 21  Incremental cost-effectiveness plane – best-case ODM scenario: ODM + CVP + conventional clinical assessment vs CVP 
+ conventional clinical assessment for critically ill patients.
FIGURE 22  Incremental cost-effectiveness plane – worst-case ODM scenario: ODM + CVP + conventional clinical assessment vs CVP 
+ conventional clinical assessment for critically ill patients.
Figures 23 and 24 show the histograms for the 
average extra cost per additional survivor that 
would need to be incurred before ODM would no 
longer be considered cost-effective for the best- and 
worst-case scenarios, respectively. For the former, a 
mean additional cost of £4978 (95% CI −£2655 to 
£12,611) would be needed for ODM to stop being 
considered cost-effective; while for the latter, a 
mean additional cost of £364 (95% CI −£1271 to 
£1998) would be needed for ODM to stop being 
considered cost-effective.
Summary
This chapter explored the cost-effectiveness 
of ODM and thus expanded upon the work 
presented in previous chapters. However, it was 
not possible to obtain quantitative results for all 
four comparisons for which balance sheets were 
produced in Chapter 4 and for those where it 
was possible, results should be interpreted with 
caution as the results presented in this chapter are 
subject to the same caveats as those noted in earlier 
chapters.Economic modelling
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FIGURE 23  Histogram: extra NHS survival costs for ODM to stop being considered cost-effective – best-case ODM scenario: ODM + 
CVP + conventional clinical assessment vs CVP + conventional clinical assessment for critically ill patients.
For high-risk patients we obtained quantitative 
results for ODM plus CVP monitoring plus 
conventional clinical assessment versus CVP 
monitoring plus conventional clinical assessment 
and for ODM plus conventional clinical assessment 
versus conventional clinical assessment. For 
critically ill hospitalised patients we obtained 
quantitative results for ODM plus CVP monitoring 
plus conventional clinical assessment versus CVP 
monitoring plus conventional clinical assessment 
only. No quantitative results were obtained for 
ODM plus conventional clinical assessment 
versus CVP monitoring plus conventional clinical 
assessment for high-risk surgical patients.
All the comparisons exploring the strategies that 
involved the use of ODM seem to have a reasonable 
chance of being considered cost-effective given the 
assumptions that we have made. However, these 
results seem to be heavily dependent on the mean 
cost for the NHS of treating those extra survivors 
and on the cost of treatments incurred because 
of monitoring. The threshold value that these 
costs would need to reach before ODM might not 
be considered cost-effective ranged from £581 
to £11,600 depending on the comparison and 
the underlying assumptions. It is not clear from 
this current work whether or not costs of this 
magnitude are likely to exist in practice.
There are further limitations to these analyses; the 
main one, perhaps, being the partial modelling 
approach adopted here. The analyses did not 
take into account other factors presented within © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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the balance sheets. This would not affect every 
comparison in the same way. For instance, 
factors such as the reduction in major and total 
complications are definitely in favour of ODM 
(i.e. higher quality of life for those not having 
these major complications) for the ODM plus CVP 
monitoring plus conventional clinical assessment 
within surgery comparison. Therefore, including 
these into a full economic model would improve 
the cost-effectiveness of ODM (however, part 
of the effect of complications within the model 
should have been reflected within length of stay 
differences). For the other comparisons it is 
unclear what the effect would be of including these 
additional factors into an economic model.
Finally, as stated earlier in this report, the cost-
effectiveness of any strategy depends on the 
alternative strategies with which it is being 
compared. For this reason, a full economic model 
should include all the relevant alternatives; these 
are all the potential relevant pathways of care that 
include and do not include ODM, as well as current 
practice.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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T
he original protocol for this study proposed 
to conduct a systematic review of the 
RCTs comparing ODM with no cardiac output 
monitoring perioperatively among patients 
undergoing major surgery, and with other methods 
of monitoring heart function (see Appendix 
1 for the protocol). A recent systematic review 
focusing on the safety and effectiveness of ODM 
was identified after this protocol was finalised but 
before the project was started. Following discussion 
with the NCCHTA it was agreed that the Aberdeen 
TAR group should base its review on the evidence 
contained in the AHRQ report, supplemented by 
any additional studies identified, should the AHRQ 
report be judged to be of sufficiently high quality. 
Had the review been judged not to be good enough 
this study would have followed the plan set out in 
our original protocol.
Statement of 
principal findings
Review of effectiveness
This review is based on the AHRQ report with 
eight included RCTs, supplemented by two 
additional RCTs identified, by the Aberdeen group 
that assessed the effects of ODM-guided fluid 
administration in patients during surgery (AHRQ 
report key question 2) or during critical care 
(AHRQ report key question 3). Studies assessing 
ODM in patients during surgery reported data for 
three comparisons:
ODM plus CVP monitoring plus conventional  1. 
clinical assessment versus CVP monitoring plus 
conventional clinical assessment (five studies 
involving 453 patients)
ODM plus conventional clinical assessment  2. 
versus CVP monitoring plus conventional 
clinical assessment (one study involving 61 
patients)
ODM plus conventional clinical assessment  3. 
versus conventional clinical assessment (two 
AHRQ studies involving 99 patients and one 
additional study involving 40 patients).
No studies were identified that compared different 
methods of ODM.
It should be noted that cardiac and non-cardiac 
surgery (major general, gynaecological, urological, 
vascular and orthopaedic surgery) are usually not 
considered together when analysing outcomes as 
they are considered non-comparable groups of 
patients owing to differences in type of surgery and 
presence of co-morbidities, etc. In this study, the 
results from the one study among cardiac surgery 
patients20 has been included in the review and 
generally reported results consistent with those 
from the other studies.
Studies assessing ODM in patients in critical 
care reported data for only one comparison: 
ODM plus CVP monitoring plus conventional 
clinical assessment versus CVP monitoring plus 
conventional clinical assessment (one AHRQ study 
involving 174 patients and one additional study 
involving 162 patients). The patient groups in 
these two studies were quite different. One study 
investigated patients in a cardiac care unit post 
cardiac surgery, and the other focused on patients 
suffering from major trauma.
The AHRQ report considered four outcomes: 
mortality, major complications, total complications 
and length of hospital stay; data were extracted 
from the additional studies on these four outcomes. 
Data were also sought on a fifth outcome, quality of 
life, from both the studies included in the AHRQ 
report and the studies identified by our additional 
searches.
In terms of total mortality, across all comparisons 
fewer patients in the ODM group died. The 
exceptions to this were the study by Venn and 
colleagues23 comparing ODM plus conventional 
clinical assessment with conventional clinical 
assessment during surgery, and the study by 
McKendry and colleagues19 comparing ODM 
plus CVP monitoring plus conventional clinical 
assessment with CVP monitoring plus conventional 
clinical assessment following cardiac surgery. The 
AHRQ report stated that, as the total number 
of deaths was too low to allow pooling and none 
of the individual studies showed a statistically 
significant between-group difference, the evidence 
was insufficient to allow conclusions to be reached 
concerning relative mortality rates for any of the 
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comparisons.6 A meta-analysis (Peto method) 
undertaken by the Aberdeen group of the five 
studies reporting ODM plus CVP monitoring 
plus conventional clinical assessment versus CVP 
monitoring plus conventional clinical assessment 
did show statistically significantly fewer deaths in 
the ODM group (OR 0.13, 95% CI 0.02–0.96). 
However, as the number of deaths was low and the 
total combined sample size was still modest, these 
results should be interpreted with caution.
Major complications were only reported for one 
comparison: ODM plus CVP monitoring plus 
conventional clinical assessment versus CVP 
monitoring plus conventional clinical assessment 
for patients undergoing surgery. All three studies 
reporting this outcome showed a statistically 
significant reduction in the rate of major 
complications and the AHRQ report stated that 
the strength of evidence supporting this conclusion 
was strong.6 A meta-analysis undertaken by the 
Aberdeen group of the three studies reporting this 
outcome showed statistically significantly fewer 
major complications in the ODM group (OR 0.12, 
95% CI 0.04–0.31).
In terms of total complications, across all 
comparisons fewer patients in the ODM group 
experienced complications, with some studies 
showing statistically significant differences. The 
AHRQ report stated that for the comparison of 
ODM plus CVP monitoring plus conventional 
clinical assessment versus CVP monitoring plus 
conventional clinical assessment in patients 
undergoing surgery, the ODM group experienced 
a clinically significant reduction in the rate of total 
complications and that the strength of evidence 
supporting this conclusion was strong.6 A meta-
analysis undertaken by the Aberdeen group of 
the three studies reporting this outcome showed 
statistically significantly fewer complications in the 
ODM group (OR 0.43, 95% CI 0.26–0.71). The 
AHRQ stated that for all of the other comparisons 
no conclusions could be reached owing to the small 
number of studies reporting this outcome, with 
none reporting a statistically significant between-
group difference. However, for the comparison 
of ODM plus CVP monitoring plus conventional 
clinical assessment versus CVP monitoring 
plus conventional clinical assessment during 
hospitalisation, including the additional study by 
Chytra and colleagues25 with that of McKendry and 
colleagues,19 a meta-analysis undertaken by the 
Aberdeen group showed a statistically significant 
reduction in total complications in terms of patient 
numbers in the ODM group (OR 0.49, 95% CI 
0.30–0.81).
In terms of length of hospital stay, the AHRQ 
report stated that the comparison of ODM 
plus CVP monitoring plus conventional 
clinical assessment versus CVP monitoring plus 
conventional clinical assessment in patients 
undergoing surgery showed a reduced length of 
hospital stay for the ODM group, and that the 
strength of evidence supporting this conclusion was 
strong.6 The precise magnitude of the reduction 
is uncertain and the meta-analysis undertaken 
by the Aberdeen group reported in Chapter 3 
for this comparison needs to be interpreted very 
cautiously. The AHRQ report also stated that the 
comparison of ODM plus conventional clinical 
assessment versus conventional clinical assessment 
during surgery showed a reduced length of stay 
for the ODM group, although the strength of 
evidence supporting this conclusion was weak.6 
The additional study by Dodd and colleagues26 
also reported a shorter length of stay for the ODM 
group.
The AHRQ report stated that because only one 
small study compared ODM plus conventional 
clinical assessment with CVP monitoring plus 
conventional clinical assessment during surgery, 
and another small study compared ODM plus CVP 
monitoring plus conventional clinical assessment 
with CVP monitoring plus conventional clinical 
assessment during hospitalisation, no conclusions 
were possible for these comparisons.6 However, 
although there was no statistical difference 
between the groups in the study reporting the 
former comparison, for the latter comparison 
both the study included in the AHRQ report and 
the additional study by Chytra and colleagues25 
reported a statistically significantly shorter median 
length of hospital stay for the ODM group.
The AHRQ report also considered which ODM-
related complications had been reported in the 
literature (AHRQ report key question 4), with 
studies of any design considered. Study designs 
other than RCTs were not considered eligible 
for our review but collectively these different 
study designs provide a good indication of the 
safety of ODM. Twenty-three studies addressed 
this question, including four RCTs,17,21–23 18 case 
series7,10,11,34–48 and one article containing two case 
reports.49 Three case series11,39,42 and the article 
containing two case reports49 reported minor 
patient-related complications associated with 
oesophageal Doppler probes. Nineteen studies 
involving 654 patients specifically stated that there 
were no ODM-related complications. The AHRQ 
report stated that currently no serious adverse 
events had been reported in the literature and © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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concluded that the available evidence suggested 
that ODM probes were relatively low-risk devices.6 
Of the 10 studies included in this review, five 
(Chytra,25 Conway,17 Noblett,21 Sinclair22 and 
Venn23) (including four referred to above and one 
of the additional studies identified) reported that 
no ODM-related complications occurred. The 
remaining five studies (Dodd,26 Gan,18 McKendry,19 
Mythen20 and Wakeling24) made no mention of 
ODM-related complications.
None of the studies reported quality of life data, 
although the study by Wakeling and colleagues24 
did state that the EORTC QLQ-C30 and QLQ-
CR38 quality of life questionnaires, completed 4–6 
weeks after surgery, showed no differences between 
the groups.
Review of cost-effectiveness
No economic evaluations relevant to this review 
were identified. Information reported on the 
website www.reducinglengthofstay.org.uk50 has 
suggested that the use of ODM in one NHS 
hospital has saved approximately £1M a year 
since 2004, mainly as a result of the need for 
less postoperative care. The formal analyses 
underpinning such information, however, are not 
readily available. Nevertheless, despite the absence 
of formal evaluations, information was available 
from the review of effectiveness for measures of 
effectiveness and cost-generating events (e.g. 
length of stay, risk of complications). These data, 
along with some initial consideration of resources 
required to provide ODM or its alternatives, were 
organised in a series of balance sheets so that 
choices and trade-offs between alternative courses 
of action could be highlighted.
Very simply, these balance sheets show those factors 
that favour the use of ODM and those factors that 
favour the alternative. They also highlight those 
factors for which we are currently unsure whether 
they favour ODM or not. As highlighted above, 
the evidence base for some comparisons is limited. 
In the high-risk surgical patient population, from 
the comparison of ODM plus CVP monitoring 
plus conventional clinical assessment with CVP 
monitoring plus conventional clinical assessment, 
it appears likely that ODM is more effective and 
that the savings made by a reduced length of stay 
would more than offset the cost (in terms of staff, 
equipment and consumables) of the set-up and use 
of ODM. In terms of the comparison of ODM plus 
conventional clinical assessment with conventional 
clinical assessment alone, it is likely that the savings 
made as a result of reduced hospitalisation would 
offset the costs of ODM. However, in this situation 
the overall difference in costs and effectiveness is 
unclear as there is insufficient evidence regarding 
the effect on mortality and complications. Where 
data are available the confidence intervals 
are sufficiently wide to cover clinically and 
economically important differences that might 
favour either intervention. The balance sheet for 
the comparison of ODM plus conventional clinical 
assessment with CVP monitoring plus conventional 
clinical assessment really serves only to highlight 
the need for more evidence with respect to this 
comparison.
Where ODM might be used in the care of critically 
ill patients, data were available for only one 
comparison: ODM plus CVP monitoring plus 
conventional clinical assessment versus CVP 
monitoring plus conventional clinical assessment. 
Furthermore, the patient groups from the two 
identified studies were different. One study 
considered patients cared for in a cardiac care unit 
following cardiac surgery and the other considered 
patients with major trauma. For this comparison 
it is likely that the reductions in length of stay 
would compensate for the cost of ODM and that 
the use of ODM would reduce the incidence 
of complications, but the effect on mortality is 
uncertain.
Although it has been argued that the use of ODM 
may not be associated with a net increase in cost 
to the NHS, this is based on the assumption that 
the savings associated with a reduced length of stay 
can be freed up to pay for the ODM. In reality this 
is unlikely to happen, but the use of ODM does 
release the hospital beds for other patients. The 
net financial cost of ODM is unclear at present, as 
although ODM equipment and consumables would 
need to be purchased, fewer consumables and less 
equipment may be required for other monitoring 
and for the management of complications.
No evidence was identified relevant to the 
comparison of pulse contour analysis monitoring. 
This is not altogether surprising given the 
relatively recent growth in this technology.
Economic modelling
The scope for a formal economic model was 
explored using information from the balance 
sheets. It was plausible to develop partial models 
for three of the four comparisons for which 
balance sheets were constructed (ODM plus CVP Discussion
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monitoring plus conventional clinical assessment 
versus CVP monitoring plus conventional 
clinical assessment, and ODM plus conventional 
clinical assessment versus conventional clinical 
assessment, for high-risk surgical patients; and 
ODM plus CVP monitoring plus conventional 
clinical assessment versus CVP monitoring plus 
conventional clinical assessment comparison only, 
for critically ill hospitalised patients). These are 
partial models in the sense that they only take 
into account differences in mortality and length of 
stay and do so only for those strategies compared 
in the balance sheets. Results were expressed in 
terms of additional cost per QALY gained and 
the average extra cost per additional survivor that 
would need to be incurred before ODM would no 
longer be considered cost-effective. ODM best-case 
and worst-case scenarios were constructed and 
probabilistic analyses conducted.
For the three comparisons the likelihood for the 
use of ODM being cost-effective seems high given 
the comparators and the underlying assumptions 
within the analyses (e.g. limitations and caveats of 
the data used in the analyses). Results also depend 
on the cost to the NHS of treating the extra 
survivors and the costs of interventions prompted 
by the monitoring. The magnitude that these 
costs would need to reach before ODM might not 
be considered cost-effective ranged from £581 to 
£11,600 depending on the comparison and the 
underlying assumptions.
Strengths and limitations
The strengths of this review include the fact that 
the AHRQ report upon which it is based is a high-
quality study (scored as 5, ‘minor bias’ on the 
Oxman and Guyatt systematic review checklist). 
Also, an additional two studies were identified 
to add to the evidence base of the eight studies 
included in the AHRQ review. In addition, all 
included studies were RCTs, which are less prone to 
bias than non-randomised study designs, and the 
outcomes assessed were all patient related.
As noted above there may be some concerns about 
combining data relating to cardiac surgery patients 
with data relating to non-cardiac surgery patients. 
In terms of the use of ODM during surgery the 
results from both groups of patients are broadly 
consistent. However, it is less clear whether it is 
appropriate to combine the data from the two 
studies identified that considered using ODM 
among critically ill patients, as the patient groups 
in these two studies are different.
In terms of limitations, both the AHRQ report 
and this review excluded non-English language 
studies. Of the eight studies included in the AHRQ 
report and the two additional studies identified, 
five involved fewer than 100 patients. Only 2 of 
the 10 studies assessed ODM in critical illness. 
The AHRQ review’s outcomes were broadly similar 
to those included in the original protocol for this 
review, with the exception of quality of life, which 
the AHRQ report did not include as an outcome. 
However, none of the included studies assessing 
ODM during surgery or postoperatively reported 
quality of life data.
A limitation of the technology noted by Chytra 
and colleagues was that in their study of ODM 
during critical illness it was difficult to keep the 
Doppler probe in the correct position without 
frequent adjustments during the 12-hour period 
that it was being assessed in the ICU.25 The 
authors also found the 12-hour study protocol to 
be time consuming and noted that it would not 
have been feasible without the co-operation of 
nursing staff. Gan and colleagues stated that there 
was a learning curve to achieve placement of the 
probe to capture the maximal signal.18 A study by 
Lefrant and colleagues recommended a period 
of training involving no more than 12 patients to 
ensure reliability of cardiac output measurements 
by ODM. 7
Other reviews of fluid optimisation interventions 
have been published that reported patient-
related outcomes. A Cochrane review by Price and 
colleagues51 included RCTs comparing a fluid 
optimisation intervention with normal practice 
or with another fluid optimisation intervention in 
patients undergoing surgery to repair proximal 
femoral fracture. The review included two 
studies, by Sinclair and colleagues22 and Venn and 
colleagues,23 both of which are included in the 
AHRQ report. The Cochrane review concluded 
that invasive methods of fluid optimisation during 
surgery may shorten hospital stay but that their 
effects on other important, patient-centred, longer-
term outcomes are uncertain.51
A review by Bundgaard-Nielsen and colleagues52 
assessed the influence of goal-directed therapy 
on postoperative outcome. Nine studies met the 
inclusion criteria; the eight reporting ODM were 
those included in the AHRQ report and the ninth © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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was a study by Pearse and colleagues53 comparing 
LiDCO with CVP monitoring. Pearse and 
colleagues53 concluded that goal-directed therapy 
reduces hospital stay, postoperative nausea and 
vomiting and complications, and facilitates faster 
gastrointestinal functional recovery.
With regard to the cost-effectiveness data the 
primary limitation is the lack of existing studies, 
which restricts the analysis of cost-effectiveness. 
Nevertheless, merely by organising the available 
data some reasonably firm conclusions could be 
drawn and the choices and trade-offs could be 
highlighted. Any judgements that utilise these data 
should consider the pros and cons for the use of 
ODM as well as the importance of the considerable 
uncertainty surrounding the estimates of relative 
effectiveness. Currently, these judgements must 
be based on the implicit valuation of these 
factors, but a more explicit consideration could 
be provided by using the available data within a 
modelling exercise. Such an exercise was explored 
and involved the more formal consideration of 
costs and partially incorporated the best available 
evidence on effectiveness. The added value of 
such work might be seen as limited for some 
comparisons, such as ODM plus CVP monitoring 
and conventional clinical assessment versus 
plus CVP monitoring and conventional clinical 
assessment, where conclusions could potentially 
be reached already. The modelling exercise 
incorporated some of the uncertainty around 
effectiveness estimates and shed some light on 
the extent to which the use of ODM might be 
considered cost-effective. A full economic model 
might serve further to inform the decision-making 
process by entirely incorporating other factors (e.g. 
number of major and/or total complications) for all 
the relevant alternatives, and not only employing 
those pairwise comparisons considered in the 
partial modelling exercises. Cardiac monitoring 
can be used in a variety of patient groups. It 
is possible that the cost-effectiveness (and the 
effectiveness) may differ between these groups. An 
indication for this is the evidence of heterogeneity 
identified in Figure 7.
Uncertainties
In terms of the type of patients considered to be 
suitable for ODM-guided fluid administration 
during surgery, the AHRQ report stated that its 
conclusions applied only to patients undergoing 
surgical procedures with an expected substantial 
blood loss or fluid shifts requiring fluid 
replacement. The types of surgery performed 
in the seven AHRQ and one additional study 
assessing ODM during surgery included moderate- 
to high-risk procedures such as elective bowel 
surgery, hip fracture repair surgery, elective 
cardiac surgery, elective general, urological 
or gynaecological surgery, and major general 
abdominal surgery.
The optimal period of ODM-guided fluid 
administration once patients have been admitted 
to critical care following surgery is unclear. 
McKendry and colleagues19 applied ODM-guided 
fluid administration for a period of 4 hours after 
patients were admitted to cardiac intensive care 
after cardiac surgery, while Chytra and colleagues25 
monitored multiple-trauma patients with major 
blood loss for a period of 12 hours following 
admission to the ICU.
All of the included studies involved unconscious 
patients, as ODM technologies currently in 
practice are unsuitable for use in postoperative 
awake patients. Although an ODM probe is now 
manufactured for per-nasal passage in awake 
patients it has yet to be fully evaluated and 
no additional studies using such a probe were 
identified that met our inclusion criteria.
In terms of cost-effectiveness, limited data are 
currently available. While it may be possible to 
draw some sensible conclusions about the use of 
ODM, additional research may be useful both in 
terms of using the available data more fully in an 
economic modelling exercise and to fill gaps in the 
primary research evidence.
Other relevant factors
Potentially relevant studies identified from a search 
of the National Research Register are listed in 
Appendix 9. The largest of the ongoing studies 
is a French multicentre study (Cholley) that is 
scheduled to run from April 2007 to April 2010. 
This study was also mentioned in the AHRQ 
report. The aim of the study is to assess whether 
intraoperative fluid supplementation to improve 
tissue perfusion can reduce the incidence of 
postoperative complications in elderly patients 
with hip fracture. The study design is described as 
randomised, double-blind and placebo controlled. 
The primary end point is to demonstrate that 
colloid titration, guided using oesophageal Discussion
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Doppler estimation of stroke volume, during the 
surgical repair of hip fracture reduces the incidence 
of postoperative complications. Secondary end 
points include (a) delay to walking without help; 
(b) increased number of days ‘out of hospital’ at 
3 months after the fracture; and (c) mortality at 1 
year. The protocol for the study indicated that 19 
centres would be participating and that the aim 
was to recruit 800 patients. This will be the largest 
study of ODM during surgery to date and its results 
should add substantially to the existing evidence 
base.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Implications for practice
Safety
No serious, and only a few minor, patient-related 
complications associated with ODM probes appear 
to have been reported and the available evidence 
suggests that ODM probes are relatively low-risk 
devices. Therefore, the use of ODM might be 
considered safe.
Effectiveness and cost-
effectiveness
The evidence base on effectiveness, based on the 
randomised evidence, is limited. Furthermore, 
there are no published cost-effectiveness analyses. 
Nevertheless, despite the limited evidence it 
is possible to draw out some implications for 
practice. These have been grouped around the 
four strategies for the use of ODM that have been 
considered.
Use of ODM for high-risk surgical patients
Evidence for three different comparisons involving 
the use or non-use of ODM in this group of 
patients was available and in all three cases 
appeared relevant to the NHS. The available 
evidence from five studies involving 453 patients 
suggests that the addition of ODM-guided 
fluid administration to CVP monitoring plus 
conventional assessment during surgery results in 
fewer major and total complications and a shorter 
length of hospital stay, and possibly fewer deaths, 
with pooled estimates for all outcomes showing a 
statistically significant difference in favour of the 
ODM group. Given these data it is quite plausible 
that the use of ODM in this situation would be less 
costly and more effective.
For the single study (n = 61) reporting ODM plus 
conventional assessment versus CVP monitoring 
plus conventional assessment during surgery, 
although all of the outcomes reported favoured 
the ODM group none were statistically significant. 
Therefore, no conclusions are possible for any 
of the outcomes reported in this comparison. 
Insufficient evidence is available to draw any 
robust conclusions about cost-effectiveness for this 
comparison.
None of the three studies (n = 139) reporting 
ODM plus conventional clinical assessment versus 
conventional clinical assessment during surgery 
showed a statistically significant difference for 
mortality; none reported the outcome of major 
complications; one reported total complications 
(a non-statistical difference favouring the ODM 
group); and all three reported a shorter length 
of stay for the ODM group, reaching statistical 
significance in one study. The addition of ODM to 
conventional assessment during surgery may lead 
to a shorter length of hospital stay. However, this 
conclusion is based on limited evidence from only 
three small studies and no conclusions are possible 
for the other outcomes. Again, only limited 
evidence is available on the cost-effectiveness 
of using ODM in this situation. On balance it 
would appear likely that the cost of ODM would 
be more than compensated for by the reduction 
in length of stay. However, the overall effect on 
costs is uncertain. As described above, owing 
to the limited evidence, firm data on measures 
of clinical effectiveness (some of which are also 
cost drivers) are not available. Therefore, should 
ODM be adopted, a judgement would be needed 
on whether the trends in favour, observed for 
other comparisons, would be maintained for this 
comparison.
Summary of evidence for 
the use of ODM in high-risk 
surgical patients in the NHS
The addition of ODM-guided fluid administration 
combined with CVP monitoring plus conventional 
assessment during major surgery results in fewer 
complications, a shorter length of hospital stay and 
possibly fewer deaths, and may be a cost-effective 
use of resources in the NHS.
Use of ODM in the critically ill
Neither of the two studies (n = 336) reporting 
ODM plus CVP monitoring plus conventional 
clinical assessment versus CVP monitoring 
plus conventional clinical assessment during 
hospitalisation showed a statistically significant 
difference in mortality, and neither reported 
major complications; therefore, no conclusions are 
possible for these outcomes. However, the addition 
of ODM to CVP monitoring plus conventional 
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assessment may lead to fewer total complications 
and a shorter length of hospital stay. In a meta-
analysis of the outcome of total complications, the 
pooled estimate showed a statistically significant 
difference in favour of the ODM group. Both 
studies also reported a statistically significantly 
shorter median length of stay in favour of the 
ODM group. However, the evidence for these two 
outcomes should be treated with caution as it is 
based on only two studies. Taking this evidence at 
face value, it would seem likely that the reduction 
in length of stay would compensate for the cost 
of using ODM. Furthermore, it seems likely 
that the use of ODM would be associated with a 
reduced cost of managing complications (as well 
as with increased benefit to the patient). Again, 
however, should ODM be adopted, a judgement 
would be required on whether the reduction in 
mortality observed for other uses of ODM would 
be continued in this setting. A prior judgement is 
required on whether the evidence base available is 
sufficient.
Summary of evidence for 
the use of ODM in critically 
ill patients in the NHS
Although there is some evidence for reduced 
complication rates and hospital lengths of stay 
in subgroups of critically ill patients, there is 
insufficient evidence to recommend the widespread 
use of ODM in critically ill patients in the NHS.
Recommendations 
for research
Surgery
Well-designed multicentre RCTs are required 
to address the following questions related to 
perioperative patients with expected substantial 
blood loss or fluid shifts requiring fluid 
replacement and/or with major co-morbidity:
Does ODM-guided fluid therapy plus  •	
conventional clinical assessment improve 
outcome compared with conventional clinical 
assessment during major surgery?
Does ODM-guided fluid therapy plus  •	
conventional clinical assessment plus or minus 
CVP monitoring improve outcome compared 
with CVP monitoring plus conventional clinical 
assessment during major surgery?
Studies should have a follow-up period of at least 6 
months and should report the following outcomes: 
mortality (hospital and longer term); length of 
stay [hospital, critical care (ICU and HDU)]; days 
of organ support in ICU and HDU; complications 
(major, total, technology-related); and quality of life 
in months after hospital discharge.
Further research is required to assess the 
additional benefit, if any, of ODM-guided fluid 
administration during surgery and continuing 
into the early postoperative period versus ODM-
guided fluid administration during surgery alone. 
Further research is also required to determine the 
optimal number of hours for ODM-guided fluid 
administration to continue after surgery once the 
patient has been admitted to a critical care facility.
Given the paucity of the existing economic 
evidence base, any further primary research should 
include an economic evaluation or should provide 
data suitable for use in an economic model.
Critical illness
A well-designed multicentre RCT is required to 
address the following question related to subgroups 
of critically ill patients, particularly those with 
major trauma and septic shock: 
Does ODM-guided fluid therapy plus  •	
conventional clinical assessment plus or minus 
CVP monitoring improve outcome compared 
with CVP monitoring plus conventional clinical 
assessment in critical illness?
Studies should have a follow-up period of at 
least 6 months and should report the following 
outcomes: mortality (critical care, hospital and 
longer term); length of stay [hospital; critical care 
(ICU and HDU)]; days of organ support in ICU 
and HDU; complications (major, total, technology-
related); and quality of life in months after hospital 
discharge. 
Again, economic evaluations should be conducted 
as part of this primary research or, at the very least, 
further primary research should seek to provide 
data that can be used in an economic model.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Summary
It is believed that measuring heart function 
during critical illness or during surgery can 
improve patient outcomes. Until recently the main 
method used to measure heart function has been 
pulmonary artery catheterisation, although for 
people undergoing surgery even this approach is 
uncommon. While providing useful information, 
PACs have not been shown to improve mortality. 
This, coupled with concerns over procedural 
complications associated with the use of these 
catheters along with the development of less 
complex heart monitors, has resulted in a global 
decline in the usage of PACs over recent years.
This review will assess the effectiveness and cost-
effectiveness of ODM when used for monitoring 
heart function in comparison with (a) standard 
care (i.e. no cardiac output monitor perioperatively 
among patients undergoing major surgery; and 
(b) other methods of monitoring heart function 
such as pulmonary artery catheterisation or pulse 
contour monitoring devices in critically ill patients 
or in patients undergoing major surgery.
The analysis will focus on outcomes of most 
importance to patients (e.g. mortality, length of 
hospitalisation, length of stay in critical care, days 
of organ support in ICU and complications). Cost-
effectiveness will be assessed from the perspective 
of the NHS and personal social services.
Information on the relative effectiveness of 
the alternative interventions will be derived by 
systematically reviewing relevant RCTs comparing 
ODM with: (a) standard care (i.e. no cardiac 
output monitor perioperatively among patients 
undergoing major surgery); and (b) other methods 
of monitoring heart function as outlined above. 
Information on cost-effectiveness will initially be 
assessed using a systematic review of economic 
evaluations comparing ODM with the relevant 
comparators for the two patient groups specified.
Decision problem
Optimal management of cardiac output and 
haemodynamic status have long been considered 
key to improving outcome in critically ill patients 
and in high-risk patients undergoing major 
surgery. Traditionally, PACs have been used to 
monitor cardiac output and haemodynamic status 
and to guide treatment. A recent HTA Programme-
funded study demonstrated that PAC insertion 
Appendix 1  
Aberdeen TAR group protocol for systematic 
review of oesophageal Doppler monitoringAppendix 1
56
and management of critically ill patients using 
the parameters monitored by pulmonary artery 
catheterisation fails to confer an outcome benefit. 
Further studies have also cast doubt on the value 
of PACs in high-risk major surgery.2 This, coupled 
with concerns related to procedural complications 
associated with the insertion and use of the PAC 
along with the development and assimilation of 
less invasive cardiac output monitors in clinical 
practice, has resulted in a global decline in the 
usage of the PAC in recent years.
Less invasive technologies to monitor cardiac 
output and other haemodynamic parameters 
include ODM and systems based on pulse contour 
analysis and dye dilution methods. Oesophageal 
Doppler monitoring measures blood flow velocity 
in the descending thoracic aorta using a flexible 
ultrasonic probe inserted into the patient’s 
oesophagus. This information is combined with 
an estimate of aortic cross-sectional area (derived 
from the patient’s age, height and weight), allowing 
haemodynamic variables to be calculated.
Pulse contour analysis devices employ algorithms 
to perform real-time continuous monitoring of 
cardiac output using arterial pulse contour analysis. 
There are several types of device available, but all 
require initial calibration which may be by means of 
either transpulmonary thermodilution or lithium 
dilution techniques.
Information on the relative effectiveness of 
the alternative interventions will be derived 
by systematically reviewing relevant RCTs. 
Information on cost-effectiveness will be assessed 
using a systematic review of economic evaluations 
of the alternative methods.
Report methods for synthesis of 
evidence of clinical effectiveness
A review of the evidence for clinical effectiveness 
will be undertaken systematically following the 
general principles recommended in the QUOROM 
statement (URL: www.consort-statement.org/
QUOROM.pdf).
Nature of existing evidence base and 
justification of approach taken
There are at least two existing reviews of ODM. 
These reviews are not systematic in that they 
did not use a search strategy likely to identify 
all relevant studies. They compared ODM 
primarily with pulmonary artery catheterisation 
and focused on measures of cardiac output. 
However, it is recognised that pulmonary artery 
catheterisation is an inappropriate gold standard 
for the measurement of cardiac output1 and the 
relationship between these surrogate measures 
and patient outcomes is unclear. Furthermore, 
as indicated above, the use of PACs is becoming 
less common while use of other less invasive 
cardiac monitoring methods is increasing. For 
these reasons, we do not propose to update these 
existing reviews; rather we aim to complete a new 
systematic review of ODM compared with relevant 
comparators (including other new methods of 
measuring heart function) which will focus on the 
outcomes of most importance to patients.
Population
Inclusion criteria:
adults being managed in critical care who  •	
require cardiac monitoring
adults during major surgery. •	
Exclusion criteria:
use of ODM in patient groups other than those  •	
specified above
studies in which ODM was used as a measure of  •	
study outcome rather than as a monitoring tool 
leading to a clinical intervention.
Relevant subgroups:
patients with sepsis versus those without sepsis. •	
Interventions
Oesophageal Doppler monitoring (ODM). •	
Comparator
For both patient groups:
no cardiac monitoring •	
PACs •	
pulse contour analysis monitoring •	
lithium dilution cardiac monitors (i.e. LiDCO  •	
monitor)
thermodilution cardiac monitors (i.e. PiCCO  •	
monitor).
Outcomes
There is no generally recognised gold standard for 
the measurement of cardiac output, and for this 
reason we are focusing on patient-related outcomes 
rather than diagnostic performance.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 16  Databases to be searched
Clinical effectiveness  Cost-effectiveness
MEDLINE MEDLINE
MEDLINE Extra MEDLINE Extra
EMBASE EMBASE
CINAHL CINAHL
Science Citation Index  Science Citation Index 
BIOSIS Health Management Information Consortium (HMIC)
UK PubMed Central UK PubMed Central
Cochrane Central Register of Controlled Trials (CENTRAL) NHS Economic Evaluation Database (NHS EED)
Health Technology Assessment Database (HTA) Health Technology Assessment Database 
Cochrane Database of Systematic Reviews (CDSR)
Database of Abstracts of Reviews of Effectiveness (DARE)
If evidence permits, the main outcome measures to 
be assessed will be:
30-day mortality •	
hospital mortality •	
longer term mortality •	
overall length of hospital stay •	
overall length of ICU stay •	
overall length of stay in critical care facilities  •	
(ICU and HDU)
days of organ support in ICU •	
postoperative complications and morbidity  •	
such as cardiac events and organ system 
failures
quality of life in year after surgery. •	
Search strategy
Reviews of ODM exist but these reviews are not 
systematic. In addition, they focus on diagnostic 
performance rather than on the impact on clinical 
management and patient-centred outcomes. Such 
comparisons may be misleading as PACs cannot 
be considered to be a gold standard. It is for 
this reason that our search strategy will focus on 
identifying RCTs that compare management based 
on ODM with management without monitoring or 
with an alternative method of monitoring. (Scoping 
searches indicate that there may be RCTs meeting 
our inclusion criteria; however, if when conducting 
the review no RCTs are found that meet our criteria 
then consideration will be given to including data 
from non-randomised designs.)
The search strategy will involve searches of 
electronic databases and relevant professional and 
manufacturers’ websites.
Electronic searches will be conducted to identify 
reports of published and ongoing studies, 
including previous systematic reviews, on the 
effectiveness and cost-effectiveness of ODM. 
Searches will be carried out for the time period 
1990 to the present, for full papers only. English 
language papers only will be considered eligible for 
inclusion; however, studies published in languages 
other than English will be noted. Databases to 
be searched are listed in Table 16. Preliminary 
MEDLINE search strategies to be used are given in 
Protocol Appendix 1 and will be adapted for use in 
the other databases.
Current research registers, including the National 
Research Register, Current Controlled Trials and 
Clinical Trials will be searched.
Inclusion criteria
For the review of clinical effectiveness, only RCTs 
will be included. Data will be systematically 
assembled and quality will be assessed using 
criteria relevant to each type of outcome. Titles 
and abstracts will be examined for inclusion by one 
reviewer. Where there is uncertainty this will be 
discussed with a second reviewer and a consensus 
will be reached.
Exclusion criteria
Non-randomised studies •	
Studies in which ODM is used to measure a  •	
study outcome rather than as a clinical monitor
RCTs comparing ODM with other  •	
interventions not specified in Comparator, 
aboveAppendix 1
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Studies published in languages other than  •	
English
Animal models •	
Pre-clinical and biological studies •	
Narrative reviews, editorials, opinions •	
Reports published as meeting abstracts only. •	
Data extraction strategy
All citations identified by the search strategy will 
be screened on the basis of the title and – where 
available – of the abstract. Full text copies of all 
potentially relevant reports will be obtained. 
One reviewer will assess studies for inclusion and 
extract data using a standard data extraction 
form (see Protocol Appendix 2). Any uncertainty 
will be resolved by discussion with a second 
reviewer and any disagreements will be resolved 
by arbitration by a third party. Information will be 
recorded on year of publication; source of funding; 
study design; methods prior to randomisation 
(e.g. stratification); method of randomisation; 
concealment of allocation; blinding procedures; 
number and characteristics of participants; 
duration of interventions; choice of outcome 
measures; and length of follow-up. Care will be 
taken to avoid double counting due to multiple 
reports of the same data set. The reviewer will not 
be blinded to authors, institutions or publications. 
Where there is insufficient information in the 
published report, no attempt will be made to 
contact the authors for clarification because of time 
constraints.
Quality assessment strategy
The study quality of RCTs will be assessed using 
the Delphi criteria list (see Protocol Appendix 3), 
adapted from Verhagen and colleagues.13
Methods of analysis/synthesis
For trials with multiple publications, only the most 
up-to-date or complete data for each outcome will 
be included. Where appropriate, meta-analysis will 
be employed to estimate a summary measure of 
effect on relevant outcomes based on intention-
to-treat analyses. Dichotomous outcome data will 
be combined using the Mantel–Haenszel relative 
risk method and continuous outcomes will be 
combined using the inverse variance weighted 
mean difference method. The 95% confidence 
intervals and p-values will be calculated for the 
estimates of RR and WMD. The results will be 
reported using a fixed-effects model. Chi-squared 
tests and I2 statistics will be used to explore 
statistical heterogeneity across studies. Possible 
reasons for heterogeneity will be explored using 
sensitivity analysis. Where there is no clear 
reason for heterogeneity, the implications will 
be explored using random-effects methods. 
Where a quantitative synthesis is considered to be 
inappropriate or not feasible, a narrative synthesis 
of results will be provided. If a lack of uniformity 
of the data is present in many studies, a qualitative 
review to look for consistency between studies will 
be performed. This will be supplemented, where 
appropriate, by investigation of the consistency in 
the direction of the results using the Sign test.16
Length of hospital stay will be defined as time from 
admission to discharge or death and length of ICU 
will be defined as time from admission to discharge 
from ICU or death in ICU. Length of stay data will 
only be interpreted in the light of the mortality 
data.
Systematic review of existing 
economic evaluations
The cost-effectiveness of ODM will be addressed 
by conducting a systematic review of economic 
evaluations of ODM against potential relevant 
comparators and for the pertinent patient 
groups as described above. Searches for this 
will be adapted to those used for the systematic 
review of clinical effectiveness but tailored to find 
relevant economic evaluation studies. Non-English 
language studies will be excluded except where an 
NHS EED English language abstract is available. In 
this situation the NHS EED abstract will be used as 
the primary reference.
One reviewer will assess all abstracts for relevance 
and will ask for full papers to be obtained for those 
that appear to be potentially relevant. Studies that 
compare relevant alternatives in terms of their 
cost and effects will be included in the analysis. 
One economist will assess included studies using 
well-known guidelines for economic evaluation 
assessment.30,54 These guidelines address all the 
important issues that should be reported when 
conducting an economic evaluation in health 
care. No attempt will be made to synthesise 
quantitatively the identified primary studies.
The following data will be extracted for each 
included study:
Study characteristics (research question; study  1. 
design; comparison; setting; basis of costing)
Characteristics of the study population  2. 
(numbers receiving or randomised to each 
intervention; other systematic differences 
in clinical management; inclusion/exclusion 
criteria; dates to which data on effectiveness 
and costs are related)© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Duration of follow-up for both effectiveness  3. 
and costs
Results (summary of effectiveness and costs  4. 
[point estimate and if reported range or 
standard deviation (SD)]; summary of cost-
effectiveness/utility (point estimate and if 
reported range or SD); sensitivity analysis)
Conclusions as reported by the authors of the  5. 
study.
Data from all included studies will be summarised 
and appraised in order to identify common 
results, variations and weaknesses between studies. 
If a study does not report ICERs but provides 
sufficient data then, where possible, the data will 
be reanalysed to provide estimates of ICERs. 
Particular attention will be given to relevant 
subgroup analyses within the included studies. 
These data will then be interpreted alongside the 
results of the systematic review of effectiveness to 
aid assessment of the relative efficiency.
Potential additional work
A health economist will explore the possibility of 
developing a simple health economic model to 
further address cost-effectiveness of ODM. The 
structure of such a model would be informed by 
advice from our clinical collaborators and would be 
parameterised using the best available UK-relevant 
data. However, owing to the very short duration of 
the present TAR, we cannot anticipate that a full 
new economic evaluation will be conducted.
Expertise in this TAR team
The TAR team is experienced in conducting 
reviews of diagnostic and therapeutic interventions 
in both the clinical and technical aspects required 
to address the commissioning brief. The Lead 
reviewer and almost all the other members of 
the review team have all been involved in a 
considerable number of similar studies. Local 
clinical expertise will be provided by Dr Brian 
Cuthbertson, Senior Lecturer in critical care 
and Dr Gordon Houston, Specialist Registrar in 
anaesthetics. Dr Cuthbertson is also an experienced 
health services researcher and has previously 
worked on NCCHTA-commissioned Health 
Technology Assessments.
TAR Centre
The Aberdeen Assessment Group has a track 
record of producing this type of focused report, 
while adhering to tight timescales for various policy 
customers such as the National Institute for Health 
and Clinical Excellence, the National Screening 
Committee and the NHS R&D HTA Programme.
In the last 12 months several similar studies 
have been completed. These include reviews that 
investigate:
minimally invasive procedures for benign  •	
prostatic enlargement
screening for open-angle glaucoma •	
detection and treatment of  •	 Staphylococcus aureus 
infection for patients on peritoneal dialysis for 
end-stage renal disease
minimally invasive total hip replacement. •	
Team members’ contributions
Luke Vale, Senior Research Fellow, will be technical 
lead on this project and will be responsible for 
the day-to-day running of the review as well as 
supervision of the economic evaluation and review 
of effectiveness. Graham Mowatt, Research Fellow, 
will undertake the systematic review of effectiveness 
and Rodolfo Hernández, Research Fellow, will 
conduct the systematic review of economic 
evaluations and investigate the scope for a simple 
modelling exercise. Adrian Grant, Professor of 
Health Services Research, will provide additional 
supervision, methodological advice and comments 
on drafts of the review. Cynthia Fraser, Information 
Officer, will develop and run the search strategies 
and will be responsible for obtaining papers 
and reference management. Brian Cuthbertson, 
Clinical Senior Lecturer, and Gordon Houston, 
Specialist Registrar, will provide clinical support 
and advice as well as assisting with the review of 
effectiveness.
Contact details for clinical experts:
Dr Brian Cuthbertson MB ChB FRCA MD
Clinical Senior Lecturer
University of Aberdeen
Honorary Consultant Anaesthetist
NHS Grampian
Health Services Research Unit
Health Sciences Building
Foresterhill
Aberdeen AB25 2ZD
Dr Gordon Houston MB ChB FRCA
Specialist Registrar
Department of Anaesthetics
Aberdeen Royal Infirmary
Foresterhill
Aberdeen AB25 2ZNAppendix 1
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Appendices
Protocol Appendix 1: Draft 
search strategy
MEDLINE strategy to identify 
randomised controlled trials
Assessing clinical effectiveness:
((oesophageal or esophageal or  1. 
intra?esophageal or trans?esophageal) adj5 
doppler).tw.
((oesophageal or esophageal or  2. 
intra?esophageal or trans?esophageal) adj5 
ultrason$).tw.
cardioQ.tw. 3. 
teco.tw. 4. 
Echocardiography, Transesophageal/ 5. 
or/1–5 6. 
exp echocardiography, doppler/ 7. 
ultrasonography, doppler/ 8. 
or/7–8 9. 
(oesophageal or esophageal or  10. 
intra?esophageal or trans?esophageal).tw.
9 and 10 11. 
6 or 11 12. 
exp cardiac output/ 13. 
cardiovascular physiologic processes/ 14. 
blood circulation/ 15. 
hemodynamic processes/ 16. 
fluid therapy/ 17. 
blood flow velocity/ 18. 
hypovol?emia.tw. 19. 
cardiac output.tw. 20. 
(hemodynamic or haemodynamic).tw. 21. 
((stroke or circulatory or intravascular or fluid  22. 
or plasma) adj volume).tw.
((blood or flow) adj1 velocity).tw. 23. 
(fluid adj1 (load or preload or therap$or  24. 
management)).tw.
or/13–24 25. 
12 and 25 26. 
monitoring, physiologic/ 27. 
intraoperative monitoring/ 28. 
preoperative care/ 29. 
perioperative care/ 30. 
critical care/ 31. 
intensive care/ 32. 
((intensive or critical) adj care).tw. 33. 
ICU.tw. 34. 
(surgery or surgical).tw. 35. 
(optimis$or optimiz$).tw. 36. 
(preoptimis$or preoptimiz$).tw. 37. 
(super normalis$or supernormalis$).tw. 38. 
(super normaliz$or supernormaliz$).tw. 39. 
monitor$.tw. 40. 
or/27–40 41. 
26 and 41 42. 
clinical trial.pt. 43. 
randomi?ed.ab. 44. 
randomly.ab. 45. 
trial.ab. 46. 
groups.ab. 47. 
or/43–47 48. 
42 and 48 49. 
limit 49 to humans 50. 
limit 50 to yr=“1990 – 2007” 51. 
MEDLINE strategy to identify studies
Assessing cost-effectiveness:
1 ((oesophageal or esophageal or  1. 
intra?esophageal or trans?esophageal) adj5 
doppler).tw.
((oesophageal or esophageal or  2. 
intra?esophageal or trans?esophageal) adj5 
ultrason$).tw.
cardioQ.tw. 3. 
teco.tw. 4. 
Echocardiography, Transesophageal/ 5. 
or/1–6 6. 
exp echocardiography, doppler/ 7. 
ultrasonography, doppler/ 8. 
or/7–9 9. 
(oesophageal or esophageal or  10. 
intra?esophageal or trans?esophageal).tw.
9 and 10 11. 
6 or 11 12. 
exp cardiac output/ 13. 
cardiovascular physiologic processes/ 14. 
blood circulation/ 15. 
hemodynamic processes/ 16. 
fluid therapy/ 17. 
blood flow velocity/ 18. 
hypovol?emia.tw. 19. 
cardiac output.tw. 20. 
(hemodynamic or haemodynamic).tw 21. 
((stroke or circulatory or intravascular or fluid  22. 
or plasma) adj volume).tw.
((blood or flow) adj1 velocity).tw. 23. © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
61
DOI: 10.3310/hta13070  Health Technology Assessment 2009; Vol. 13: No. 7
(fluid adj1 (load or preload or therap$or  24. 
management)).tw.
or/13–24 25. 
12 and 25 26. 
monitoring, physiologic/ 27. 
intraoperative monitoring/ 28. 
preoperative care/ 29. 
perioperative care/ 30. 
critical care/ 31. 
intensive care/ 32. 
((intensive or critical) adj care).tw. 33. 
ICU.tw. 34. 
(surgery or surgical).tw. 35. 
(optimis$or optimiz$).tw. 36. 
(preoptimis$or preoptimiz$).tw. 37. 
(super normalis$or supernormalis$).tw. 38. 
(super normaliz$or supernormaliz$).tw. 39. 
monitor$.tw. 40. 
or/27–40 41. 
12 and 41 42. 
26 or 42 43. 
exp “costs and cost analysis”/ 44. 
economics/ 45. 
exp economics,hospital/ 46. 
exp economics,medical/ 47. 
exp budgets/ 48. 
exp models, economic/ 49. 
exp decision theory/ 50. 
ec.fs. use mesz 51. 
monte carlo method/ 52. 
markov chains/ 53. 
exp quality of life/ 54. 
“Value of Life”/ 55. 
cost of illness/ 56. 
exp health status indicators/ 57. 
cost$.ti. 58. 
(cost$adj2 (effective$or utilit$or benefit$or  59. 
minimis$)).ab.
economics model$.tw 60. 
(economics$or pharmacoeconomic$or  61. 
pharmo-economic$).ti.
(price$or pricing$).tw. 62. 
(financial or finance or finances or financed). 63. 
tw.
(value adj2 (money or monetary)).tw. 64. 
quality adjusted life.tw. 65. 
disability adjusted life.tw. 66. 
(qaly? or qald? or qale? or qtime? or daly?).tw 67. 
(euroqol or euro qol or eq5d or eq 5d).tw. 68. 
(hql or hqol or h qol or hrqol or hr qol).tw. 69. 
(hye or hyes).tw. 70. 
(health adj3 (indicator? or status or utilit?)).tw. 71. 
markov$.tw. 72. 
monte carlo.tw. 73. 
(decision$adj2 (tree? or analy$or model$)).tw 74. 
or/44–74 75. 
43 and 75 76. Appendix 1
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Protocol Appendix 2: Data extraction form
Clinical effectiveness of ODM in adults being managed in critical care or during major surgery
Reviewer:   Data extraction date:
Study design
Study:  Country:
Aim of the study:
Comparison:
 ODM versus pulmonary artery catheterisation
 ODM versus pulse contour analysis monitoring:
 Lithium dilution cardiac monitors, i.e. LiDCO monitor
 Thermodilution cardiac monitors, i.e. PiCCO monitor
 ODM versus no cardiac monitoring
Patient subgroups:
 Patients with sepsis
Setting:
Patient recruitment date:
Length of follow up [mean/median (SD), range]:
Funding: government/private/manufacturer/other (specify):
Additional information on study design:
Participants
Inclusion criteria:
Exclusion criteria:© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Patient characteristics
Intervention 1 Intervention 2 Intervention 3 Overall
Specify ODM
Number of patients
Randomised
Lost to follow-up
Reason
Analysed
Age(years) [mean/median (SD), range]
Sex M M M M
F F F F
Co-morbidities
Additional information on patients:
Indications for ODM
Intervention
Details of ODM intervention:
Practitioner experience:
Additional information:
Details of pulmonary artery catheterisation:Appendix 1
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Details of pulse contour analysis monitoring:
Details of standard care if no cardiac monitoring used:
Outcomes
Intervention 1 Intervention 2 Intervention 3
Specify ODM
30-day mortality [% (n/N)]
Hospital mortality [% (n/N)]
Longer term mortality
Length of follow up 
[% (n/N)]
Overall length of hospital stay [days, mean/median (SD), range]
Overall length of stay in ICU [days, mean/median (SD), range]
Overall length of stay in critical care facilities (ICU and HDU) [days, 
mean/median (SD), range]
Days of organ support in ICU [mean/median (SD), range]
Postoperative complications and morbidity [% (n/N)]
Cardiac events
Organ system failures
Other
Quality of life in year after intervention
Instrument(s)© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Other effectiveness outcomes
Authors’ conclusions
Additional informationAppendix 1
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Protocol Appendix 3: Quality assessment form – RCTs (adapted from Verhagen et al 199813)
Reviewer:  Date:
Criteria Yes No Unclear Comments
Was the sequence generation really random?
Adequate approaches to sequence generation
Computer-generated random tables
Random number tables
Inadequate approaches to sequence generation
Use of alternation, case record numbers, birth dates or week days
Was the treatment allocation concealed?
Adequate approaches to concealment of randomisation
Centralised or pharmacy-controlled randomisation
Serially-numbered identical containers
On-site computer-based system with a randomisation sequence 
that is not readable until allocation
Other approaches with robust methods to prevent 
foreknowledge of the allocation sequence to clinicians and 
patients
Inadequate approaches to concealment of randomisation
Use of alternation, case record numbers, birth dates or week days
Open random number lists
Serially-numbered envelopes (even sealed opaque envelopes can 
be subject to manipulation)
Were the groups similar at baseline regarding the most 
important prognostic indicators?
Were the eligibility criteria specified?
Were the groups treated in the same way apart from the 
monitoring tool used?
Was the outcome assessor blinded?
Was the care provider blinded?
Were the patients blinded?
Were the point estimates and measures of variability presented 
for the primary outcome measures?
Was the withdrawal/drop-out rate likely to cause bias?
Did the analyses include an intention-to-treat analysis?
Was the monitoring procedure undertaken by somebody 
experienced in performing the technique?© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Summary
This publication reported a well-conducted 
systematic review assessing oesophageal Doppler 
ultrasound-based cardiac output monitoring for 
real-time therapeutic management of hospitalised 
patients. Four key questions were addressed:
What types of devices/techniques are currently  1. 
used to assess cardiac output?
Does therapeutic management based on  2. 
oesophageal Doppler ultrasound-based 
cardiac output monitoring during surgery 
lead to improved patient outcomes (fewer 
complications and shorter hospital stay) 
compared with:
Pulmonary artery catheter-based  i. 
measurement of cardiac output via 
thermodilution?
Catheter-based measurement of central  ii. 
venous pressure (CVP)?
Conventional clinical assessment (physical  iii. 
examination, fluid input and output 
measurements)?
Does therapeutic management based on  3. 
oesophageal Doppler ultrasound-based cardiac 
output monitoring during hospitalisation 
lead to improved patient outcomes (fewer 
complications and shorter hospital stay) 
compared with:
Pulmonary artery catheter-based  i. 
measurement of cardiac output via 
thermodilution?
Catheter-based measurement of central  ii. 
venous pressure (CVP)?
Conventional clinical assessment (physical  iii. 
examination, fluid input and output 
measurements)?
What complications, harms, and adverse  4. 
events associated with oesophageal Doppler 
ultrasound-based monitoring have been 
reported?
Twenty-seven studies met the inclusion criteria 
for at least one key question. The ODM devices 
evaluated in the review included CardioQ (Deltex 
Appendix 2  
Aberdeen TAR group critique of the AHRQ 
report, using the Database of Abstracts of 
Reviews of Effectiveness (DARE) criteria
Medical Ltd., UK), HemoSonic 100 (Arrow 
International, USA) and TECO (Medicina Ltd., 
UK, but no longer commercially available). Earlier 
models of these devices were also included. The 
review focused on patient-orientated outcomes.
The authors’ conclusions were:
Q1. Methods used to monitor cardiac output 
in patients during surgery or intensive care. 
These methods include thermodilution, dye 
dilution, lithium dilution, methods using the 
Fick principle, pulse contour methods, thoracic 
electrical bioimpedance, transoesophageal 
echocardiography, oesophageal Doppler 
monitoring and ultrasonic cardiac output 
monitoring.
Q2. Seven publications with 583 patients addressed 
this question. None of the studies compared 
ODM with thermodilution. Five studies were of 
ODM plus CVP monitoring plus conventional 
clinical assessment versus CVP monitoring plus 
conventional clinical assessment. Two studies were 
of ODM plus conventional clinical assessment 
versus conventional clinical assessment alone.
The addition of ODM for guided fluid replacement 
to a protocol using CVP monitoring plus 
conventional clinical assessment during surgery 
leads to a clinically significant reduction in the rate 
of major complications and total complications in 
surgical patients compared with CVP monitoring 
plus conventional clinical assessment. The strength 
of evidence supporting this finding is strong.
The addition of ODM to the protocol described 
above also reduces the length of hospital stay for 
surgical patients (clinical significance uncertain). 
The strength of evidence supporting this finding is 
strong.
Only one study compared ODM plus conventional 
clinical assessment with CVP monitoring plus 
conventional clinical assessment. Because this was Appendix 2
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one small study with non-informative effect sizes, 
no evidence-based conclusions were possible for 
any of the outcomes of interest.
The addition of ODM for guided fluid replacement 
to conventional clinical assessment during 
surgery leads to a clinically significant reduction 
in the length of hospital stay compared with that 
associated with conventional clinical assessment 
alone. The strength of evidence supporting this 
finding is weak.
The evidence was insufficient to allow conclusions 
to be reached concerning relative mortality rates 
for any of the comparisons in key question 2.
The conclusions for key question 2 apply only 
to patients undergoing surgical procedures with 
an expected substantial blood loss or fluid shifts 
requiring fluid replacement.
Q3. One study addressed this question, comparing 
ODM plus CVP monitoring plus conventional 
clinical assessment with CVP monitoring plus 
conventional clinical assessment for optimisation of 
intravenous fluid replacement in patients admitted 
to intensive care following cardiac surgery. This 
was a single small study without a demonstrably 
large treatment effect on the outcomes of interest. 
Therefore, no conclusions could be drawn for this 
question.
Q4. Currently, no serious adverse events associated 
with oesophageal Doppler probes have been 
reported in the literature or in adverse event 
databases. The only minor events identified 
included two cases of incorrect probe placement 
in the left main bronchus, one case of incorrect 
placement in the trachea, a tube displacement 
during probe removal and an unspecified number 
of cases of minimal trauma in the buccal cavity 
during probe placement. Nineteen studies with 
a total of 654 patients specifically stated that 
oesophageal Doppler probes did not cause any 
complications. The number of patients represented 
in these studies is relatively small. However, the 
available evidence suggests that oesophageal 
Doppler probes are relatively low-risk devices, 
as reporting of even minor morbidity has been 
infrequent thus far.
Authors’ objective
The authors’ objective was to provide a report to 
inform the US Centers for Medicare and Medicaid 
Services of the evidence regarding oesophageal 
Doppler ultrasound-based monitoring of cardiac 
output.
Specific interventions 
included in the review
For key questions 2 and 3, ODM was compared 
with a standard of care, ideally catheter-based 
measurements of cardiac output or CVP, but also 
including other conventional clinical assessments.
The AHRQ report stated that transoesophageal 
echocardiography (TEE) with Doppler differs 
from ODM in that TEE requires more training to 
operate and is more expensive. TEE systems were 
beyond the scope of the AHRQ report.
Participants included 
in the review
The participants were patients undergoing surgery 
(key question 2), or during hospitalisation (key 
question 3) or either (key question 4).
The authors noted that inclusion/exclusion criteria 
and patient characteristics described in studies 
of cardiac output monitoring suggested that the 
target population was relatively high-risk patients 
undergoing major surgical procedures such as 
bowel resection, hip fracture repair or cardiac 
surgery, with a significant anticipated blood loss, 
or patients in intensive care. The authors stated 
that cardiac output-guided fluid replacement is not 
generally considered for low-risk patients having 
ambulatory surgery.
The participant inclusion criterion did not apply to 
key question 1, which was concerned with the types 
of device used to measure cardiac output.
Outcomes assessed in the review
For key questions 2 and 3, mortality, major 
complications, total complications and length of 
hospital stay were the main outcome measures. 
For key question 4, all outcomes reported 
complications that may be related to use of 
oesophageal Doppler ultrasound devices. The 
report evaluated only patient-orientated outcomes.
Study designs of evaluations 
included in the review
Studies were included if they were English 
language, addressed one of the four key questions, 
were published as full journal articles and, for © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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controlled studies, enrolled 10 or more patients per 
treatment group. If the same study was reported 
in multiple publications, only the most recent 
publication was included.
In addition:
For key question 1 clinical guidelines, review 
articles and US Food and Drug Administration 
(FDA) approvals were used to identify other 
methods of cardiac output monitoring.
For key questions 2 and 3, studies had to involve 
a parallel group design with a head-to-head 
comparison of ODM with standard-of-care 
monitoring in separate patients. Within a given 
trial, patients in both groups must have received 
comparable surgery (key question 2) or must have 
had comparable diagnoses (key question 3). Studies 
performing a mixed analysis of surgical and non-
surgical patients were excluded, as such studies 
could not answer key question 2 or 3.
For key question 4, studies of any design 
(controlled trials, case series, case reports), the 
ECRI’s Health Device Alerts database and other 
adverse event databases were examined for reports 
of complications, harms and adverse events. These 
sources could not be used to determine causality or 
to estimate frequency of adverse events, but were 
used to generate a list of adverse events possibly 
attributable to the technology.
What sources were searched 
to identify primary studies?
The original search was to June 2006, followed by 
an updated search to September 2006.
Electronic database searches
Seventeen external and internal databases were 
searched: MEDLINE (1966 to 11 September 
2006), EMBASE (1974 to 11 September 2006), The 
Cochrane Database of Systematic Reviews (Issue 
3, 2006), The Cochrane Database of Methodology 
Reviews (Issue 3, 2006), The Cochrane Central 
Register of Controlled Trials (Issue 3, 2006), 
Database of Abstracts of Reviews of Effectiveness 
(Issue 3, 2006), CINAHL (1982 to 11 September 
2006), ECRI Health Devices Alerts (1977 to 7 June 
2006), ECRI International Health Technology 
Assessment (inception to 7 June 2006), ECRI 
Library Catalog (inception to March 2006), Health 
Technology Assessment Database (inception to 
Issue 3, 2006), metaRegister of Controlled Trials 
(14 June 2006), PubMed (1 September 2006), NHS 
Economic Evaluation Database (inception to Issue 
3, 2006), US Centers for Medicare & Medicaid Web 
site (inception to 19 June 2006), US Food and Drug 
Administration (adverse event reports) (1977 to 7 
June 2006), US National Guideline Clearinghouse 
(14 June 2006).
Hand searches of journal and 
non-journal literature
Over 1600 journals and supplements maintained 
in the ECRI’s collections were routinely reviewed. 
Non-journal publications and conference 
proceedings from professional organisations, 
private agencies and government agencies were 
also screened. Other mechanisms used to retrieve 
additional relevant information included review of 
bibliographies/reference lists from peer-reviewed 
and grey literature.
Only published, peer-reviewed, English language 
full text articles were considered for inclusion in 
the review.
Validity assessment
Quality assessment of studies included for key 
questions 2 and 2 was undertaken using an ECRI 
25-question tool. Questions were worded so that 
study design aspects that provided evidence with 
good internal validity resulted in ‘Yes’ answers, 
design aspects that created potential for bias 
resulted in ‘No’ answers and design aspects that 
were inadequately described resulted in an answer 
of ‘NR’ (not reported). The tool considered the 
comparability of the groups at baseline, blinding, 
outcome measurement, treatment and investigator 
bias. These items were used to compute a 
summary score, where 10 indicated an ideal study 
and 0 indicated a study of the poorest possible 
quality. Studies that scored < 5 were considered 
unacceptable quality, those scoring > 5 but ≤ 6.7 
were considered low quality, those that scored > 6.7 
but ≤ 8.4 were considered moderate quality and 
studies scoring ≥ 8.5 were considered high quality.
The number of reviewers conducting the quality 
assessment was not stated.
The information used for key question 1 was not 
formally evaluated. The quality of the evidence for 
key question 4 was not formally evaluated as the 
intent of the question was simply to list reported 
harms of oesophageal Doppler ultrasound probes 
from any available data sources.Appendix 2
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How were decisions on 
the relevance of primary 
studies made?
From 317 potentially relevant citations identified, 
75 full text articles were retrieved. Each article was 
read to determine whether it met a set of general 
and question-specific a priori inclusion criteria. 
Twenty-seven of the retrieved articles met the 
inclusion criteria for at least one key question, and 
four addressed more than one key question. Seven 
included studies addressed key question 2, one 
addressed key question 3 and 23 addressed key 
question 4. The authors stated that as key question 
1 was a survey of current techniques rather than 
an evaluation of evidence the papers addressing 
it were not included in the above figures. The 
number of reviewers who selected reports for 
inclusion was not stated.
How were the data extracted 
from the primary studies?
Data were extracted that described patient 
inclusion/exclusion criteria, design details 
(prospective, blinding status, etc), information on 
enrolled patients (demographics, underlying risk, 
etc), and study results. When study authors did not 
report dichotomous data as percentages, these were 
computed. Only outcome data relevant to the key 
questions in the report were extracted. The number 
of reviewers who extracted data was not stated.
Number of studies included
As key question 1 required a summary of the 
technologies used to measure cardiac output, it 
was derived primarily from review articles written 
by experts in the field and was not truly evidence 
based, and the number of studies providing 
information for this question was not reported. 
Seven studies (n = 583) were included for key 
question 2, one study (n = 174) was included for 
key question 3 and 23 studies were included for 
key question 4. Because the intent of key question 
4 was simply to list reported harms of oesophageal 
Doppler ultrasound probes from any available 
data source, details of study participants were not 
reported.
How were the studies combined?
Individual study effect sizes were calculated 
from dichotomous data using the log odds ratio 
(summary log odds ratios were converted to odds 
ratios in the text and conclusion statements). If 
there were no events in one of the study groups, 
the Peto log odds and odds ratios were used. Effect 
sizes for continuous data were calculated in the 
original metric.
In some instances, certain studies presented data 
for a continuous outcome (length of hospital stay) 
in a form that did not allow calculation of a precise 
effect size. Whereas accurate calculation of an effect 
requires means and standard deviations or 95% 
confidence intervals, some studies report length 
of stay as medians and ranges. The authors based 
their primary analysis of length of stay on medians 
and ranges when available, arguing that in some 
studies the mean may be considerably skewed by 
outliers. Imputation methods were used to estimate 
effect sizes from the median, range and sample 
size when possible. If studies reported medians and 
IQRs, the distance between the median and the 
25th percentile was assumed to be 0.67 standard 
deviations. If medians were not available, effect 
sizes were calculated from means and standard 
deviations.
Whenever relevant data from three or more studies 
were available and combining them was considered 
appropriate, the results were summarised using 
meta-analysis. The available data were first tested 
to determine whether the results of the studies 
included in the meta-analysis differed from 
one another by more than would be expected 
by chance (heterogeneity testing) using the I2 
statistic (I2 ≥ 50% indicating notable unexplained 
inconsistency). If study results did not differ in 
this manner, the study results were pooled in a 
fixed-effects model to obtain a summary estimate. 
Random-effects meta-analysis was performed to 
enable a qualitative conclusion if I2 ≥ 50% or if 
fewer than 80% of studies reported the outcome of 
interest or had calculable effect sizes.
How were the differences 
between studies investigated?
Having obtained a summary estimate of the results, 
the robustness of the findings was tested by means 
of sensitivity analysis. Each study was removed 
separately to determine whether any one study 
had a substantial influence on the meta-analytic 
findings. The systematic addition of each study 
(cumulative meta-analysis) was also performed to 
determine the study’s effect on the summary result. 
Studies were added in order, beginning with the 
highest-weighted study and ending with the lowest-
weighted study (studies were also added in reverse 
order). These sensitivity analyses were used for © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
71
DOI: 10.3310/hta13070  Health Technology Assessment 2009; Vol. 13: No. 7
testing both quantitative and qualitative robustness. 
As a further test of qualitative robustness, summary 
effects were recalculated in a different metric 
(Cohen’s h in place of the log odds ratio, Hedges’ 
g in place of the weighted mean difference) to 
see if this overturned the qualitative conclusions. 
Because of the assumptions used in meta-analysis 
of length of stay, additional sensitivity analyses were 
undertaken on this outcome.
In instances where the evidence base consisted of 
two studies and the median quality of the studies 
was high, the studies were combined in a meta-
analysis in an attempt to reach a qualitative (but 
not quantitative) conclusion.
Results of the review
Key question 1 (What types of 
devices/techniques are currently 
used to assess cardiac output?)
Methods used to monitor cardiac output in 
patients during surgery or intensive care included 
thermodilution, dye dilution, lithium dilution, 
methods using the Fick principle, pulse contour 
methods, thoracic electrical bioimpedance, 
transoesophageal echocardiography, ultrasonic 
cardiac output monitoring and ODM.
Key question 2 (Does therapeutic 
management based on oesophageal 
Doppler ultrasound-based cardiac 
output monitoring during surgery lead 
to improved patient outcomes?)
Seven RCTs17,18,20–24 involving 583 patients 
addressed this question, reporting three 
comparisons. None of the studies compared ODM 
with thermodilution. Although all of the studies 
except that by Venn and colleagues23 reported 
placing Doppler probes in the control group 
patients during surgery. Doppler monitoring was 
not used in the fluid maintenance protocol in 
control patients.
Six of the seven studies used the CardioQ ODM 
system or an earlier model of this system while 
Conway and colleagues17 used the TECO system. 
The types of surgery performed included elective 
bowel surgery,17,21,24 hip fracture repair surgery,22,23 
elective cardiac surgery20 and elective general, 
urological or gynaecological surgery.18
The five studies comparing ODM plus CVP 
monitoring plus conventional clinical assessment 
with CVP monitoring plus conventional clinical 
assessment had a median quality score of 8.9 
(range 8.1–9.7) on the ECRI quality scale, resulting 
in a quality rating of high for this evidence base. 
The two studies comparing ODM plus conventional 
clinical assessment with conventional clinical 
assessment had a median quality score of 9.0 
(range 8.9–9.0), also resulting in a quality rating of 
high. One of these studies23 also compared ODM 
plus conventional clinical assessment with CVP 
monitoring plus conventional clinical assessment.
ODM plus CVP plus conventional 
assessment versus CVP plus 
conventional assessment
Five studies involving 453 patients reported this 
comparison. The types of surgery performed 
included elective bowel surgery,17,21,24 elective 
cardiac surgery20 and elective general, urological or 
gynaecological surgery.18
Mortality
No study reported any deaths during surgery. 
Three studies17,20,21 reported one death each in the 
control group within 30 days following surgery, and 
one study24 reported a death in the control group 
within 60 days following surgery, but the between-
group differences were not statistically significant.
Major complications
Three of five studies reported major 
complications,17,20,21 generally defined as life 
threatening or requiring intensive or high-
dependency care. All studies showed a statistically 
significant reduction in major complications in 
the Doppler-monitored group. Because each study 
reported no major complications in the ODM 
group, the Peto method was used for calculating 
odds ratios. The Peto ORs (95% CIs) for the three 
studies were −2.08 (−3.72 to −0.44),21 −2.19 
(−4.01 to −0.37)17 and −2.19 (−3.86 to −0.51).20 
Although a Peto random-effects meta-analysis 
was undertaken, an overall pooled estimate was 
not presented as only three of the five studies 
presented separate data on major complications. 
However, the 95% CI was 0.04–0.31, indicating 
statistically significantly fewer major complications 
associated with ODM.
Total complications
Four of five studies reported total 
complications.17,18,21,24 Two of these four studies 
showed a statistically significant difference 
indicating fewer total complications in the 
Doppler-monitored group, with OR (95% 
CI) 0.23 (0.10–0.54)18 and 0.41 (0.20–0.84),24 
while the remaining two studies also showed 
fewer complications but the difference was not Appendix 2
72
significant, with OR 0.44 (0.13–1.54)17 and OR 
0.47 (0.20–1.07).21 Gan and colleagues18 reported 
the total number of complications rather than the 
number of patients with complications. Although 
a random-effects meta-analysis was undertaken, 
an overall pooled estimate was not presented as 
the studies reported complications somewhat 
differently (patients versus events). However, the 
95% CI was −1.43 to −0.57, indicating statistically 
significantly fewer total complications associated 
with ODM.
Length of hospital stay
All five studies reported this outcome. Four 
studies reported a statistically significant reduction 
in length of stay (based on either medians or 
means) associated with Doppler-monitored fluid 
replacement, with a median of 6 versus 7 days, 
p = 0.03,18 7 (IQR 3–35) versus 9 (IQR 4–45) days, 
p = 0.005,21 10 (IQR 5.75) versus 11.5 (IQR 4.75) 
days, p = 0.03,24 and a mean of 6.4 (range 5–9) 
versus 10.1 (range 5– 48) days, p = 0.01.20 The 
fifth study, by Conway and colleagues,17 reported a 
median of 12 (range 7–103) days for the Doppler 
group versus 11 (range 7–30) days for the control 
group (p-value not reported). In this study, one 
patient in the Doppler group remained in hospital 
for 103 days, not because of complications but 
because a social/community placement could not 
be found. Although a random-effects meta-analysis 
was undertaken, an overall pooled estimate was 
not presented on the grounds that three of the five 
studies reporting this outcome did not present data 
that allowed a precise effect size to be calculated. 
However, the 95% CI was −2.21 to −0.57, 
indicating a statistically significantly shorter length 
of hospital stay associated with ODM.
ODM plus conventional 
assessment versus CVP plus 
conventional assessment
One study23 compared ODM plus conventional 
assessment (n = 30) with CVP monitoring plus 
conventional assessment (n = 31) [and also with 
conventional assessment alone (n = 29), see below] 
in patients undergoing surgery for hip fracture 
repair.
Mortality
There were fewer deaths in the ODM group (3/30 
versus 6/31, p = 0.30), although the difference was 
not statistically significant.
Major complications
Venn and colleagues23 did not report major 
complications separately from total complications.
Total complications
There were 46.7% (14/30) complications in 
the ODM plus conventional assessment group 
compared with 51.6% (16/31) in the CVP 
monitoring plus conventional assessment group. 
The difference in the rate of total complications 
(comprising mostly infections and cardiovascular 
events) favoured the ODM group without 
being statistically significant (OR 0.82, 95% CI 
0.30–2.25). In terms of the number of patients 
experiencing complications, 33.3% (10/30) patients 
in the ODM group experienced complications 
compared with 45.2% (14/31) patients in the CVP 
monitoring group. The difference in the number of 
patients experiencing complications also favoured 
the ODM group, but again without reaching 
statistical significance (OR 0.61, 95% CI 0.21–1.72).
Length of hospital stay
The difference in the mean length of hospital stay 
between the ODM and CVP monitoring group was 
not statistically significant (13.5 versus 13.3 days, 
respectively, p = 0.96).
ODM plus conventional assessment 
versus conventional assessment
Two studies involving 130 patients undergoing 
surgery for hip fracture repair reported this 
comparison.22,23
Mortality
No deaths occurred during surgery in either study. 
Venn and colleagues23 reported three (3/30) deaths 
in the ODM group and two (2/29) in the control 
group within 30 days following surgery, while 
Sinclair and colleagues22 reported no (0/20) deaths 
in the ODM group and one (1/20) in the control 
group during this period. Sinclair and colleagues22 
reported a further two deaths (one in the ODM 
group and one in the control group) after this 
period and within 3 months following surgery. In 
terms of total mortality rates, neither study showed 
a statistically significant difference between the two 
treatment groups.
Major complications
The study by Sinclair and colleagues22 did not 
report complications and the study by Venn and 
colleagues23 did not report major complications 
separately from total complications.
Total complications
Only Venn and colleagues23 reported total 
complications. The ODM group experienced 
statistically significantly fewer complications 
(46.7%, 14/30) than the control group (79.3%, © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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23/29) (OR 0.23, 95% CI 0.07–0.72). However, 
in terms of the number of patients experiencing 
complications the difference between the ODM 
group (33.3%, 10/30) and the control group 
(55.2%, 16/29) was not statistically significant (OR 
0.41, 95% CI 0.14–1.16).
Length of hospital stay
Both studies reported a shorter length of stay for 
the ODM group. Sinclair and colleagues22 reported 
a statistically significantly shorter length of stay for 
the ODM group compared with the control group, 
with a median of 11 (range 3–23) days versus 
20 (range 5–220) days, p < 0.05. In the study by 
Venn and colleagues,23 although the ODM group 
experienced a shorter length of stay (mean 13.5 
days, 95% CI 10.9–17.5) compared with the control 
group (mean 17.5 days, 95% CI 13.9–24.4) the 
difference was not statistically significant (p = 0.31). 
In a random-effects meta-analysis the pooled 
estimate was statistically significant in favour of 
patients receiving ODM (OR −6.76, 95% CI −1.83 
to −1.68).
Key question 3 (Does therapeutic 
management based on oesophageal 
Doppler ultrasound-based cardiac 
output monitoring during hospitalisation 
lead to improved patient outcomes?)
One study19 addressed this question, comparing 
ODM (CardioQ system) plus CVP monitoring plus 
conventional assessment with CVP monitoring plus 
conventional assessment in 174 patients admitted 
to cardiac intensive care following cardiac surgery. 
The study achieved a quality score of 8.5 on the 
ECRI quality scale, resulting in a quality rating of 
high.
ODM plus CVP plus conventional 
assessment versus CVP plus 
conventional assessment
Mortality
There were more deaths in the ODM group (4/89 
versus 2/85) although the difference was not 
statistically significant (p = 0.43).
Major complications
Although McKendry and colleagues19 stated 
that there was a trend towards fewer major 
postoperative complications and deaths in the 
ODM group, the authors did not report major 
complications separately from total complications.
Total complications
Although fewer patients in the ODM group (19.1%, 
17/89) experienced complications compared with 
the control group (30.6%, 26/85), the difference 
was not statistically significant (p = 0.08).
Length of hospital stay
There was a statistically significantly shorter 
median length of stay in the ODM group (7 days, 
range not reported) compared with the control 
group (9 days), p = 0.02. The mean length of stay 
was also shorter in the ODM group (11.4 days) 
compared with the control group (13.9 days), 
p-value not reported.
Key question 4 (What complications, 
harms and adverse events associated 
with oesophageal Doppler ultrasound 
monitoring have been reported?)
Twenty-three studies addressed this question, 
including four RCTs,17,21–23 18 case series7,10,11,34–48 
and one article containing two case reports.49 
Because the intention was just to generate a list 
of all reported harms of oesophageal Doppler 
ultrasound probes, these studies were not assessed 
for quality.
Nineteen studies (four RCTs and 15 case 
series) involving 654 patients specifically stated 
that oesophageal Doppler probes led to no 
complications in any of the patients included in the 
studies.
Three case series11,39,42 and the article containing 
two case reports49 reported complications, harms 
or adverse events associated with oesophageal 
Doppler probes. A case series by Iregui and 
colleagues39 involving 106 critically ill patients 
reported accidental removal of an orogastric tube 
during oesophageal probe removal. A study by 
Moxon and colleagues42 involving 13 patients 
reported incorrect placement of an oesophageal 
Doppler probe in one patient’s trachea, although 
this did not cause any adverse effect. A study by 
Singer and colleagues11 involving 60 patients 
reported occasional minimal trauma in the buccal 
cavity during placement of the oesophageal 
probe but did not state the number of patients 
who experienced this problem. Chandan and 
Hull49 reported two case reports of incorrect 
placement of an oesophageal Doppler probe 
in the left main bronchus, which led to adverse 
symptoms (increasing airway resistance and oxygen 
requirement) in one of the patients.
The authors stated that a search of the FDA’s 
Manufacturer and User Facility Device Experience 
(MAUDE) database identified one report of a 
mechanical problem with a CardioQ Doppler Appendix 2
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probe. While a nurse was cleaning one of these 
probes with a tissue, the probe boot (distal end of 
the probe) separated from the rest of the probe 
body. However, this particular probe did not cause 
any complication in the patient.
Was any cost information 
reported?
No.
Authors’ conclusions
Key question 1
Several methods are currently used to monitor 
cardiac output in patients during surgery 
or intensive care. These methods include 
thermodilution, dye dilution, lithium dilution, 
methods using the Fick principle, pulse contour 
methods, thoracic electrical bioimpedance, 
transoesophageal echocardiography, ultrasonic 
cardiac output monitoring and ODM.
Key question 2
The addition of ODM for guided fluid replacement 
to a protocol using CVP monitoring and 
conventional clinical assessment during surgery 
leads to a clinically significant reduction in the 
rate of major and total complications in surgical 
patients compared with CVP monitoring plus 
conventional clinical assessment alone. The 
strength of evidence supporting this conclusion is 
strong.
The addition of ODM to the protocol described 
above also reduces the length of hospital stay for 
surgical patients (clinical significance uncertain). 
The strength of evidence supporting this 
conclusion is strong.
Only one study compared ODM plus conventional 
clinical assessment with CVP monitoring plus 
conventional clinical assessment. Because this 
was one small study with non-informative effect 
sizes, no conclusions were possible for any of the 
outcomes of interest.
The addition of ODM for guided fluid replacement 
to conventional clinical assessment during surgery 
leads to a clinically significant reduction in the 
length of hospital stay compared with conventional 
clinical assessment alone. The strength of evidence 
supporting this conclusion is weak. Because only 
a single study reported total complications, no 
conclusion was possible concerning this outcome.
No conclusion could be drawn concerning relative 
mortality rates for any of the comparisons in key 
question 2.
The AHRQ report stated that the conclusions 
reached for key question 2 applied only to 
patients undergoing surgical procedures with 
an expected substantial blood loss or significant 
fluid compartment redistribution requiring fluid 
replacement.
Key question 3
The evidence base contained only one small 
study that was insufficient to allow conclusions 
to be reached about the effectiveness of ODM in 
hospitalised patients in non-operative settings.
Key question 4
Currently, no serious adverse events associated 
with ODM have been reported in the literature 
or the MAUDE database. The only minor events 
identified included two cases of incorrect probe 
placement in the left main bronchus, one case 
of incorrect placement in the trachea, a tube 
displacement during probe removal and an 
unspecified number of cases of minimal trauma 
in the buccal cavity during probe placement. 
Nineteen studies with a total of 654 patients 
specifically stated that oesophageal Doppler probes 
did not cause any complications. The number of 
patients represented in these studies is relatively 
small. However, the available evidence suggests 
that oesophageal Doppler probes are relatively low-
risk devices, as reporting of even minor morbidity 
has been infrequent thus far.
Commentary
This systematic review addressed four clearly 
stated questions, three of which (key questions 2–4) 
were clinically relevant, and appropriate inclusion 
criteria were specified. The search strategy used 
to identify studies was comprehensive in terms of 
the sources searched, although it was restricted 
to published, peer-reviewed, English language 
full text articles, which might have resulted in the 
omission of some relevant data. Relevant details of 
the included studies that addressed key questions 
2 and 3 were reported clearly and in full. Fewer 
details were given of the included studies that 
addressed key question 4, and no details were 
given of the studies that addressed key question 
1, but this was appropriate given the nature of 
the evidence being sought. The methods used to 
minimise the introduction of error or bias during © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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the review process were partly described; no 
details were given of the number of reviewers who 
selected reports for inclusion. The methods used 
to synthesise the data were clearly described and 
appropriate. In general, this was a well-conducted 
and clearly-reported study and the authors’ 
conclusions followed on from the data presented.
What are the implications 
of the review?
Implications for practice
The authors did not state any implications for 
practice.
Implications for research
The authors did not state any implications for 
future research.
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Clinical effectiveness
Search strategies used to identify reports of clinical 
effectiveness of ODM
MEDLINE (1990 to May week 3 2007), 
EMBASE (1990 to 2007 week 20), 
(MEDLINE In Process 23 May 2007))
Ovid Multifile Search – URL: http://gateway.ovid.
com/athens
((oesophageal or esophageal or  1. 
intra?esophageal or trans?esophageal) adj5 
doppler).tw.
((oesophageal or esophageal or  2. 
intra?esophageal or trans?esophageal) adj5 
ultrason$).tw.
Echocardiography, Transesophageal/ 3. 
or/1–3 4. 
exp echocardiography, doppler/ 5. 
doppler echocardiography/ 6. 
doppler flowmeter/ 7. 
ultrasonography, doppler/ 8. 
or/5–8 9. 
(oesophageal or esophageal or  10. 
intra?esophageal or trans?esophageal).tw.
9 and 10 11. 
4 or 11 12. 
exp cardiac output/ 13. 
heart output/ 14. 
cardiovascular physiologic processes/ 15. 
cardiovascular function/ 16. 
hemodynamic processes/ 17. 
heart hemodynamics/ 18. 
hemodynamic monitoring/ 19. 
fluid therapy/ 20. 
blood flow velocity/ 21. 
hypovol?emia.tw. 22. 
cardiac output.tw. 23. 
(hemodynamic or haemodynamic).tw. 24. 
((stroke or circulatory or intravascular or fluid  25. 
or plasma) adj volume).tw.
((blood or flow) adj1 velocity).tw 26. 
(fluid adj1 (load or preload or therap$or  27. 
management)).tw.
hemodynamic monitoring/ 28. 
heart output monitoring/ 29. 
monitoring, physiologic/ 30. 
intraoperative monitoring/ 31. 
monitor$.tw. 32. 
((optimis$or optimiz$) adj1 fluid).tw 33. 
(preoptimis$or preoptimiz$).tw 34. 
(super normalis$or supernormalis$).tw. 35. 
(super normaliz$or supernormaliz$).tw. 36. 
or/13–36 37. 
12 and 37 38. 
cardioQ.tw,dv. 39. 
teco.tw,dv. 40. 
hemosonic.tw,dv. 41. 
dynemo.tw,dv. 42. 
odm.tw,dv. 43. 
or/38–43 44. 
preoperative care/ 45. 
exp perioperative care/ 46. 
critical care/ 47. 
intensive care/ 48. 
((intensive or critical) adj3 care).tw. 49. 
(surgery or surgical).tw,hw 50. 
trauma.tw,hw 51. 
icu.tw. 52. 
or/45–52 53. 
44 and 53 54. 
clinical trial.pt. 55. 
exp clinical trials/ 56. 
randomi?ed.ab. 57. 
randomly.ab. 58. 
trial.ab. 59. 
groups.ab. 60. 
or/55–60 61. 
54 and 61 62. 
animals/not humans/ 63. 
nonhuman/ 64. 
62 not (63 or 64) 65. 
limit 65 to yr=“1990–2007” 66. 
remove duplicates from 66 67. 
CINAHL (1990 to May week 2 2007)
Ovid Multifile Search – URL: http://gateway.ovid.
com/athens
((oesophageal or esophageal or  1. 
intra?esophageal or trans?esophageal) adj5 
doppler).tw.
((oesophageal or esophageal or  2. 
intra?esophageal or trans?esophageal) adj5 
ultrason$).tw.
Echocardiography, Transesophageal/ 3. 
or/1–3 4. 
exp echocardiography, doppler/ 5. 
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doppler echocardiography/ 6. 
ultrasonography, doppler/ 7. 
or/5–7 8. 
(oesophageal or esophageal or  9. 
intra?esophageal or trans?esophageal).tw.
8 and 9 10. 
4 or 10 11. 
exp cardiac output/ 12. 
fluid therapy/ 13. 
blood flow velocity/ 14. 
hypovol?emia.tw 15. 
cardiac output.tw. 16. 
(hemodynamic or haemodynamic).tw. 17. 
((stroke or circulatory or intravascular or fluid  18. 
or plasma) adj volume).tw.
((blood or flow) adj1 velocity).tw. 19. 
(fluid adj1 (load or preload or therap$or  20. 
management)).tw.
monitoring, physiologic/ 21. 
intraoperative monitoring/ 22. 
monitor$.tw. 23. 
((optimis$or optimiz$) adj1 fluid).tw. 24. 
(preoptimis$or preoptimiz$).tw. 25. 
(super normalis$or supernormalis$).tw. 26. 
(super normaliz$or supernormaliz$).tw. 27. 
or/12–27 28. 
11 and 28 29. 
cardioQ.tw,dv 30. 
teco.tw,dv. 31. 
hemosonic.tw,dv 32. 
dynemo.tw,dv 33. 
odm.tw,dv 34. 
or/29–34 35. 
clinical trial.pt. 36. 
exp clinical trials/ 37. 
randomi?ed.ab. 38. 
randomly.ab. 39. 
trial.ab. 40. 
groups.ab. 41. 
or/36–41 42. 
35 and 42 43. 
Science Citation Index 
(1990 to 20 May 2007)
BIOSIS (1990 to17  May  2007)
ISI Web of Knowledge – URL: http://wok.mimas.
ac.uk/
TS=(oesophageal SAME (doppler or  #1. 
ultason*)
TS=(esophageal SAME (doppler or ultason*)) #2. 
TS=(intraoesophageal or intraesophageal or  #3. 
intra) SAME (doppler or ultason*)
TS=(transoesophageal or transesophageal or  #4. 
trans) SAME (doppler or ultason*))
#1 or #2 or #3 or #4 #5. 
TS=(hemodynamic or haemodynamic) #6. 
TS=((stroke or circulatory or intravascular or  #7. 
fluid or plasma) SAME volume)
TS=(fluid SAME (load or preload or therap*  #8. 
or management))
TS=((blood or flow) SAME velocity) #9. 
TS=heart output #10. 
TS=cardiac output #11. 
TS=(hypovolemia or hypovolaemia) #12. 
TS=(fluid SAME (optimis* or optimiz*)) #13. 
TS=(preoptimis* or preoptimiz*) #14. 
#6 or #7 or #8 or #9 or #10 or #11 or #12  #15. 
or #13 or #14
#5 and #15 #16. 
TS=(cardioq or teco or hemosonic or dynemo  #17. 
or odm)
MQ=esophageal doppler monitor #18. 
#18 or #19 or #20 #19. 
TS=surgical #20. 
TS=surgery #21. 
TS=icu #22. 
TS=perioperative #23. 
TS=preoperative #24. 
TS=(critical SAME (care or illness)) #25. 
TS=(intensive SAME care) #26. 
#22 or #23 or #24 or #25 or #26 or #27 or  #27. 
#28
#21 and #29 #28. 
TS=randomized #29. 
TS=randomised #30. 
TS=trial* #31. 
TS=(random or randomly) #32. 
#31 or #32 or #33 or #34 #33. 
#21 and #35 #34. 
Cochrane Library (Issue 2, 2007)
URL: http://www3.interscience.wiley.com/cgi-bin/
mrwhome/106568753/HOME
(oesophageal NEAR/5 (doppler or ultrason*))  #1. 
or (esophageal NEAR/5 (doppler or 
ultrason*)) or (intra?esophageal NEAR/5 
(doppler or ultrason*)) or (trans?esophageal 
NEAR/5 (doppler or ultrason*))
MeSH descriptor Echocardiography,  #2. 
Transesophageal, this term only
(#1 OR #2) #3. 
MeSH descriptor Echocardiography, Doppler  #4. 
explode all trees
MeSH descriptor Ultrasonography, Doppler  #5. 
explode all trees
(oesophageal) or (esophageal) or  #6. 
(intra?esophageal) or (trans?esophageal)
((#4 OR #5) AND #6) #7. © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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(#3 OR #7) #8. 
MeSH descriptor Cardiac Output explode all  #9. 
trees
MeSH descriptor Hemodynamic Processes,  #10. 
this term only
MeSH descriptor Cardiovascular Physiologic  #11. 
Processes, this term only
MeSH descriptor Fluid Therapy, this term  #12. 
only
MeSH descriptor Blood Flow Velocity, this  #13. 
term only
(hypovol?emia) or (cardiac output) or  #14. 
(hemodynamic) or (haemodynamic)
(stroke next volume) or (circulatory next  #15. 
volume) or (intravascular next volume) or 
(fluid next volume) or (plasma next volume)
((blood or flow) near/1 velocity) #16. 
(fluid near/1 (load or preload or therap* or  #17. 
management))
MeSH descriptor Monitoring, Physiologic,  #18. 
this term only
MeSH descriptor Monitoring, Intraoperative,  #19. 
this term only
(monitor*) or (preoptimis*) or (preoptimiz*)  #20. 
or (optimis* near/1
fluid) or (optimiz* near/1 fluid) #21. 
(#9 OR #10 OR #11 OR #12 OR #13 OR  #22. 
#14 OR #15 OR #16 OR #17 OR
OR #19 OR #20) #23. 
(#8 AND #21) #24. 
(cardioq) or (teco) or (hemosonic) or  #25. 
(dynemo) or (odm)
(#22 OR #23) #26. 
(#24), from 1990 to 2007 #27. 
National Research Register 
(Issue 2, 2007)
URL: www.update-software.com/National/
ECHOCARDIOGRAPHY  #1. 
TRANSESOPHAGEAL single term (MeSH)
(esophageal near doppler) #2. 
(oesophageal near doppler) #3. 
ECHOCARDIOGRAPHY DOPPLER explode  #4. 
tree 1
ULTRASONOGRAPHY DOPPLER explode  #5. 
all trees (MeSH)
(oesophageal or esophageal or  #6. 
intraesophageal or transesophageal)
((#4 or #5) and #6) #7. 
(#1 or #2 or #3 or #7) #8. 
(cardioq or teco or hemosonic or dynemo or  #9. 
odm)
(#8 or #9) #10. 
DARE and HTA Databases (May 2007)
NHS Centre for Reviews & Dissemination
URL: www.crd.york.ac.uk/crdweb/
MeSH Echocardiography, Transesophageal 1. 
(Oesophageal AND (DOPPLER OR  2. 
ULTRASON*))
(esophageal AND (DOPPLER OR  3. 
ULTRASON*))
(intra AND esophageal AND (DOPPLER OR  4. 
ULTRASON*))
(intra AND oesophageal AND (DOPPLER OR  5. 
ULTRASON*))
(trans AND oesophageal AND (DOPPLER OR  6. 
ULTRASON*))
(trans AND esophageal AND (DOPPLER OR  7. 
ULTRASON*))
#8(transesophageal AND (DOPPLER OR  8. 
ULTRASON*))
(intraesophageal AND (DOPPLER OR  9. 
ULTRASON*))
#1 or #2 or #3 or #4 or #5 or #6 or #7 or  10. 
#8 or #9
Clinical Trials (May 2007)
URL: http://clinicaltrials.gov/ct/gui/c/r
Current Controlled Trials (May 2007)
URL: www.controlled-trials.com/
(oesophageal or esophageal) and Doppler
Cost-effectiveness and 
economic evaluations
Search strategies used to identify 
reports of cost-effectiveness and 
economic evaluations of ODM
MEDLINE (1990 to June week 3 2007), 
EMBASE (1990 to week 26 2007), 
(MEDLINE in Process 29 June 2007)
Ovid Multifile Search – URL: http://gateway.ovid.
com/
((oesophageal or esophageal or  1. 
intra?esophageal or trans?esophageal) adj5 
doppler).tw.
((oesophageal or esophageal or  2. 
intra?esophageal or trans?esophageal) adj5 
ultrason$).tw.
Echocardiography, Transesophageal/ 3. 
or/1–3 4. 
exp echocardiography, doppler/ 5. 
doppler echocardiograph/ 6. 
doppler flowmeter/ 7. Appendix 3
80
ultrasonography, doppler/ 8. 
or/5–8 9. 
(oesophageal or esophageal or  10. 
intra?esophageal or trans?esophageal).tw
9 and 10 11. 
4 or 11 12. 
exp cardiac output/ 13. 
heart output/ 14. 
cardiovascular physiologic processes/ 15. 
cardiovascular function/ 16. 
hemodynamic processes/ 17. 
heart hemodynamics/ 18. 
fluid therapy/ 19. 
blood flow velocity/ 20. 
hypovol?emia.tw. 21. 
cardiac output.tw. 22. 
(hemodynamic or haemodynamic).tw. 23. 
((stroke or circulatory or intravascular or fluid  24. 
or plasma) adj volume).tw.
((blood or flow) adj1 velocity).tw. 25. 
(fluid adj1 (load or preload or therap$or  26. 
management)).tw.
hemodynamic monitoring/ 27. 
heart output monitoring/ 28. 
monitoring, physiologic/ 29. 
intraoperative monitoring/ 30. 
monitor$.tw. 31. 
((optimis$or optimiz$) adj1 fluid).tw. 32. 
(preoptimis$or preoptimiz$).tw 33. 
(super normalis$or supernormalis$).tw. 34. 
(super normaliz$or supernormaliz$).tw 35. 
or/13–36 36. 
12 and 37 37. 
cardioQ.tw,dv. 38. 
teco.tw,dv 39. 
hemosonic.tw,dv. 40. 
dynemo.tw,dv. 41. 
odm.tw,dv. 42. 
or/38–43 43. 
preoperative care/ 44. 
exp perioperative care/ 45. 
critical care/ 46. 
intensive care/ 47. 
critical illness/ 48. 
((intensive or critical) adj3 care).tw. 49. 
(surgery or surgical).tw,hw. 50. 
icu.tw. 51. 
or/45–52 52. 
44 and 53 53. 
exp “costs and cost analysis”/ 54. 
economics/ 55. 
exp economics,hospital/ 56. 
exp economics,medical/ 57. 
economics,pharmaceutical/ 58. 
exp budgets/ 59. 
exp models, economic/ 60. 
exp decision theory/ 61. 
ec.fs. use mesz 62. 
cost of illness/ 63. 
cost$.ti. 64. 
(cost$adj2 (effective$or utilit$or benefit$or  65. 
minimis$)).ab
economics model$.tw 66. 
(economics$or pharmacoeconomic$or  67. 
pharmo-economic$).ti.
(price$or pricing$).tw. 68. 
(financial or finance or finances or financed). 69. 
tw.
(value adj2 (money or monetary)).tw. 70. 
or/55–71 71. 
54 and 72 72. 
remove duplicates from 73 73. 
Science Citation Index 
(1990 to 1 July 2007)
ISI Web of Knowledge – URL: http://wok.mimas.
ac.uk/
TS=(oesophageal SAME (doppler or  #1. 
ultason*)
TS=(esophageal SAME (doppler or ultason*)) #2. 
TS=(intraoesophageal or intraesophageal or  #3. 
intra) SAME (doppler or ultason*)
932 TS=(transoesophageal or  #4. 
transesophageal or trans) SAME (doppler or 
ultason*))
#1 or #2 or #3 or #4 #5. 
TS=(hemodynamic or haemodynamic) #6. 
TS=((stroke or circulatory or intravascular or  #7. 
fluid or plasma) SAME volume)
TS=(fluid SAME (optimis* or optimiz*)) #8. 
TS=(preoptimis* or preoptimiz*) #9. 
TS=(hypovolemia or hypovolaemia) #10. 
TS=heart output #11. 
TS=cardiac output #12. 
TS=(fluid SAME (load or preload or therap*  #13. 
or management))
TS=((blood or flow) SAME velocity) #14. 
#6 or #7 or #8 or #9 or #10 or #11 or #12  #15. 
or #13 or #14
TS=(cardioq or teco or hemosonic or dynemo  #16. 
or odm)
(#5 and #15) or #16 #17. 
TS=economic* #18. 
TS=cost* #19. 
TS=(price* OR pricing*) #20. 
TS=(financial or finance*) #21. 
TS=(decision* SAME (tree* OR analy* or  #22. 
model*))
TS=markov* #23. 
TS=monte carlo #24. 
TS=(health SAME (indicator* or status or  #25. 
utilit*))© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TS=quality of life #26. 
TS=quality adjusted life #27. 
TS=disability adjusted life #28. 
TS=(qaly* or qald* or qale* or qtime* or  #29. 
daly*)
TS=(euroqol* or euro qol* or eq5d or eq 5d) #30. 
TS=(hql or hqol or h qol or hrqol or hr qol) #31. 
TS=(hye or hyes) #32. 
#18 or #19 or #20 or #21 or #22 or #23 or  #33. 
#24 or #25 or #26 or #27 or #28 or #29 or 
#30 or #31 or #32
#17 AND #33 #34. 
NHS EED (May 2007)
URL: www.crd.york.ac.uk/crdweb/
MeSH Echocardiography, Transesophageal #1. 
(Oesophageal AND (DOPPLER OR  #2. 
ULTRASON*))
(esophageal AND (DOPPLER OR  #3. 
ULTRASON*))
(intra AND esophageal AND (DOPPLER OR  #4. 
ULTRASON*))
(intra AND oesophageal AND (DOPPLER OR  #5. 
ULTRASON*))
(trans AND oesophageal AND (DOPPLER  #6. 
OR ULTRASON*))
(trans AND esophageal AND (DOPPLER OR  #7. 
ULTRASON*))
(transesophageal AND (DOPPLER OR  #8. 
ULTRASON*))
(intraesophageal AND (DOPPLER OR  #9. 
ULTRASON*))
#1 or #2 or #3 or #4 or #5 or #6 or #7 or  #10. 
#8 or #9
HMIC (1990 to May 2007)
URL: http://gateway.ovid.com/
((oesophageal or esophageal or  1. 
intra?esophageal or trans?esophageal) adj5 
doppler).tw.
((oesophageal or esophageal or  2. 
intra?esophageal or trans?esophageal) adj5 
ultrason$).tw.
1 or 2 3. 
hypovol?emia.tw. 4. 
cardiac output.tw. 5. 
(hemodynamic or haemodynamic).tw. (125044) 6. 
((stroke or circulatory or intravascular or fluid  7. 
or plasma) adj volume).tw.
((blood or flow) adj1 velocity).tw 8. 
(fluid adj1 (load or preload or therap$or  9. 
management2 monitor$.tw.
((optimis$or optimiz$) adj1 fluid).tw. 10. 
(preoptimis$or preoptimiz$).tw. 11. 
or/4–11 12. 
3 and 12 13. 
cardioQ.tw 14. 
teco.tw 15. 
hemosonic.tw 16. 
dynemo.tw 17. 
odm.tw 18. 
or/13–18 19. 
Websites searched for other evidence-
based reports and background information
Anaesthesia UK – URL: www.frca.co.uk/
Critical Care – URL: http://ccforum.com/home/
Deltex Medical – URL: www.deltexmedical.com/
Hemosonic – URL: www.hemosonic.com/
Intensive Care Society – URL: www.ics.ac.uk/index.
asp
International Collaboration for Excellence in 
Critical Care Medicine – URL: http://ice-ccm.
medtau.org/
Merck Manual: Patient Monitoring and Testing – 
URL: www.merck.com/mmpe/sec06/ch063/ch063b.
html
TriP Database – URL: www.tripdatabase.com/index.
html
Surgical Critical Care – URL: www.
surgicalcriticalcare.net/© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Questions
Study
Chytra 200725 Dodd 200426
1.  Were patients randomly assigned to groups? Yes Yes
2.  Did the study employ stochastic randomisation? No NR
3.  Were any methods used to make the groups comparable – randomisation, matching, etc? Yes Yes
4.  Were patients assigned to groups based on factors other than patient or physician 
preference? 
Yes Yes
5.  Were the characteristics of the patients in different groups comparable? Yes Yes
6.  Did the patients in the different study groups have similar levels of performance on 
outcomes at baseline?
Yes Yes
7.  Was the study prospectively planned? Yes Yes
8.  Did 85% or more of the patients complete the study? Yes Yes
9.  Was there a less than 16% difference in completion rates between the study’s groups?  Yes Yes
10.  Were all of the study’s groups concurrently treated? Yes Yes
11.  Was compliance with treatment greater than or equal to 85% in both of the study’s 
groups? 
Yes Yes
12.  Were all of the study’s groups treated at the same centres? Yes Yes
13.  Were subjects blinded to treatment? No Yes
14.  Did the authors test and confirm that blinding of patients was maintained? No NR
15.  Was the treating physician blinded to group assignment? No Yes
16.  Were the outcome assessors blinded to group assignment? No Yes
17.  Was there concealment of allocation? NR NR
18.  Was the outcome of interest objective and was it objectively measured?  Yes Yes
19.  Were the same methods used to measure outcomes in all of the study’s groups? Yes Yes
20.  Was the instrument used to measure the outcome standard? Yes Yes
21.  Was the same treatment given to all of the patients enrolled in the experimental group? Yes Yes
22.  Was the same treatment given to all of the patients enrolled in the control group? Yes Yes
23.  Were the follow-up times in all of the study’s relevant groups approximately equal? Yes Yes
24.  Was the funding for this study derived from a source that does not have a financial 
interest in its results?
NR NR
25.  Were the authors’ conclusions supported by the data in the results section? Yes Yes
Quality score 7.4 8.8
Quality rating Moderate High
NR, not reported.
ECRI uses these 25 items to compute a summary score ranging from 0 to 10, where 10 indicates an ideal study and 0 
indicates a study of the poorest quality. Individual item answers were converted to numeric scores by counting 1 for each 
‘Yes’ answer, −1 for each ‘No’ answer and −0.5 for each ‘NR’ answer. The numeric scores for all 25 items were then added 
and 25 was added to the total; this number was then divided by 50 and multiplied by 10. These calculations yielded the 0–10 
summary scale. Studies that scored < 5 were considered to be of unacceptable quality, those scoring > 5 but ≤ 6.7 were 
considered to be of low quality, those that scored > 6.7 but ≤ 8.4 were considered to be of moderate quality and those 
scoring ≥ 8.5 were considered to be of high quality.
Appendix 4 
ECRI quality assessment scale applied to the 
two additional studies© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Assessor initials: GM
Study identifier: AHRQ 20076
(Surname of first author and year of publication)
1.  Were the search methods used to find evidence (primary studies) on the primary question(s) stated?
No
Partially
Yes 
Comments:
2.  Was the search for evidence reasonably comprehensive?
No Following done:
Partially  Language restrictions  Yes
Yes   Hand searching  Yes
Reference lists  Yes
Authors contacted  Yes
Comments: Only published, peer-reviewed, English language full text articles were 
considered for inclusion.
Appendix 5  
ODM in critically ill and high-risk surgical 
patients: quality assessment checklist for 
systematic reviewsAppendix 5
86
3.  Were the criteria used for deciding which studies to include in the review reported?
No Author specifies:
Partially Type of study Yes
Yes  Participants Yes
Intervention(s) Yes
Outcome(s) Yes
Comments: 
4.  Was bias in the selection of articles avoided?
No Author specifies:
Partially  Explicit selection criteria used? Yes
Yes  
Independent screening of full text by at least 
two reviewers?
Not stated
Comments: No information was given on the number of reviewers who screened full 
text articles.
5.  Were the criteria used for assessing the validity of the studies that were reviewed reported?
No Author specifies:
Partially Criteria used to assess methodological quality? Yes
Yes 
Comments: 
6.  Was the validity of all of the studies referred to in the text assessed using appropriate criteria (either in selecting 
studies for inclusion or in analysing the studies that are cited)?
No Author specifies:
Partially
Assessments of included studies using explicit 
criteria reported?
Yes
Yes 
Comments: © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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7.  Were the methods used to combine the findings of the relevant studies (to reach a conclusion) reported?
No Author specifies:
Partially Meta-analysis Outcome of interest? Yes
Yes  Model used? Yes
Test for heterogeneity? Yes
Qualitative Why meta-analysis 
inappropriate?
Yes
How then made sense of data? Yes
Both Sensitivity analysis? Yes
Comments: 
8.  Were the findings of the relevant studies combined appropriately relative to the primary question the review 
addresses?
No Interventions homogeneous? Yes
Partially  Outcome measures homogeneous? Yes
Yes Participants homogeneous? No
How unit analysis errors were handled? Not stated
Settings comparable? Yes
Comments: Although the types of surgery differed, they all involved procedures 
anticipating a major loss of blood or significant fluid shifts requiring fluid replacement.
9.  Were the conclusions made by the author(s) supported by the data and/or the analysis reported in the review?
No Conclusions consistent with results? Yes
Partially Conclusions do not go beyond the data? Yes
Yes  No evidence not interpreted as no effect? Yes
Strength of recommendations for practice 
consistent with level of evidence (uncertainty)?
Yes
Recommendations for research consistent 
with identified shortcomings?
Not stated
Comments: Appendix 5
88
10.  Overall, how would you rate the methodological quality of this review?
Extensive bias Major bias Minor bias Minimal bias
1 2 3 4 5 6 7
Comments: © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Colbert S, O’Hanlon DM, Duranteau J, Ecoffey C. 
Cardiac output during liver transplantation. Can J 
Anaesth 1998;45(2):133–8.
Collins S, Girard F, Boudreault D, Chouinard P, 
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Study
Stroke 
volume FTc
Cardiac 
output CVP
Mean 
arterial 
pressure Control group management
Conway 
200217
  a Conventional management
Gan 200218    Conventional management plus triggers for fluid 
bolusb
McKendry 
200419
c  Conventional management that may include 
cardiac output monitoring
Mythen 
199520
  Conventional management
Noblett 
200621
  Conventional management
Sinclair 
199722
  Conventional management
Venn 200223 
(CVP group)
 Conventional management aiming for heart rate 
and arterial pressure within 20% of pre-induction 
of anaesthesia baseline Venn 200223 
(ODM group)
 
Wakeling 
200524
  Targeted CVP 12–15 mmHg
Chytra 
200725
  Conventional management
Dodd 200426   Conventional management
FTc, corrected flow time. 
a  If cardiac output, stroke volume and waveform shape suggest fluid overload or impaired cardiac function, the investigator 
alerted the anaesthetist, ceased blinding of Doppler results and advised on the use of inotropes or vasodilators.
b  Urine output < 0.5ml/kg/hour, heart rate increased either by > 20% from baseline or to greater than 10 beats per 
minute, blood pressure decreased by > 20% from baseline or to less than 90 mmHg systolic pressure, or fall in CVP (if 
monitored) of > 20%.
c  Stroke index used instead of stroke volume.
Appendix 7  
Indices used to guide clinical intervention in 
trial protocols/algorithm© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Appendix 8  
Characteristics and results  
of the two additional studies Appendix 8
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Appendix 9  
List of potentially relevant studies identified 
from a search of the National Research Register 
Study Location Title Start and end dates Notes
Cholleya Hopital 
Lariboisière, 
Paris, France
Stroke volume optimisation in patients 
with hip fracture
April 2007–April 2010 Contacted – study protocol 
provided
Dorman 
(Dodd)b
Poole Hospital, 
UK
Oesophageal Dopplers in major 
abdominal surgery
February 2001–May 
2002
Contacted – electronic 
version of poster provided
Kinsellac Glasgow Royal 
Infirmary, UK
The effect of intraoperative fluid 
status guided by oesophageal Doppler 
monitoring on outcome of patients 
following urgent or emergency 
laparotomy
Not stated Contacted – project 
abandoned at early stage; 
no information available 
Merrickd North 
Manchester 
General 
Hospital, UK
Clinical trial to assess whether 
transoesophageal Doppler monitoring 
can optimise intraoperative 
intravascular volume replacement 
and improve outcome in the surgical 
management of head and neck cancer 
patients 
February–December 
2002
Contacted – project 
abandoned after 
unsuccessful pilot; no 
information available
Pateye Aberdeen Royal 
Infirmary, UK
Perioperative fluid resuscitation 
guided by Doppler ultrasound stroke 
volume measurement in patients with 
hip fractures
February 
1997–February 1998
Contacted – study results 
not obtainable within 
timescale
Smith 
(Kong)f
Royal Sussex 
County 
Hospital, UK
Does haemodynamic optimisation, as 
guided by ODM, produce a greater 
reduction in complications and length 
of stay, if used intraoperatively, 
postoperatively, or both?
October 
2006–October 2007
Contacted – no response 
received
a  ClinicalTrials.gov NCT00444262.
b  National Research Register N0186092455.
c  Currrent Controlled Trial ISRCTN 11799696.
d  National Research Register N0155107830.
e  National Research Register N0411167547.
f  National Research Register N0051189167.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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